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Populations in Western countries are ageing. At the same time, use of medications is increasing among 
older people. Age-related changes in the body make the elderly vulnerable to adverse drug events. 
Thus, ensuring medication safety among this patient group is a growing health care concern. For this 
purpose, several criteria to indicate inappropriate prescribing among the aged have been developed. 
Also, different types of medication review procedures have been created in several countries to identify 
drug-related problems (DRPs).  
The aim of this study was to develop a collaborative Comprehensive Medication Review (CMR) 
procedure applicable to the Finnish health care system and evaluate its usefulness as a means to 
improve the appropriateness of pharmacotherapy among community-dwelling elderly. The specific 
aims were 1) to determine the prevalence of potentially inappropriate medication use according to the 
Beers 2003 criteria among Finnish non-institutionalized population aged ≥65 years; 2) to describe the 
development and assess participant satisfaction on the CMR accreditation training; 3) to describe the 
development of the CMR procedure and related documentation, and to assess CMR training 
participants’ satisfaction on the documentation; and 4) to assess the DRPs pharmacists report to 
collaborating physicians during CMR and the resulting interventions among outpatients aged ≥65 
years. 
This study applied both quantitative and qualitative methods. The prevalence of potentially 
inappropriate drug use according to the Beers criteria was studied by using the drug reimbursement 
register of the Finnish Social Insurance Institution covering the entire non-institutionalized population 
aged ≥65 years in 2007 (n=841 509, Study I). The development of the CMR procedure and 
accreditation training involved a review of literature and medication review procedures used in other 
countries as well as pilot testing by 26 experienced pharmacists undergoing the CMR training in 2005–
2006 (Studies II, III). Participants’ satisfaction on the CMR training (n=38) and documentation (n=27) 
were assessed by surveys completed by pharmacists attending CMR training in 2006–2007 (Studies II, 
III). The DRPs identified and reported to the collaborating physicians during CMR were studied by a 
retrospective review of CMR case reports (n=121) by 26 community pharmacists attending the CMR 
training in 2006–2007 (Study IV).   
Approximately 15% of the entire non-institutionalized population aged ≥65 years used potentially 
inappropriate medications in Finland in 2007. This prevalence is low compared to studies in other 
countries. The most worrying finding was the common use of benzodiazepines: one third of the 
potentially inappropriate drug use involved these drugs, particularly high-dose temazepam. The 1.5-
year CMR accreditation training for practicing pharmacists combines distance learning and face-to-face 
learning and consists of 5 modules: 1) Multidisciplinary Collaboration; 2) Clinical Pharmacy and 
Pharmacotherapy; 3) Rational Pharmacotherapy; 4) CMR Tools; and 5) Optional Studies. The 
participating pharmacists’ satisfaction with the training was high but several factors prevent them from 
conducting CMRs after the training. The collaborative CMR procedure involves access to clinical 
patient information, home visit with patient interview, a case conference with the collaborating 
physician and extensive documentation to support the process. The procedure covers four main 
dimensions critical for safe and appropriate pharmacotherapy for the aged: Aging and Safety; Co-
Morbidities; Polypharmacy; and Adherence. When using the CMR procedure, pharmacists reported to 
collaborative physicians an average of 6.5 DRPs per patient. Most common DRPs were inappropriate 
drug selection, especially involving psychotropic drugs, and undertreatment. Also treatment of pain 
was often found to need improvement. Approximately half of the pharmacists’ recommendations led to 
medication changes, i.e., to an average of 3 changes/patient. The most common agreed change was to 
stop hypnotics or sedatives. 
The results of this study confirm many well-known problems in elderly pharmacotherapy: 
prescribing of inappropriate drugs, undertreatment, and issues related to inadequate management of 
pain. The CMR procedure could be beneficial for improving pharmacotherapy among older outpatients 
as a large portion of DRPs identified by pharmacists led to medication changes. Actions to facilitate 
implementation of the model to Finnish health care system are needed. Also, further studies are needed 
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Definitions of the Key Concepts 
Adverse drug event 
Any injury occurring during the patient’s medicine therapy and resulting either from 
appropriate care or from unsuitable or suboptimal care. Includes adverse drug reactions 
during normal use of the medicine, and any harm secondary to a medication error, both 
errors of omission or commission (Council of Europe 2006).  
 
Adverse drug reaction  
A response to a medicinal product which is noxious and unintended, and occurs at doses 
normally used in man (Council of Europe 2006). In such patient responses, individual 
properties may play an important role (WHO 2000).   
 
Adverse event 
An unintended injury caused by medical management rather than by a disease process 
(Council of Europe 2006). Medication errors are one potential cause of adverse events. 
 
Community-dwelling elderly 
In this study, the term community-dwelling elderly is used to refer to persons aged 65 and 
older not residing in a nursing home or hospital ward. Terms aged/elderly outpatient, 
ambulatory patient, and primary care patient have been used as synonyms to this term. 
 
Comprehensive medication review 
A medication review procedure applied nationally in Finland and requiring accreditation 
training for pharmacists conducting it. The procedure is based on collaboration between 
pharmacist and other health care professionals, particularly physicians, and includes 
access to clinical patient data, a home visit with a patient interview, a comprehensive 
clinical review of all used medication, case conference with the physician and an extensive 
documentation to support the process. 
 
Disease management 
Patient care services focused on a specific disease, e.g., hypertension, asthma and diabetes, 
to ensure that population guidelines are followed and to provide patients with the tools and 
knowledge they need to assume responsibility for their own care (McGivney et al. 2007).  
 
Drug-related problem  
Originally defined as “An undesirable patient experience that involves drug therapy and 
that actually or potentially interferes with a desired patient outcome” (Strand et al. 1990). 
Currently most often defined as “An event or circumstance involving drug therapy that 
actually or potentially interferes with the desired health outcomes” (PCNE 2010). Often 
used as a synonym with a term “drug-therapy problem” which is defined as “any 
undesirable event experienced by the patient that involves or is suspected to involve drug 
therapy and that actually or potentially interferes with desired health outcomes” (Cipolle et 






Home medicines review 
Medication review procedure for home-dwelling people in Australia. Includes patient 
home-visit, review of all medications and collaboration between an accredited pharmacist 
and physician (Pharmaceutical Society of Australia 2011). 
 
Medication error 
Any deviation from ordinary standards of care appropriate for the time of the medicine 
therapy of a patient. A non-intentional, preventable omission or failed activity related to 
the medication use system, which can be the cause of a risk or an adverse event reaching 
the patient. Medication errors can concern one or several stages of medication use system, 
e.g., prescription, dispensing, administration, therapeutic monitoring and information 
(Council of Europe 2006). 
 
Medication review 
An evaluation of patient’s medicines with the aim of managing the risk and optimizing the 




Freedom from accidental injury during the course of medication use; activities to avoid, 
prevent, or correct adverse drug events which may result from the use of medicines 
(Council of Europe 2006).  
 
Medication therapy management 
In the United States a service or group of services to eligible patients to ensure that 
medications are used appropriately, enhance understanding of the appropriate use of 
medications, increase adherence with prescription medication regimens, reduce the risk for 
potential adverse drug events, and reduce the need for other costly medical services 
through better management of medication therapy (Bluml 2005, McGivney et al. 2007). 
 
Pharmaceutical care 
The provision of patient-centered practice in which the practitioner assumes responsibility 
for a patient’s medication-related needs and is held accountable for this commitment for 
the purpose of achieving definite outcomes through designing, implementing, or 
monitoring a therapeutic plan (Hepler and Strand 1990, Cipolle et al. 2004). 
 
Potentially inappropriate medications 
In this thesis, the term potentially inappropriate medications refers to medications that are 
considered to be inappropriate for persons aged 65 or older because of questionable 
efficacy, unfavourable benefit-risk or because safer alternatives exist (Fick et al. 2003). 
 
Psycholeptic drug 
Medications classified under ATC code N05. These drugs include N05A antipsychotics 







Includes above mentioned psycholeptic drugs, and in addition, N06A antidepressants. 
 
Side effect 
Any unintended effect of a pharmaceutical product occurring at doses normally used in 
man, which is related to the pharmacological properties of the drug (WHO 2000). It differs 








ADE  Adverse Drug Event 
ADR  Adverse Drug Reaction 
APhA  American Pharmacists Association 
ATC  Anatomic Therapeutic Chemical classification 
CMR  Comprehensive Medication Review 
CMS  Cipolle-Morley-Strand classification for DTPs 
CNS  Central Nervous System 
DDI  Drug-drug interaction 
DMMR Domiciliary Medication Management Review (Australia) 
DRP  Drug-Related Problem 
DTP  Drug Therapy Problem 
DUR  Drug Utilization Review (USA) 
ED  Emergency department 
GI  Gastrointestinal 
GP  General practitioner 
HMR  Home Medicines Review (Australia) 
HRQoL Health-related quality of life 
MAI  Medication Appropriateness Index (Hanlon et al. 1992) 
MTR  Medication Therapy Review (in MTM) 
MMA  Medicare Prescription Drug Improvement and Modernization Act (USA)  
MRR  Medication Regimen Review (USA) 
MTM  Medication Therapy Management (USA) 
MUR  Medicines Use Review (England, Wales) 
NACDS National Association of Chain Drug Stores Foundation (USA) 
NSAID Non-steroidal anti-inflammatory drug 
OR  Odds ratio 
OTC  Over-the-counter  
PCNE  Pharmaceutical Care Network Europe  
PIM  Potentially Inappropriate Medication 
PSA  Pharmaceutical Society of Australia 
RCT  Randomized Controlled Trial 
RMMR Residential Medication Management Review (Australia) 
SII  Social Insurance Institution of Finland 
START Screening Tool to Alert doctors to Right Treatment (Barry et al. 2007) 
STOPP Screening Tool of Older Person’s Prescriptions (Gallagher et al. 2008a) 
TIPPA Tarkoituksenmukainen Informaatio Potilaan Parhaaksi Apteekista; 
Customized Information for the Benefit of the Patient from the Community 







The populations in Western countries are ageing. In Finland, people aged ≥65 years 
comprised 16.5% of the population at the end of 2007 (Statistics Finland 2011). By 2020 
the corresponding percentage is estimated to rise to 23%. Thus, the increasing elderly 
population with its special needs has become a priority in health care services planning.  
Age-related changes in the body (Mangoni 2003, ELDesoky 2007) make the elderly 
more susceptible to drug-related adverse reactions and hospitalizations (Beijer and de 
Blaey 2002, Budnitz et al. 2006, van der Hooft et al. 2008a). However, ageing people 
often have multiple co-morbidities, which leads to increased use of medications. For 
example in Finland both the overall use of medicines and polypharmacy (>5 medicines) 
among the aged have increased (Linjakumpu et al. 2002a, Jyrkkä et al. 2006, Jyrkkä 
2011). Polypharmacy is an independent risk factor for adverse drug reactions (ADRs) 
among frail elderly (Hanlon et al. 2006). It can also increase the risk of potentially harmful 
interactions, especially among the aged (Barat et al. 2000, Bjerrum et al. 2003). Despite 
the commonness of polypharmacy, undertreatment can also be a significant problem in 
older people (Ruths et al. 2003, Sloane et al. 2004).  
A significant proportion of adverse drug events (ADEs) and ADRs, including those 
leading to hospitalization, among the elderly are preventable (Beijer and de Blaey 2002, 
Gurwitz et al. 2003, van der Hooft et al. 2008a). Thus, pharmacotherapeutic decisions for 
elderly patients should be made with careful consideration and by emphasizing regular 
monitoring and follow-up. In order to help clinicians make safe medical decisions for their 
elderly patients, various recommendations and explicit criteria on potentially inappropriate 
medications (PIMs) and drug-disease combinations have been created in different 
countries (Kivelä and Räihä 2007, Socialstyrelsen 2003, 2010, Dimitrow et al. 2011). Yet, 
the use of PIMs continues to be common in many countries, including Finland (Fialova et 
al. 2005, Hosia-Randell et al. 2008). 
Pharmacists have taken action in several countries to be more actively involved in 
assuring rational pharmacotherapy and medication safety. Different medication review 
procedures and services have been developed and made available both in inpatient and 
outpatient settings, e.g., in the Unites States, Australia and UK (Harjivan and Lyles 2002, 
Fulda et al. 2004, Sorensen et al. 2004, Department of Health 2005, American Pharmacists 
Association (APhA) and National Association of Chain Drug Stores Foundation 
(NACDS) 2008, Australian Government 2011a,b). A core idea of these procedures is to 
recognize, resolve and prevent drug-related problems, DRPs (Hepler and Strand 1990).  
In Finland, the Ministry of Social Affairs and Health has placed regular medication 
reviews and multiprofessional collaboration as key solutions to promote rational 
pharmacotherapy and to prevent medication-related problems among the aged (The 
Ministry of Social Affairs and Health 2007). Finnish community pharmacies have taken 
persistent actions to promote safe use of medicines since the early 1990’s. The most 
remarkable effort has been a national programme in 2000–2003 (TIPPA) where all the key 
pharmacy stakeholders, including government, universities, continuing education centres 
and professional organizations united in an effort to improve patient counseling services in 






TIPPA follow-up programme in 2004–2007 was built on the findings and experiences of 
the first phase and focussed on creating more advanced services based on 
multidisciplinary collaboration. The key service developed under the follow-up 
programme was the comprehensive medication review (CMR) involving collaboration 
between pharmacists and physicians, which is the focus of this doctoral thesis. 
The literature review of this thesis aims to provide a conceptual, theoretical and 
contextual framework for the study (Chapters 2–4) The Finnish CMR is based on two 
international collaborative medication review models, i.e., Home Medicines Review 
(HMR) in Australia (Sorensen et al. 2004, Pharmaceutical Society of Australia 2011) and 
Medication Therapy Management (MTM) in the United States (APhA and NACDS 2008). 
Thus, these procedures and related evaluation studies are described (Chapter 2). As all 
medication review models basically aim at recognition, prevention and resolving of DRPs, 
DRP-classification systems and studies on recognition of DRPs by pharmacists during 
MTM and HMR are reviewed (Chapter 3). Methods to classify PIMs, prevalence of PIM 
use and association of PIM use with adverse outcomes among the aged are also discussed 
(Chapter 4). Special focus throughout this thesis is on community-dwelling patients aged 
65 and older, from now on referred also as elderly outpatients. 
The theoretical framework of this thesis is based on patient-oriented collaborative 
community pharmacy practice and service development in order to assure safe and 
appropriate pharmacotherapy with optimum outcomes (Chapter 2). These principles were 
first introduced in to community pharmacy practice by American scientists Hepler and 
Strand in 1990 under the concept Pharmaceutical Care (Hepler and Strand 1990). Their 
landmark article led to worldwide discussion about community pharmacists’ contribution 
to patient care and need for extending their services beyond dispensing. The key idea is to 









2 Medication Review as an Implementation of 
Pharmaceutical Care 
2.1 Pharmaceutical Care as Professional Philosophy 
The traditional pharmacists’ role in health care focused on compounding and dispensing 
medicines (Berenguer et al. 2004). This role started to expand in the 1960’s when clinical 
pharmacy services evolved in US hospitals (Berenguer et al. 2004). Through the 
development of clinical pharmacy services pharmacists started to take greater 
responsibility for patient care and optimization of drug therapy. The need for this role 
extension stemmed from alarming reports showing high rates of preventable adverse drug 
events leading to hospital admissions and extra health care costs. 
In the community pharmacy setting the first examples of patient-centered services 
related to medication counseling services. They started to evolve in the 1960’s and 1970’s 
as a consequence of drug catastrophes, particularly thalidomide, which set a demand for 
more open access to drug information to medicine users. The importance of more patient-
centered clinical practice was recognized in a large scale in 1990, when Hepler and Strand 
published their landmark article “Opportunities and Responsibilities in Pharmaceutical 
Care” (Hepler and Strand 1990). 
According to Hepler’s and Strand’s (1990) original definition: “Pharmaceutical care is 
the responsible provision of drug therapy for the purpose of achieving definite outcomes 
that improve a patient’s quality of life”. Cure of disease, elimination or reduction of 
symptomatology, arresting or slowing of a disease process, and preventing a disease or 
symptomatology were stated as desired outcomes. Consistent with this definition, 
pharmaceutical care is provided for the direct benefit of the patient, and the pharmacist 
needs to collaborate closely with the patient, but also with other health professionals so 
that specific therapeutic objectives will be achieved (Hepler and Strand 1990).  
Even if the current definition of pharmaceutical care has slightly changed from the 
original version, the principles and purpose remain the same (Cipolle et al. 1998, 2004). 
Pharmaceutical care is “a patient centered practice in which the practitioner assumes 
responsibility for a patient’s drug-related needs and is held accountable for this 
commitment.” The drug-related needs of a patient include 1) appropriateness of the 
medication; 2) effectiveness of the medication; 3) safety of the medication; and 4) 
compliance of the patient (Cipolle et al. 2004). If all of these drug-related needs are not 
met, a drug-therapy problem (DTP) exists. In pharmaceutical care, the responsibility of the 
practitioner is to ascertain, that all drug-related needs of the patient are met and to identify, 
resolve and prevent DTPs (Cipolle et al. 2004).  
2.1.1 Patient Care Process in Pharmaceutical Care  
In pharmaceutical care, a key idea is to provide standardised care for all patients during all 






pharmaceutical care process (Table 1). The process includes 3 main activities: 1) 
assessment; 2) care plan development; and 3) follow-up evaluation (Cipolle et al. 2004, 
Strand et al. 2004).  
 
Table 1. The activities and standards of care for the process of pharmaceutical care 
(modified from Cipolle et al. 2004, Strand et al. 2004)  




1. Collection of patient specific information 
The practitioner collects patient-specific information for decision-
making concerning all drug therapies. This includes meeting with 
and collecting information from the patient. 
 
2. Assessment of drug-related needs 
The practitioner analyses the collected assessment data to 
determine if the patient’s drug-related needs are being met. That is, 
all the patient’s medications are appropriately indicated, the most 
effective available, the safest possible, and the patient is able and 
willing to take the medications as intended. 
 
3. Identification of drug therapy problems 
The practitioner analyses the assessment data to determine if any 
DTPs are present (includes prioritization of the DTPs to select the 





4. Development of goals of therapy 
The practitioner identifies individualized goals of therapy for the 
patient. 
 
5. Statement of interventions 
The practitioner develops a care plan that includes interventions to 
resolve DTPs, achieve goals of therapy, and prevent DTPs. 
 
6. Establishing a schedule for follow-up evaluations 
The practitioner develops a schedule to follow-up and evaluate the 
effectiveness of drug therapies and assess any adverse events 




7. Follow-up evaluation 
The practitioner evaluates the patient’s actual outcomes and 
determines the patient’s progress toward the achievement of the 
goals of therapy, determines if any safety or compliance issues are 







Assessment. Before making any decisions, patient-specific data, e.g., demographic 
data, clinical information, medical history, medications, but also patient’s attitudes, 
concerns, and medication taking behaviors need to be collected. As a part of the data 
collection, discussion with the patient is necessary for attaining all relevant information. 
The collected information is used to determine if the patient’s drug-related needs are being 
met (Standard 2 in Table 1). Pharmacotherapy workup is a decision-making framework or 
process, by which these determinations can be done systematically (Figure 1).  
 
              Signs and symptoms 
    Abnormal laboratory values         Labs               Clinical 
               Goals of therapy Effectiveness 
   Indication Drug product Dosage regimen Outcomes 
 
    Adverse drug reaction 
       Toxity Safety 
         Labs                  Clinical 
 
Figure 1 Structure of the Pharmacotherapy workup for systematic assessment of patient’s 
drug-related needs (Cipolle et al. 2004) 
The first step is to ascertain whether there is an indication for each medication, what 
product is used to treat the indication, what dosage is taken, and what has been the 
response (gray line in Figure 1). Also untreated indications need to be assessed. If there is 
an appropriate indication for all the used drugs, the outcomes of drug therapy are 
determined both in regard to effectiveness and safety (Figure 1). Effectiveness needs to be 
evaluated against the determined, desired goals of therapy based on laboratory values and 
by the signs and symptoms experienced by the patient (upper part of Figure 1). 
In the next step the safety of drug therapy is assessed similarly to effectiveness (lower 
part of Figure 1). Unsafe pharmacotherapy can be related to the drug product, which is 
causing an ADR, or to too high drug dose causing toxity. After ascertaining the indication, 
effectiveness and safety of the drug therapy, the patient’s compliance needs to be 
evaluated.  
The order of assessing drug-related needs and making decisions is crucial, as there is 
no reason to judge medicine’s effectiveness or safety, if there is no indication for it. Also, 
if the medication is not effective or safe, there is no need for the patient to be compliant. If 
all the patient’s medications are not indicated, effective, safe or taken as indicated, a DTP 
is present. DTPs can exist at any phase of the decision-making framework (Figure 2). 
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Figure 2 Structure of the Pharmacotherapy workup and points where DTPs can occur (Cipolle 
et al. 2004) 
Care plan development. After assessment, individualized, realistic and measurable 
goals of therapy for each indication are identified (Cipolle et al. 2004). Then a care plan 
with interventions to resolve DTPs, achieve goals of therapy, and to prevent new DTPs is 
developed and documented. Both the therapeutic goals and the care plan are discussed 
with the patient, and when appropriate, also with other health care providers. In addition, a 
schedule for future follow-up and evaluation is documented.   
Follow-up evaluation. Follow-up is important part of patient care process that aims to 
determine if the desired goals of therapy have been achieved. The outcomes need to be 
evaluated both for effectiveness and safety. During the follow-up it also needs to be 
assessed whether new DTPs have emerged. 
2.1.2 Implementing Pharmaceutical Care Through Professional Services 
Various pharmaceutical services and practices to implement the philosophy of 
pharmaceutical care have been developed in different countries (Berenguer et al. 2004, 
Farris et al. 2005, Figure 3). Cooperation with medicine users and communication on their 
medications is an essential part of any service designed to be an implementation of the 
philosophy, although patient counseling as such does not meet all the requirements of the 
definition of pharmaceutical care (McGivney et al. 2007). 
Different disease management programs are typical services developed (Figure 3). 
They are available for example in the US, Australia and Portugal to improve clinical 
outcomes in some common chronic conditions, such as diabetes, asthma or hypertension 
(Farris et al. 2005, Knapp et al. 2005). These programs have been demonstrated to be 
successful in improving therapeutic outcomes and quality of life, and in decreasing health 
care costs (Cranor and Christensen 2003, Cranor et al. 2003, Bunting and Cranor 2006). 
These various disease management programs target to specific diseases and do not take 
into account the patient’s entire drug regimen (McGivney et al. 2007). Thus, they do not 
necessarily address all “patient’s drug-related needs” as stated in the definition of 






More comprehensive procedures that take into account all of the patient’s clinical 
conditions and related medication needs have evolved in different countries under the 
concept of medication review (Sorensen et al. 2004, APhA and NACDS 2005, 2008, 
Pharmaceutical Society of Australia 2011). Medication review procedures apply patient 
counseling and disease management as elements to the patient-oriented service (Figure 3). 
These advanced procedures require close collaboration with other health care 
professionals, particularly with physicians (Chen and de Almeida Neto 2007, International 
Pharmaceutical Federation 2009). 
Even if patient counseling as such is not considered as an implementation of 
pharmaceutical care, patient counseling services may serve as a first necessary step for 
community pharmacists towards taking more responsibility in patient care. This happened 
e.g., in Finland: the evolution of pharmaceutical care services started from national, 
coordinated efforts to improve patient counseling services in community pharmacies. For 
that purpose, a national program (TIPPA) was run in 2000–2003 (TIPPA Project 2004, 
Puumalainen 2005, Kansanaho 2006). The program aimed at patient-oriented 
communication practices (TIPPA=Customized Information for the Benefit of the Patient 
from the Community Pharmacy). All the key pharmacy stakeholders, including 
authorities, universities, continuing education centres and professional organizations were 
involved in this extensive program. As pharmacists started to communicate more with 
medicine users they started to see more of the many problems people have with their 
medications. It became evident that all of the problems cannot be solved by counseling, 
and community pharmacists could not solve them alone, without cooperating with other 
health care providers involved in the patient’s care. As a result, a follow-up program for 
TIPPA was implemented in 2004–2007 which focused on developing more advanced 
community pharmacy services and strengthening collaboration between pharmacists and 
other local health care providers. The most important development under the follow-up 
program was establishment of the national procedure for collaborative comprehensive 








Figure 3 Comprehensiveness of patient-oriented services based on the philosophy of 
pharmaceutical care (modified from McGivney et al. 2007). MTM=Medication 
Therapy Management (APhA and NACDS 2008), HMR=Home Medicines Review 
(Sorensen et al. 2004), CMR=Comprehensive Medication Review  
2.2 Medication Review  
There are several definitions of the term medication review. The Australian National 
Prescribing Service (2000) has defined medication review as “a retrospective critical 
review of all prescribed, over-the-counter, and complementary (herbal) medications” with 
the aim to “optimise therapy and minimise medication-related problems”. In the UK the 
task force on Medicines Partnership and the National Collaborative Medicines 
Management Services Programme places more emphasis on the patient in its definition “a 
structured, critical examination of a patient’s medicines with the objective of reaching an 
agreement with the patient about treatment, optimizing the impact of medicines, 
minimizing the number of medication-related problems and reducing waste” (Shaw et al. 
2002). Pharmaceutical Care Network Europe has defined medication review as “an 
evaluation of patient’s medicines with the aim of managing the risk and optimizing the 







Since the definitions of medication review are different, the actual medication review 
procedures created in different countries also differ (Lyles et al. 2001, Harjivan and Lyles 
2002, Fulda et al. 2004, Sorensen et al. 2004, APhA and NACDS 2008, Australian 
Government 2011a,b). The procedures vary from reviews consisting mostly of patient 
counseling aimed at improving adherence, such as Medicines Use Review (MUR) in the 
UK (Department of Health 2005) to comprehensive clinical medication reviews, such as 
HMR in Australia (Sorensen et al. 2004, Pharmaceutical Society of Australia 2011) and 
MTM in the US (APhA and NACDS 2008). Some procedures assess the appropriateness 
of pharmacotherapy against predetermined criteria and standards at the patient level 
during dispensing, such as prospective Drug Utilization Review (pDUR; Fulda et al. 
2004), or on the system level as Drug Regimen Review or retrospective DUR (rDUR; 
Lyles et al. 2001, Harjivan and Lyles 2002) in the US.  
The Pharmaceutical Society of Australia defines medication review as “a systematic 
assessment of a consumer’s medications and the management of those medications, with 
the aim of optimising consumer health outcomes and identifying potential medication-
related issues within the framework of the quality use of medicines. The term ‘medication 
review’ encompasses a continuum of processes in various formats and complexities, 
ranging from an opportunistic discussion to a more comprehensive and proactive approach 
to reviewing the consumer’s medication regimen” (Pharmaceutical Society of Australia 
2010). This definition takes well into account the different levels of medication review.  
Diversity of the medication review procedures has resulted in attempts to categorize 
various procedures by their characteristics and complexity (Shaw et al. 2002, Clyne et al. 
2008, Pharmaceutical Society of Australia 2010). Shaw et al. (2002) classified medication 
reviews into four levels based on the patient involvement and the amount of clinical 
information available to the pharmacist (Table 2). Level 0 medication reviews are 
opportunistic, unstructured ad-hoc reviews. Level 1 prescription reviews are technical 
reviews of patient medication lists without access to medical records or discussions with 
the patient. Level 2 reviews, i.e., treatment reviews are also usually conducted without 
patient involvement, but they include access to full patient notes. Most comprehensive 
third level reviews, “clinical medication reviews”, involve access to medical records, 
assessment of all medications, including OTC and complementary medicines, as well as a 
strong component of patient involvement. 
 
Table 2. Levels of medication reviews according to Shaw et al. (2002) 
Level 0 Level 1 Level 2 Level 3 





A technical review 




A review of 
medicines with 
patient’s full notes 
(not necessarily with 




review of medicines 







The classification by Shaw et al. (2002) fails however to allow categorization of all 
medication review services available in different countries. For example, the MUR by 
community pharmacists in the UK is “a structured adherence-centred review” 
(Pharmaceutical Services Negotiating Committee 2011) which is conducted in 
collaboration with the patient, like the highest Level 3 medication review in the Shaw et 
al. (2002) classification. Still, during MUR, the pharmacist does not have access to full 
patient notes as should be the case even in Level 2 reviews.  
Australian classification of medication reviews resembles the Shaw et al. (2002) 
classification, but is less precise (Figure 4). Different medication review procedures can be 
classified according to how complex and systematic they are. More complex procedures 
require additional training and skills from a pharmacist (Pharmaceutical Society of 
Australia 2010). However, the Australian classification is incomplete in describing patient 
involvement or clinical information available for the reviewing pharmacist. 
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Figure 4 Categorization of medication reviews according to the Pharmaceutical Society of 
Australia (2010, modified). MUR=Medication Use Review; HMR=Home Medicines 
Review; RMMR=Residential Medication Management Review.  
In conclusion, it is most appropriate to use a non-hierarchical classification of 
medication review procedures based on the purpose of the review as suggested by Clyne at 
al. (Table 3; Clyne et al. 2008). Type 1 reviews aim to address prescription-related 
technical issues, e.g., cost-effectiveness, without a requirement of a patient’s presence. A 
prescription review may involve all prescriptions but may cover only one therapeutic area 
(Clyne et al. 2008). Type 2 “Concordance and compliance reviews” aim to explore 
patient’s actual medicine use behaviours and factors that may influence medicines taking. 
Unlike type 1 reviews, OTC and complementary medications are included in type 2 
reviews and patient involvement is usually needed. Type 3, clinical medication reviews 
are conducted with the patient present and with full access to patient’s medical notes and 
laboratory test results which allows review of medications against clinical conditions. 







Table 3. Types of medication review according to Clyne et al. (2008, modified) 
 Type 1  
Prescription review 
Type 2  
Concordance and 
compliance review 
Type 3  
Clinical medication 
review 
Purpose Address technical 
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clinical patient notes, 
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prescription 
medications included 
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In addition to differing in complexity, patient involvement and availability of clinical 
patient information, various medication reviews also have dissimilarities with regard to 
level of multiprofessional collaboration and the setting where the reviews are conducted. 
Some review procedures are developed only for inpatient settings like Residential 
Medication Management Review (RMMR) in Australia. Other are aimed only at 
community-dwellers, like the HMR in Australia. In some procedures the pharmacist’s 
communication with the physician is mandatory (HMR), in others the physician is 
contacted as needed (MUR). 
The literature review for this thesis focuses on Type 3 (Clyne et al. 2008) clinical 
medication review procedures in outpatient settings focusing on studies describing 
reviews among elderly patients. Because HMR in Australia and MTM in the US were 
used as models when the Finnish CMR procedure was developed, only these two are 






2.2.1 Medication Therapy Management (MTM)  
Background 
In the United States Johnson and Bootman estimated in 1995 that annual costs associated 
to mortality and morbidity due to DRPs in the ambulatory setting would amount to USD 
76.6 billion (Johnson and Bootman 1995). When Ernst and Grizzle (2001) updated the 
estimate for year 2000, the annual costs of drug-related morbidity and mortality exceeded 
USD 177.4 billion. In 1998 it was estimated, that ADRs were between the fourth and sixth 
frequent cause for death in US hospitals (Lazarou et al. 1998). Among older outpatients 
the medication-related problems have been frequent in the USA with 50.1 ADEs occurring 
per 1000 person years (Gurwitz et al. 2003). It is noteworthy, that 27.6% of the ADEs 
were estimated as preventable. 
The health care system in the USA is diverse because of the variety of insurance 
providers. The public sector is responsible for providing two types of insurance: state-
managed Medicaid for low-income citizens, and government-provided Medicare for 
people aged >65 years, and for younger disabled persons (Christensen and Farris 2006). 
Most citizens however obtain insurance through their employers or purchase it themselves. 
The private sector is not required to follow the regulations of the public sector. Also the 
fact that the pharmacies in the US are regulated by the individual states instead of the 
Federal Government makes pharmacy services in different parts of the country diverse.  
Various pharmaceutical care services for outpatients have been available in the US for 
almost two decades (Cranor et al. 2003, Kuo et al. 2004, Knapp et al. 2005, Stubbings et 
al. 2011). In some states’ Medicaid programs pharmacists have been paid for resolving 
DRPs and providing disease management services for individual patients since the mid-
1990’s (Kuo et al. 2004). Also private payers have had successful programs to involve 
pharmacists in patient care almost as long (Cranor and Christensen 2003, Kuo et al. 2004). 
Different disease management programs have been successful in improving care results 
and quality of life, and in decreasing health care costs (Cranor and Christensen 2003, 
Cranor et al. 2003, Bunting and Cranor 2006, Bunting et al. 2008, Carter et al. 2009).  
Nationally pharmaceutical care services became recognized in the US in 2003 when 
the Federal Government passed the Medicare Prescription Drug, Improvement and 
Modernization Act; MMA 2003 (The Medicare Prescription Drug, Improvement and 
Modernization Act 2003). MMA 2003 required that from January 2006 Medicare part D 
insurers provide Medication Therapy Management (MTM) services for their selected 
beneficiaries to optimize therapeutic outcomes by improving medication use and reducing 
adverse drug events (The Medicare Prescription Drug, Improvement and Modernization 
Act 2003, Pellegrino et al. 2009). MMA 2003 identified three key goals for MTM 
services: 1) provision of education and counseling to improve enrollee’s understanding of 
their medication; 2) improvement of medication adherence; and 3) detection of ADRs and 
patterns of improper prescription drug use (MMA 2003, Pellegrino et al. 2009). 
Pharmacists were the only health care professionals specifically named as providers of 






eligibility criteria, and determination of the details of service provision, including 
interventions were left to be determined by the Part D Providers (Medicare Prescription 
Drug, Improvement, and Modernization Act of 2003). In 2010, the minimum Medicare 
MTM eligibility criteria included drug cost threshold of USD 3000 for part D drugs, use 
of 2–8 drugs, and having 2 or 3 chronic conditions (Centers for Medicare & Medicaid 
Services 2010). In contrast to Medicare programs, MTM programs provided in the private 
sector rarely have specific eligibility criteria depending on specific number of drugs or 
condition or specific drug cost threshold (Abt Associates 2008). 
As a response to MMA legislation, 11 US pharmacy organizations developed a 
consensus definition for MTM in 2004 (Bluml 2005). According to this statement MTM is 
“a distinct service or group of services that optimize therapeutic outcomes for individual 
patients” and are independent of provision of a medication product, but can occur in 
conjunction with that. Based on the consensus definition, MTM encompasses a wide range 
of activities and responsibilities based on the needs of the individual patient. These 
include, e.g., formulation of a medication treatment plan, monitoring and evaluating the 
patient’s response to therapy, including safety and effectiveness, performing a 
comprehensive medication review to identify, resolve, and prevent medication-related 
problems, and providing information, support services, and resources designed to enhance 
patient adherence. 
Operationally, MTM programs should provide individualized, patient-specific care. 
Face-to-face interaction between the patient and the pharmacist was defined as the ideal 
method for providing this care (Bluml 2005). In practice, MTM services vary from 





















Figure 5 Medication Therapy Management (MTM) services to optimize therapeutic outcomes 






Core Elements of MTM Service Model 
Building on the MTM consensus definition (Bluml 2005), The American Pharmacists 
Association (APhA) and the National Association of Chain Drug Stores Foundation 
(NACDS) established a model framework for implementing MTM services in the 
community pharmacy setting (APhA and NACDS 2005). A 2008 update of the document 
focuses on providing MTM in settings where the patients or care givers can be actively 
involved in the process (APhA and NACDS 2008). In all, collaboration between patients, 
pharmacists, physicians and other health care professionals is important in the MTM 
service model.  
According to the framework, MTM services include five core elements: 1) a 
medication therapy review (MTR); 2) an intervention and/or a referral; 3) a personal 
medication record; 4) a medication-related action plan; and 5) documentation and follow-












Medication therapy review can be comprehensive or targeted, depending on the needs 
of the patient (APhA and NACDS 2008). In comprehensive MTR the patient provides the 
pharmacist with information of all medications taken, including OTC medicines and 
complementary medicines. The pharmacist may also gather data on e.g., medical history 
and patient thoughts and experiences of their pharmacotherapy. Interpretation of 
laboratory test results and assessment of quality of life can also be part of the procedure. 
The pharmacist reviews the medications for medication-related problems against the 
patient’s complete medical and medication history. Consistent with the principles of 
pharmaceutical care (Chapter 2.1), DRPs related to indication, effectiveness, safety and 
adherence are covered (Figure 6). After identifying the problems, the pharmacist develops 
a care plan to resolve them. The interventions resulting from MTR depend on the nature of 
the problems (Figure 6), and may involve collaboration with physician or other health care 
professionals to agree on actions. Targeted MTRs are ideally meant to complement 
comprehensive MTRs, so that the pharmacist can monitor the patient’s situation and 
address new medication-related problems. 
In order to improve medication self-management, a personal medication record and a 
medication action plan are developed for the patient (APhA and NACDS 2008; Figure 6). 
The medication record includes a comprehensive list of the patient’s medications, possibly 
complemented with indications, instructions for use and other useful information (APhA 
and NACDS 2008). The medication action plan contains actions for the patient’s self-
management of his/her conditions to achieve specific health goals. In 2010 Medicare 
required some kind of written or printed material of MTM to be provided to the patient, 
but medication action plan and personal medication record are stated only as possible 
options not as mandatory documents (Centers for Medicare & Medicaid Services 2010).  
Follow-up MTM visits or transition of care are agreed on based on individual needs of 
the patient (APhA and NACDS 2008, Figure 6). All services and interventions are 
documented in order to follow patient progress and to be used in billing of the services.  
The MTM procedure described in this chapter represents a preferred method of service 
delivery by pharmacists, but MTM guidelines have been developed also from the 
perspective of other stakeholders (Consensus Document Workgroup 2006, APhA and 
NACDS 2008, Pellegrino et al. 2009). For example, insurers prefer other than face-to-face 
methods of MTM delivery in their guidelines, in particular telephonic communication 
(Pellegrino et al. 2009). 
Outcomes of MTM Studies 
As a result of the lack of rigorous official guidance, the MTM services developed under 
Medicare part D have great variability in their patient eligibility criteria, type of services 
provided and the way services are provided (Touchette et al. 2006, Schommer et al. 2008 
a,b, Centers for Medicare & Medicaid Services 2010). In addition, there are various MTM 
programs independent of Medicare. Many pharmaceutical care services implemented 
before the MTM legislation comply with the principles of MTM (Barnett et al. 2009, 






significantly changing from providing mainly patient education regarding acute 
medications towards services involving collaboration with prescribers and focusing more 
on cost-effective management of chronic conditions (Barnett et al. 2009). Simultaneously, 
the estimated cost avoidance due to diminished use of other health care resources 
increased from USD 24/encounter in 2000 to USD 429 in 2006 (Barnett et al. 2009).  
Because of the significant variation in and evolution of MTM services, this literature 
review will focus on recent studies where the intervention is comparable to the core 
elements of MTM service model presented in the previous chapter (APhA and NACDS 
2008) or complies with the standards of practice of pharmaceutical care (Cipolle et al. 
2004, Strand et al. 2004; Table 1). Thus, the studies reviewed should have a pharmacist 
intervention that includes a direct patient contact and a MTR where the entire drug 
regimen is reviewed for effectiveness, safety, indication and adherence. According to the 
overall context of this thesis, i.e., elderly outpatients, studies that involve inpatients or 
only patients aged <65 years, e.g., employees, are excluded. However, MTM studies 
involving only elderly patients are rare, and thus, other studies with at least some elderly 
patients involved are included to provide better insight on the potential outcomes of 
MTM. Disease state management programs that focus solely on management of certain 
chronic conditions such as asthma or diabetes, and lack comprehensive review of the 
patient’s complete medication regimen, were excluded. Overall, there are hundreds of 
studies examining patient-related outcomes of pharmacist-provided direct patient care in 
the USA. A meta-analysis of these studies indicates that pharmacist-provided care is 
beneficial in e.g., improving therapeutic outcomes, reducing ADEs and increasing 
adherence (Chisholm-Burns et al. 2010). 
In total 17 published MTM studies matching the inclusion criteria were found (Table 
4). The quality of most studies was good in relation to having a controlled study design 
and long follow-up periods (Table 4). However, several of the studies had a relatively 
small study sample or were based solely on retrospective analysis of MTM documentation 
and even if controlled, lacked randomization of patients (Table 4). Also, in several studies 
a significant proportion of patients were younger than 65 years.  
Several studies indicate that MTM services can improve clinical health outcomes and 
result in cost-savings through avoidance of the need to use other health care resources 
(Isetts et al. 2003, 2008, Lewis et al. 2008, Fox et al. 2009, Planas et al. 2009, Ramalho de 
Oliveira et al. 2010; Table 4). Even if not the strongest in its methodology, the largest of 
such studies with the longest follow-up period was conducted in Minnesota, where a large 
health care provider organization, Fairview Health Services, implemented standardized 
pharmaceutical care service in 1998 (Ramalho de Oliveira et al. 2010). In the Fairview 
MTM program pharmaceutical care, including desired goals of therapy, change in clinical 
status at the follow-up encounters and estimated health care savings, are systematically 
documented by the pharmacists. According to a large retrospective study analyzing such 
MTM documentation of 9 068 patients during 1998–2008, more than half (55%) of the 12 
851 medical conditions not at goal at enrollment improved during MTM and 23% were 
unchanged (Ramalho de Oliveira et al. 2010). For a subset of 110 patients with diabetes 
the therapeutic goals were met by 43% after MTM, compared to 17% at the initial visit. 






outpatient visits or hospitalizations, was USD 86, which exceeds the costs of MTM by 
USD 19/encounter. Another study using 4 years of pharmacists’ MTM documentation 
from 2000 to 2003 (n=2 985) indicated that 32% of the total of 16 132 conditions 
improved as a result of MTM while there was no change in 56% (Strand et al. 2004). In 
this study the estimated cost avoidance was USD 98 per encounter, which is USD 50 more 
than the average cost of one MTM visit. Other studies from Minnesota indicate that MTM 
increases the overall percentage of therapeutic goals achieved from 74–76% to 89–90% 
according to pharmacists’ documentation (Isetts et al. 2003, 2008, Table 4). According to 
chart audits, the proportion of patients meeting goals for hypertension (71% vs. 59%, 
p=0.03) and cholesterol (52% vs. 30%, p=0.001) was higher among MTM patients than 
among control patients with hypertension and hyperlipidemia (Isetts et al. 2008). 
The IMPROVE study, a prospective RCT among high-risk patients of 9 Veterans 
Affairs Medical centers (n=523) evaluated the effect of MTM on several outcomes over a 
1-year follow-up period (Ellis et al. 2000a, Malone et al. 2000, Malone et al. 2001, Table 
4). Among a subgroup of patients with hypercholesterolemia (n=208) the total cholesterol 
levels (-17.7 vs. 7.4 mg/dl) and LDL (-23.4 vs. -12.8 mg/dl) decreased significantly more 
for intervention than for control patients (Ellis et al. 2000a). However, there was no 
difference in the proportion of patients achieving goal lipid values. With regard to HRQoL 
the bodily pain domain and change in health status -rating declined significantly less 
compared to controls over time (Malone et al. 2001). However, the changes were not 
considered to be clinically meaningful. The intervention had no effect on hospitalizations, 
but increased the number of clinic visits compared to the controls (p=0.003), mainly 
because of pharmacist encounters (Malone et al. 2000). However, there was no difference 
in overall health care costs (Malone et al. 2000). Consistently, in another non-randomized 
controlled study among patients with heart or lung disease (n=231) MTM had no effect on 
hospitalizations or total health care charges compared to controls, but resulted in 
significantly greater increase in the number of clinic visits (1.2 vs. -0.9) and medications 
(1.0 vs. 0.2) (Fischer et al. 2002). 
Studies on the effects of MTM on hospitalizations show inconsistent results (Malone et 
al. 2000, Fischer et al. 2002, Taylor et al. 2003, Welch et al. 2009). Some studies show no 
effect compared to controls (Malone et al. 2000, Fischer et al. 2002). In a RCT conducted 
in Alabama MTM patients had significantly greater decrease in annual number of 
hospitalizations and emergency department (ED) visits compared to controls (Taylor et al. 
2003). In Colorado, on the other hand, patients opting in to a MTM program (n=459) were 
more likely to have a hospitalization (OR 1.4) than the control patients opting out (n=336), 
but there was no difference in ED visit rates (Welch et al. 2009). However, the 
intervention patients were less likely to die than the controls (OR 0.5). 
The economic impact of MTM is variable (Table 4). Several studies indicate that there 
is no effect on total health care costs (Malone et al. 2000, Fischer et al. 2002, Chrischilles 
et al. 2004). Beneficial results have been found e.g., in Minnesota, where total annual 
health care expenditures per intervention patient (n=285) decreased from USD 11 965 to 
USD 8 197 (p<0.001) according to claims data (Isetts et al. 2008). Thus, the reduction in 
other health care costs exceeded the cost of providing MTM services by 12:1. In 






savings according to claims data were USD 472/MTM patient compared to the previous 
year (Smith et al. 2011). The savings of medication claims costs were even higher, USD 
1123/patient. However, lack of a control group may skew the results. Some studies have 
shown no significant change in prescription costs (Christensen et al. 2007, Fox et al. 2009) 
and even increased costs have been reported (Isetts et al. 2008, Welch et al. 2009). 
MTM can have a beneficial effect on appropriateness of pharmacotherapy (Taylor et 
al. 2003, Chrischilles et al. 2004). In two studies MTM improved the Medication 
Appropriateness Index and in one decreased the use of potentially inappropriate 
medications by elderly patients (Taylor et al. 2003, Chrischilles et al. 2004). 
Patient satisfaction in MTM has been high (Christensen et al. 2007, Ramalho de 
Oliveira et al. 2010). In Minnesota a survey was administered to all 1132 patients enrolled 
to MTM program in 2008 (Ramalho de Oliveira et al. 2008). Of the respondents (n=317) 
94% indicated that their overall health and wellbeing had improved after MTM. MTM has 
also increased patient knowledge on their medications (Taylor et al. 2003, Lewis et al. 
2008). Still, results of the impact of MTM on adherence remain controversial (Taylor et al. 












Study population Outcome measures Main results 
Chrischilles 










Medicaid enrollees: ≥4 
medications, including 
≥1 for 12 specific 
diseases (n=524 
interventions, n=1 687 
controls), mean age 53 
years (28% aged ≥65) 
Medication Appropriateness 
Index (MAI) 
Use of PIMs (Beers 1997) 
Health care utilization 
(inpatient, outpatient, 
medical service and ED 
utilization and charges) 
MAI score improved (from 9.4 to 8.3, p<0.001) 
Proportion of recipients aged 65 years or older using 
inappropriate medications decreased (from 43% to 
32%, p<0.05) 
No difference in health care utilization or charges 
between cases and controls. 
Christensen 






with claims analysis 
6 months before and 
after MTM, 2 control 
groups  
Polypharmacy patients 
enrolled to State Health 
Plan (n=67), mean age 
68 years, 60% aged ≥65, 
2 control groups (n=689, 
n=870) 
DTPs* 
Number and costs of 
dispensed medications 
Patient satisfaction with 
services 
Prescription drug use decreased only among control 
group patients. 
No change in prescription costs. 
Patients valued the service (89% were satisfied with 
the review of medications and quality of information 
provided by the pharmacist) 








Patients from 9 Veterans 
Affairs medical centers 
meeting ≥3 of 
predetermined 6 criteria 
e.g., ≥5 medications, ≥3 
diseases (n=208 
interventions, n=229 
controls), mean age 67 
Change in cholesterol and 
LDL 




visits, drug costs, laboratory 
costs) 
Greater positive change in the total cholesterol and 
LDL in the intervention group (p<0.05) 
No differences between groups in patients achieving 










HMO enrollees with 
heart or lung disease in 
3 intervention (n=231) 
and 3 control 
pharmacies (n=444), 
aged ≥18, mean age 57 
Change in: 
Number of clinic visits,  
Number of unique medications 
Total (inpatient, outpatient, 
pharmacy) charges 
DTPs* 
Greater increase in number of clinic visits (p<0.01) 
and number of unique medications (p<0.05) 
compared to controls 
No difference in total number of prescriptions 
dispensed, mean number of hospital days, proportion 










Study population Outcome measures Main results 








Medicare enrollees with 
diabetes, ≥3 chronic 
conditions, ≥4 drugs, 
estimated annual drug 
costs >USD 4000. 
(n=255 MTM, n=56 
MTM eligible not 
having MTM, n=1 803 
not MTM eligible, 
having comprehensive 
diabetes care), mean age 
68 years 
LDL  
Drug costs (9 first months of 
the intervention year vs. 9 




Higher proportion of patients in the MTM group 
(69%) had appropriate LDL levels compared to 
MTM nonparticipants (50%) and enrollees with 
comprehensive diabetes care (54%), p<0.001 
Average LDL in the MTM group was lower (83 
mg/dl) compared to the diabetes care patients (94 
mg/dl; p<0.001), but not to MTM non-participants 
(91 mg/dl) 
No significant drug cost savings compared to 
controls 
 












decisions by a 12-
member expert panel 
Patients seen at 6 
Fairview clinics  (n=2 
524), 48% aged ≥65 
years (range 3–97 years) 
Rate of therapeutic goals 
achieved as documented by 
pharmacists (n=16 406 
medical conditions) 
Quality of pharmacists’ 
therapeutic determinations 
(sample of 15 patient 
records) 
The rate of therapeutic goals achieved increased from 
74% to 89% of the medical conditions 
94% of the pharmacists’ decisions were clinically 
credible 
 







controls (for patients’ 
perception of care) 
Uncontrolled before-
after study (for 
HRQoL)  
6 months follow-up 
 
Patients with expected 
high resource use and 
≥1 of 12 conditions 
(n=285 interventions in 
6 clinics, 285 matched 
controls in 9 clinics), 
median age 54 years 
(range 20–85), 14% 
aged ≥65 years 
Patients’ perception of care 
HRQoL (SF-12) 
No difference in perception of care between 
interventions and control patients 
Improvement in 3 of 10 dimensions of HRQoL: 
physical role (p=0.001); social functioning 
(p=0.014); and physical component summary scale 










Study population Outcome measures Main results 







with control groups 
(for hypertension and 
hypercholesterolemia)
Uncontrolled before-
after study based on 
MTM documentation 
(for all goals of 
therapy) 
1-year follow-up 
Same study group as in 
Isetts et al. 2006 (n=285 
interventions, n=126 
comparisons with 
hypertension and n=128 
with hyperlipidemia) 
DRPs* 
Proportion of intervention 
patients’ all goals of therapy 
achieved as documented by 
pharmacists 
Proportion of patients 
achieving goals for hypertension 
and hypercholesterolemia 
based on chart audit 
Total health expenditures 
(facility, medical and 
prescription claims) 1 year 
before and after MTM 
Percentage of intervention patients’ goals of therapy 
achieved increased from 76% to 90% 
Proportion of patients meeting goals for hypertension 
(71% vs. 59%, p=0.03) and cholesterol management 
(52% vs. 30%, p=0.001) was greater in the 
intervention than control group 
Total annual health expenditures/intervention person 
decreased 32% from USD 11 965 to USD 8 197 
(p<0.001), even if drug costs increased by 12% 







3 months follow-up 
Patients with ≥4 long-
term medications 
(n=67), aged ≥18, mean 




Patient knowledge on 
medications, diagnoses, and 
healthy lifestyle practices 
Patients’ opinion on their health 
Effects on patient outcomes 
as assessed by pharmacists 
Patient knowledge better at final evaluation 
compared to initial assessment (p<0.001) 
59% of patients indicated improved health at follow-
up visit 
Pharmacists evaluated that disease control improved 
for 75% of patients, adherence improved for 56% and 











12 months follow-up 
Patients from 9 Veterans 
Affairs medical centers 
meeting ≥3 of 6 
predetermined criteria 
(e.g., taking ≥5 drugs, 
≥3 chronic conditions)  
(n=523 interventions, 
n=531 controls), mean 
age 67 years 
Health care resource 
utilization 12 months before 
and after the intervention 
(number of clinic visits, 
number of drug fills, 
hospitalizations, clinic and 
total health care costs) 
HRQoL (SF-36) 
Number of clinic visits increased more for 
intervention patients (p=0.003) 
No difference in number of hospitalizations, prescription 
fills or total health care costs between groups 
Intervention patients declined less than controls for 
bodily pain domain (-2.4 vs. -6.3 units; p=0.004) and 
for change in health status -rating (-6.3 vs. -2.4 units; 
p<0.004), not considered as clinically significant. No 










Study population Outcome measures Main results 






9 months follow-up 
 
Patients with diabetes 
and hypertension, (n=32 
interventions, n=20 
controls), mean age 64 
years 
Systolic blood pressure 
(SBP) 





Mean SBP decreased 17.32 mmHg, increased 2.73 
mmHg in controls (p=0.003) 
Proportion of patients at goal BP increased from 16% 
to 48%, decreased from 20% to 7% in controls. 
Intervention patients 12.9 times more likely to 
achieve goal SBP (p=0.021) 










survey for new MTM 
enrollees in 2008 
Patients enrolled in 
Fairview Health 
Service’s MTM 
program, aged ≥21 (n=9 
068), 45% aged ≥65 
years 
DRPs* 
Change in clinical outcome 
status as evaluated by the 
pharmacist during follow-up 
Estimated cost-avoidance 
Clinical status of diabetes 
(n=110) 
Patient satisfaction (n=317, 
response rate 28%) 
Of the 12 851 medical conditions not in goal, 55% 
improved during MTM. 
Proportion of diabetics meeting clinical goals 
increased (17% vs. 43%) 
Pharmacist-estimated cost-saving of USD 2.9 
million, USD 86/encounter 
Cost of providing MTM USD 67/encounter (return of 
investment 1.29) 
94% of respondents agreed that their overall health 
and wellbeing had improved. 




after study with 
claims analysis 12 
months before and 
after MTM 
Medicaid patients, mean 
age 51 years (n=88) 
DTPs* 
Annual health care costs 
(total medical, hospital, 
pharmacy and ED Medicaid 
claims) 
Total annual cost saving compared to the year before 
MTM) USD 434 465/study group. 
Annual medication claim cost saving USD 
1123/patient. 
Annual cost saving USD 472/patient for medical, 
hospital and ED visits. 








Patients aged 18–100 
years, 52% aged >65 
years (n=2 985) 
Change in clinical status 
Health care cost savings 
(both evaluated by 
pharmacists) 
Clinical status improved for 32% of the total 16 132 
medical conditions, no change for 56%. 
Total health care savings USD 1 134 162, mostly 
relating to avoiding outpatient clinic visits (USD 585 











Study population Outcome measures Main results 






12 months follow-up 
 
High risk patients of 3 
family medicine clinics 
with 3 or more of 6 risk 
factors, e.g., ≥5 
medications, ≥3 diseases 
(n=33 intervention, 
n=36 control), mean age 
64 years 
Annual hospital and ED 
visits compared to the year 
before enrollment 
Meeting of therapeutic goals 








Greater decrease in annual number of hospitalizations 
(-22 vs. 0; p=0.003) and ED visits (-12 vs. 0; 
p=0.044) compared to controls 
Proportion of patients responding to hypertension, 
diabetes, dyslipidemia and anticoagulation therapy 
increased significantly in the intervention group and 
decreased in the control group. 
MAI index improved in all 10 domains, decreased in 
5 domain for controls. 
No difference in HRQoL between groups. 
Medication compliance scores improved in 
intervention, not in control group. 
Medication knowledge scores improved 36%, 
decreased 15% in control group (p<0.0001) 





out patients as 
controls) 
Follow-up 180 days 
Medicare enrollees with 
≥2 chronic conditions, 
≥5 medications, at least 
USD 4000 medication 
costs (n=459 opt-in, 
n=336 opt-out), mean 
age 69 years 
Mortality 
Health care utilization 
(hospitalization, ED visits) 
Prescription medication costs 
(changes 180 days following 
the intervention) 
DRPs* 
Opted-in less likely to die (OR 0.5), 
but more likely to have a hospitalization (OR 1.4) or 
increased medication costs (OR 1.4) 
No difference in ED visit rates between groups 
DRP=Drug-related problem, DTP=Drug therapy problem, ED=Emergency department, HRQoL=Health-related quality of life, MAI= Medication Appropriateness 
Index (Hanlon et al. 1992), OR=Odds ratio, PIM=Potentially inappropriate medication, RCT=Randomized controlled study 







2.2.2 Home Medicines Review (HMR) 
Background 
In Australia 2–4% of hospital admissions, i.e., approximately 150 000 admissions 
annually, are estimated to be medication-related (Runciman et al. 2003). Among elderly 
Australians as much as 26% of hospital admissions have been attributable to ADEs. Of 
medication-related hospital admissions, 32–77% are estimated to be preventable. In the 
community setting in Australia there are 10 million physician consultations every year, 
more than 10% of all general practitioner (GP) visits, estimated to involve a patient with 
an ADE, the problem being more common among older people (Miller et al. 2006).  
In the late 1980’s and early 1990’s the Australian government recognized the need to 
improve the quality and safety of medication use in aged care facilities (Roughead et al. 
2003). As a result, the first medication review service in Australia, the Residential 
Medication Management Review (RMMR), was granted commonwealth funding in 1995 
by the Australian Government Department of Health and Ageing (Roughead et al. 2003). 
The RMMR services are aimed at permanent residents of aged care facilities, and thus, are 
not in the scope of this literature review. Nevertheless, studies of pharmacist-provided 
services in aged care facilities resulted in positive outcomes including medication cost 
savings, improvement of quality of life and decreased use of potentially harmful 
medicines, such as benzodiazepines (Roberts et al. 2001, Roughead et al. 2003). As a 
result, funding for medication review services for home-dwelling elderly was agreed on in 
2000 (Commonwealth of Australia 2000) and introduced in the Medical Benefits Scheme 
in 2001 (Benrimoj and Roberts 2005).  
HMR Procedure 
The Home Medicines Review (HMR), earlier referred as Domiciliary Medication 
Management Review (DMMR), is aimed at home-dwelling people to maximize benefits 
of medicine regimen and prevent medication-related problems (Australian Government 
2011b). The main objective is to achieve safe, effective and appropriate use of 
medications by detecting and addressing medication-related problems, to improve the 
patients’ quality of life and health outcomes, and to increase the patients’ and health 
professionals’ knowledge on medicines.  
Cooperation between health professionals is important in HMR. The procedure 
involves the patient’s general practitioner, an accredited pharmacist, and other relevant 
health care practitioners, e.g., community nurses or carers, as well as the patient’s regular 
community pharmacy (Pharmaceutical Society of Australia 2011). From the development 
phase of HMR, close collaboration between community pharmacists and GPs was seen as 
a key to successful establishment of new clinical pharmacy services in the ambulatory care 
setting (Chen et al. 1999a, Roberts et al. 2005) and innovative initiatives to enhance the 






The pharmacist providing HMR must be accredited by the Australian Association of 
Consultant Pharmacy or the Society of Hospital Pharmacists of Australia (Australian 
Association of Consultant Pharmacy 2011, Pharmaceutical Society of Australia 2011). 
The accreditation process includes completing a preparatory training course, submission 
of a mandatory portfolio of experience, and completing a multiple-choice-question exam 
and a case-study-based assessment. The accreditation must be renewed annually by a self-
assessment survey and completion of a continuing professional development log for the 
previous 12 months. The multiple-choice-question exam is repeated every three years.  
The HMR follows a systematic structure (Figure 7). Patients likely to benefit from 
HMR may be identified by a GP, hospital pharmacist at discharge, community pharmacist, 
another member of the health care team, the patient, or their care giver (Pharmaceutical 
Society of Australia 2011). The HMR process is officially initiated by the GP who 
determines that the review is clinically necessary to ensure quality use of medicines or to 
address patient’s needs (Australian Government 2011b). Examples of risk factors that may 
result in referral for HMR include e.g., patients that are taking ≥5 regular medicines, more 
than 12 doses of medicines per day or a medicine that has narrow therapeutic index or 
requires therapeutic monitoring (Australian Government 2011b, Pharmaceutical Society of 
Australia 2011). In addition, patients with symptoms suggestive of an ADR, or who are 
seen by a number of different physicians, or who have been recently discharged from 
hospital or had remarkable changes in their medicines, or have difficulty managing their 
medicines because of e.g., impaired sight are also likely to benefit from HMR.  
 






The GP obtains an informed consent from the patient and makes a referral with 
relevant patient information to the patient’s preferred pharmacy or directly to an 
accredited pharmacist (Pharmaceutical Society of Australia 2011). An accredited 
pharmacist conducts a patient interview, preferably at the patient’s home. The aim of the 
interview is to collect information to inform the HMR report and to provide medicines- 
and health-related education and support. The responsiveness to home visits has been 
good, as it provides a comfortable environment for conversation compared to the 
pharmacy and gives an opportunity to ask questions and learn more about medications in 
familiar surroundings (Chen and Larkin 2002). The findings from the patient interview 
together with clinical patient data are used to conduct the review and to identify range of 
medication-related problems (Pharmaceutical Society of Australia 2011). These include: 
• Medication use without indication 
• Untreated indication 
• Improper drug selection, including inappropriate cost-effectiveness 
• Sub-therapeutic dosage, overdosage 
• Continued use of medication for a condition that has been resolved or step 
down therapy for a condition that is well controlled 
• ADRs 
• Drug-drug, drug-disease, drug-food or drug-laboratory test interaction 
• Failure to receive medication 
• Dose/drug related issues, such as confusing schedules, storage issues, dosage 
forms, dosing interval, timing or dosing 
• Medication management issues, such as incorrect medication use 
• Incorrect use and suitability of, or the need for, compliance aids, therapeutic 
devices and appliances 
• Need for written/verbal information and education regarding safe and effective 
use of medications, therapeutic devices, compliance aids and self care activities 
  
In order to identify potentially inappropriate prescribing, the following tools are 
suggested to be used as reference guides (Pharmaceutical Society of Australia 2011): Drug 
Burden Index (Hilmer et al. 2007); The Beers criteria (Fick et al. 2003); McLeod criteria 
(McLeod et al. 1997); The Medication Appropriateness Index (MAI) (Hanlon et al. 1992); 
the Screening Tool of Older Persons’ Prescriptions (STOPP) and the Screening Tool to 
Alert doctors to the Right Treatment (START) (Gallagher et al. 2008a); and/or the 
Australian Prescribing Indicators Tool (Basger et al. 2008). Several software programs are 
available for the pharmacists to assist in conducting the reviews and reporting the findings 
to physicians (Rigby 2004). Some of the programs also contain decision support tools 
(Rigby 2004). 
After reviewing medications the pharmacist prepares a written report with findings and 
evidence-based recommendations. The report is sent to the referring GP and the patient’s 
preferred pharmacy. The pharmacist may discuss the findings with the GP, but a face to-
face case conference is not mandatory even if it has resulted in higher acceptance rate of 
pharmacist recommendations by physicians than a written report (Penrose-Wall et al. 






management plan with agreed therapeutic goals, treatment regimens and lifestyle 
adjustments (Pharmaceutical Society of Australia 2011). The management plan is 
delivered to the community pharmacy to be used as a basis for ongoing follow-up, 
monitoring and support.  
Outcomes of HMR Studies 
The outcomes of HMR studies were assessed by searching articles from the databases 
PubMed and Scopus and by completing the search with articles retrieved from the 
reference lists of reviewed relevant articles and received from collaborative Australian 
researchers. Two comprehensive reports about HMR Program were used to ascertain that 
all relevant articles were found. The first was prepared by Urbis Keys Young for the 
Pharmacy Guild of Australia in 2005 to evaluate the pharmacy component of the HMR 
Program. It included HMR-related literature review up to April 2005 (Urbis Keys Young 
2005). The second was prepared by Campbell Research & Consulting (2008) for the 
Australian Department of Health & Ageing, Medication Management & Research Section. 
Their report included review of medication management and HMR Program related 
articles, including grey literature from 2005 to January 2008. In addition, the report 
included articles retrieved by a public call for submissions. Based on the two reports, there 
is no strong clinical evidence to support the effectiveness of HMR (Urbis Keys Young 
2005, Campbell Research and Consulting 2008).  
A total of 9 HMR-related studies published in the scientific literature and three 
research reports were retrieved for this literature review (Nissen and Tett 2002, Urbis 
Keys Young 2005, Stafford et al. 2011, Table 5). Several of the studies have small study 
populations or are otherwise methodologically weak (Table 5). This is particularly true of 
the research report by Urbis Keys Young (2005). The study is based on an interview of 
patients (n=57) who had received a HMR 3–12 months earlier. During the interview, they 
retrospectively evaluated their HRQoL and health care use before and after HMR – a 
method which cannot be considered as reliable. In addition, 7 of the 12 retrieved studies 
were partly or entirely based on an analysis of HMR case reports (Table 5). 
Only two randomized, controlled trials have been published regarding outcomes of 
HMR services (Sorensen et al. 2004, Nissen and Tett 2005, Table 5). In the first study 
pharmacists made to physicians an average of 6.8 recommendations per intervention 
patient (n=110), of which 54% were acted on (Sorensen et al. 2004). Six months after the 
intervention physicians reported that the proportion of intervention patients experiencing 
ADEs had decreased from 37% to 9% while there was no significant change for the 
control patients (Sorensen et al. 2004). There were no statistical differences in the number 
of hospital admissions, cumulative bed days, number of GP visits, self-reported ADEs, 
severity of illness scores or HRQoL between intervention and control patients. The 
intervention had no effect on medication costs and only an ongoing trend towards 
reduction in healthcare service costs. According to the authors, the lack of statistical 






study outcomes, 92% of GPs and 94% of pharmacists perceived that HMR had improved 
the care of participating patients (Sorensen et al. 2004).  
The second RCT was a project funded by the Australian Government Department of 
Health and Ageing and involved patients from two rural study sites (Nissen and Tett 
2005). Pharmacists made on the average 7.6 recommendations per intervention patient 
(n=88), of which 61% were accepted by physicians. Analysis of the recommendations 
revealed that 91% of them were evidence-based. When using both Pharmaceutical and 
Medical Benefit Scheme data, annual before-after health care costs rose for both 
intervention and control patients, but the increase was AUD 1411 lower for intervention 
patients. However, the intervention had no effect on the patients’ HRQoL when measured 
after 12 months.   
Only two studies of the economic effects of HMR (Krass and Smith 2000, Stafford et 
al. 2011) were retrieved in addition to the two RCTs described earlier. The first was based 
on an analysis of HMR case reports and a GP survey to see if the changes suggested by 
community pharmacists were implemented (Krass and Smith 2000). In the first phase of 
the study pharmacists conducted HMRs while attending a HMR training program and in 
the second phase the same pharmacists conducted additional HMRs after the training. In 
the phase I study, 2.5 changes in drug treatment had been implemented per patient three 
months after HMR. The corresponding figure was 3.4 changes per patient in phase II 
(Krass and Smith 2000). The changes resulted in a significant reduction in the mean 
number of medications per patient and in significant medication cost-savings which were 
greater than AUD 200 per year (Table 5). A clinical expert panel reviewed 141 HMRs 
conducted in phase II of the study. Of the patients (n=103) with drug regimen changes the 
panel rated at least 40% of the changes as leading to a significant positive effect on the 
patient’s health.  
In the study by Stafford et al. (2011) pharmacists’ HMR reports and physicians’ 
medication management plans prepared after HMR were used to count the effect of HMR 
on drug costs (n=560). Annual drug cost savings were only AUD 20 (Table 5), which is 
not surprising since the most common DRPs reported by pharmacists were untreated 
indications (Table 11). In the same study a subgroup of 180 cases were analyzed by 
experienced physicians and clinical pharmacists to estimate the probable clinical 
consequences that were avoided as a result of HMR. Each assumed consequence was 
linked to predetermined values for quality of life and health care resource utilization by 
the researchers. The interventions were not cost-effective, as the gain in quality of life was 
small and savings in health care costs (AUD 128) were AUD 200 less than the cost of 
HMR (Table 5). Because the assumptions on clinical outcomes resulting from HMRs were 
based solely on expert opinions, the reliability of the results is questionable. 
The outcomes of HMR may differ depending on the patient population involved. In a 
retrospective cohort study among veterans treated for heart failure HMR delayed the time 
to hospitalization (Roughead et al. 2009). After adjustment for confounding factors HMR 
patients (n=273) had a 45% reduction in the rate of hospitalization at any time compared 
to controls (n=5 444, Roughead et al. 2009; Table 5). Also among veterans using warfarin, 
HMR (n=816) reduced the likelihood of hospitalization for bleeding by 79% compared to 






However, the effect was not sustained 6–12 months after the review, which may indicate 
that patients treated with warfarin and at high risk for bleeding might benefit from 
biannual HMRs. 
Despite of lacking or modest evidence on beneficial clinical or humanistic patient 
outcomes, HMRs may result in improved and safer pharmacotherapy. First, pharmacists 
visit patients at home and may inform physicians of drug use they would not otherwise be 
aware of (Bell et al. 2006). For example in a HMR study the mean number of drugs used 
by mental health patients was significantly higher in the reports of pharmacists compared 
to those by physicians (7.8 vs. 9.1; p<0.001) (Bell et al. 2006). Second, as described in 
more detail in Chapter 3.2.2, pharmacists are able to recognize and report a high number 
of DRPs to physicians during HMR (Krass and Smith 2000, Roughead et al. 2004, 
Sorensen et al. 2004, Bell et al. 2006, Stafford et al. 2009, Castelino et al. 2011). 
Physicians have accepted 46–90% of pharmacists’ recommendations (Bell et al. 2006, 
Castelino et al. 2011) and 35–54% of findings have resulted in change of drug regimen or 
been actually acted on (Krass and Smith 2000, Gilbert et al. 2002, Sorensen et al. 2004). 
The relatively low acceptance and implementation rates don’t necessarily reflect the 
reliability of pharmacists’ recommendations (Castelino et al. 2011). Among patients aged 
≥65 yearsmore than 90% of pharmacists’ recommendations during HMR have been 
consistent with existing evidence-based guidelines for drug use in older adults (Castelino 
et al. 2011). Still, the physician acceptance rate in the same study was only 55%.  
Two studies that analyzed pharmacists’ recommendations from HMR case reports 
indicated that the recommendations could improve the appropriateness of 
pharmacotherapy and reduce the use of PIMs, if acted on (Castelino et al. 2010a,b, Table 
5). In the first study (Castelino et al. 2010a) 40% (n=148) of older HMR patients (n=372) 
were using PIMs according to the Beers 2003 criteria (Fick et al. 2003). If the 
pharmacists’ recommendations were implemented, 28% (n=105) of the patients would be 
using PIMs after HMR. This corresponds to a 29% reduction in the number of PIM users 
(Castelino et al. 2010a). Implementation of the pharmacists’ recommendations during 
HMR could also significantly improve The Drug Burden Index, which is a tool that 
measures total exposure to drugs that possess anticholinergic and/or sedative properties 
(Hilmer et al. 2007, Castelino et al. 2010a). In a HMR study among elderly patients 
(n=270) mean Medication Appropriateness Index (MAI) score improved significantly 
based on the assumption that pharmacists’ recommendations were accepted by physicians 
(Castelino et al. 2010b). Results on the actual uptake of pharmacists’ recommendations 
(n=102) also revealed significantly lowered MAI scores after HMR (Castelino et al. 
2010b). 
In addition to HMR, other medication review services involving pharmacists in the 
Australian community setting have been studied (Stewart et al. 1998, Graffen et al. 2004). 
These interventions have lacked patient interview (Graffen et al. 2004) or focused mainly 
on patient education and counseling instead of clinical medication review (Stewart et al. 
1998) and are thus beyond the scope of this literature review. Also, studies on post-
hospital discharge HMRs are excluded, because the procedures do not always comply with 
the HMR procedure described in this chapter (Nguyen et al. 2007, Yu et al. 2007, Ponniah 






Table 5. Studies on Home Medicines Review (HMR) in Australia (includes 9 studies found in scientific literature and 2 project reports*). Presented 
in alphabetical order. 
Reference Study design/method Study population Outcome measures Key findings 
Bell et al. 
2006  
Retrospective analysis 
of HMR referrals and 
case reports 
Patients with mental 
illness (n=49) 
selected by 11 GPs, 
aged 21–87 years, 
mean age 66 years 
Drug use 
Pharmacists’ findings (i.e., 
DRPs) and recommendationsa 
Pharmacists identified higher incidence of drug use 
than documented by physicians (mean 9.1 




of HMR case reports 
send to AACP for 
reaccreditation (n=148) 




people aged ≥65 
years (n=372), mean 
age 76 years 
Change in Drug Burden Index 
(DBI) score and PIM use if 
pharmacists’ recommendations 
will be acted on 
Significant reduction in the sum total of DBI scores 
for all patients (207 vs. 157; p<0.001) 
Decrease in % of patients exposed to DBI 




of HMR case reports 
from 7 pharmacists  
Community-dwelling 
people aged ≥65 
years (n=270), mean 
age 75 years 
MAI scores at baseline, based 
on pharmacists’ 
recommendations, and 
following GP uptake of 
recommendations (n=102) 
Significant decrease in mean MAI score both based 
on recommendations (18 vs. 9) and following GP 





of HMR case reports 
from 7 pharmacists  
Community-dwelling 
people aged ≥65 years 
(n=224), mean age 75 
Consistency of recommendations 
with evidence-based guides 
DRPsa 
94% of pharmacists’ recommendations were in 








Phase I: Retrospective 
analysis of HMR case 
reports (completed by 
45 pharmacists during 
HMR training) 
Follow-up by a GP 
survey after 3 months  
Community-dwelling 
patients selected by 
12 GPs (n=105), age 
not stated 
 
Pharmacists’ findings and 
recommendationsa 
Change in mean number of 
drugs 
Medication costs 
Decrease in number of drugs (7.4 vs. 6.5; p<0.001) 
Mean medication cost saving of AUD 19/month, 










Phase II: Retrospective 
analysis of HMR case 
reports (completed by 
35 pharmacists after 
HMR training) 
Follow-up after 3 
months  
Community-dwelling 
patients selected by 
22 GPs (n=170), 
mean age 71 years 
 
 
Pharmacists’ findings and 
recommendationsa 
Mean number of drugs 
Medication costs 
Clinical significance of 
resulting medication changes 
(subset of 141 cases) 
Decrease in mean number of drugs (8.5 vs. 7; 
p<0.001) 
Mean medication cost saving of AUD 22/month, 
corresponding to annual saving of AUD 262 
(p<0.001) 
40% of actual medication changes (of the 103 
reviews with actual medication changes) would result 




(12 month follow-up) 
(Costs 12 months 
before and after HMR) 
Rural patients with 
e.g., ≥5 medications 
(n=88 interventions, 
82 controls), mean 
age 70 years  
Pharmacists’ interventions 
HRQoL (SF-36, QWB) 
Cost-effectiveness 
(Pharmaceutical and Medical 
Benefit Scheme service costs) 
91% of interventions evidence based. 
Physicians adopted 61% of interventions. 
No improvement in HRQoL 
Annual costs per patient rose AUD 1411 less 




of HMR case notes, 
semi-structured 
telephone interview of 
HMR patients 
All HMR cases 
(n=49) of one GP 
clinic, median age 63 
years 
Number of medication changes 
Patients’ (n=44) and 
pharmacists’ (n=4) opinions on 
HMR  
84% of patients had changes made to medications by 
GP (33%: 1 change, 37%: 2, 14%: 3) 
All patients felt comfortable having pharmacist in 
their home, 20% reported discarding a medication 
and 25% taking medications differently after HMR. 
Pharmacists indicated better communication with 
patients and GPs. 
Roughead 
et al. 2009 
Retrospective cohort 
(administrative claims 
data, Jan 2004–July 
2006) 
 
Veterans aged ≥65 
receiving β-blocker 
for heart failure 
(n=273 exposed to 
HMR, n=5 444 
controls), mean age 
82 
Time to next hospitalization 
for heart failure 
 
 
45% reduction in rate of hospitalization for heart 










Reference Study design/method Study population Outcome measures Key findings 
Roughead 
et al. 2011 
Retrospective cohort 
(administrative claims 





war widows and their 
dependents aged ≥65 
dispensed warfarin 
(n=816 exposed to 
HMR, n=16 320 
controls), mean age 
81 years 




79% reduction in likelihood of hospitalization for 
bleeding between 2 and 6 months (HR 0.21) among 
patients that had received HMR. 
No difference in the time period from review to 2 





(for costs 8 months) 
 
Community-dwelling 
people aged 37–100 
years (mean age 72), 
(n=400, follow-up 




27 intervention GPs 
and 32 pharmacists 
HRQoL physical and mental 
component (SF-36) 
Physician- and self-reported 
ADEs 
Number of GP visits, use of 
hospital services 
Severity of illness  
Participant satisfaction 
Drug and health service costs 
DRPsa 
HMR improved the care of participants according to 
92% of physicians and 94% of pharmacists. 97% of 
patients reported benefiting from participation. 
Physician-reported percentage of patients 
experiencing an ADE decreased in intervention group 
(37% vs. 9%), no change in the control group. 
No difference in HRQoL, use of hospital services, 
self-reported ADEs, severity of illness scores, 
number of GP visits or cumulative medication costs 




(analysis of HMR 
documentation 
submitted by 149 
pharmacists) 
Community-dwelling 
people aged 30–98 
years (mean age 76), 
(n=661, data for drug 
cost analysis 
available for 560)  
DRPsa 
Drug costs (at the time of 
HMR vs. after changes) 
Clinical outcomes: Avoided 
hospital days, GP and/or 
specialist consultations, and 
medical investigations (as 
estimated by an expert panel, 
random sample of 180 cases) 
Effect of assumed clinical 
outcomes on QoL and costs 
paid by the health system  
Monthly drug cost saving AUD 1.7/patient 
Average avoided health care use/costs per 
patient/year:  
0.065 hospital days / saving AUD 65 
0.63 GP visits / saving AUD 21 
0.16 specialist visits / saving AUD 11 
Savings in medical investigations AUD 12 
Savings in drug costs AUD 20 
Total savings (AUD 128) do not cover the cost of 
HMR (AUD 329) 












Telephone (n=50) and 
face-to-face (n=7) 
interviews after HMR 





HMR in previous 3–
12 months (n=57), 
79% aged ≥65 years 
HRQoL (EQ-5D) 
Number of patients reporting a 
medication-related event 
(hospital admissions, hospital 
stays, ED visits, GP visits, 
specialist visits, number of 
days off work, days unable to 
do usual tasks at home, days 
off work by carer) in the past 2 
years vs. after HMR 
Consumer opinions and 
attitudes 
Mean HRQoL utility score improved (0.562 vs. 
0.681; p<0.001), most responsive attributes 
anxiety/depression and pain.  
More patients reported having a medication-related 
event before than after HMR: hospital admission (4 
vs. 0); hospital stay (3 vs. 0); ED visit (3 vs. 0); GP 
visit (5 vs. 2); specialist visit (3 vs. 0); unable to do 
usual tasks at home (6 vs. 0); days off work by carer 
(1 vs. 0). No change in days off work (0 vs. 0). No 
statistical analyses. 
21% of patients reported reduced symptoms or side 
effects after HMR. 44% indicated reassurance and 
improved confidence in relation to medications. 98% 
satisfied or very satisfied with HMR. 
a Results regarding DRPs are presented in Table 11. 
AACP=Australian Association of Consultant Pharmacy, ADE=Adverse drug event, DRP=Drug-related problem, ED=Emergency department, GP=General 
practitioner, HR=Hazard ratio, HRQoL=Health-related quality of life, MAI=Medication Appropriateness Index (Hanlon et al. 1992), PIM=Potentially inappropriate 






3 Drug-Related Problems (DRPs) in Pharmaceutical Care 
Pharmaceutical Care and related medication review services aim at recognition, 
prevention and resolution of drug-related problems (DRPs). DRPs were defined by Strand 
and colleagues in 1990 (Strand et al. 1990) as “an undesirable patient experience that 
involves drug therapy and that actually or potentially interferes with a desired patient 
outcome” (Strand et al. 1990). Later, they used the term drug-therapy problem (DTP) and 
changed the definition to refer with DTP to “Any undesirable event experienced by the 
patient that involves or is suspected to involve drug therapy and that actually or potentially 
interferes with desired health outcomes” (Cipolle et al. 1998, 2004). 
The pioneering work by the Strand’s research group stimulated other researchers to 
develop their own definitions and classification systems for DRPs. DRPs have grown to 
become a special area of clinical pharmacy research. The definitions and terminology 
related to DRPs are still far from uniform. In addition to the terms DRP and DTP, 
corresponding terms of medicine-related problem and medication-related problem have 
been used (Fernandez-Llimos et al. 2005). Also definitions differ from the ones by Stand 
et al. (1990) and Cipolle et al. (1998, 2004) by placing less emphasis on the patient’s 
experience. For example, according to the Pharmaceutical Care Network Europe (PCNE) 
DRP is “an event or circumstance involving drug therapy that actually or potentially 
interferes with the desired health outcomes” (PCNE 2010). Sometimes a very non-clinical 
approach has been taken, and a DRP has been defined as ”any problem that impacts on the 
patients’ ability to manage or take their medicines effectively” (Gordon et al. 2004). 
Fernandez-Llimos and colleagues (2005) have even suggested that the term DRP should 
be replaced with a term “negative clinical outcome”. This suggestion, however, prevents 
recognition and classification of potential problems and risks, the recognition of which is 
important in pharmaceutical care and medication review.  
3.1 Systems to Classify DRPs 
Numerous systems for classifying DRPs have been created in different countries to be 
used for the purposes of pharmaceutical care and research (van Mil et al. 2004). An 
optimal system should be validated, have a clear definition for DRPs in general and for 
each individual DRP category, be usable in practice, have a hierarchical structure and 
separate the problem from its cause and preferably also have an intervention section (van 
Mil et al. 2004). Based on a review by van Mil and colleagues (2004), no DRP 
classification meets all these requirements. Closest to an optimal classification system is 
the PCNE classification for DRPs (van Mil et al. 2004).  
In this literature review, three classifications are described in detail because they were 
selected to be applied in the Finnish CMR procedure (see Chapter 6.2.4). These are 
Cipolle-Morley-Strand Classification, Westerlund classification and Pharmaceutical Care 






3.1.1 Cipolle-Morley-Strand (CMS) Classification 
The first systematic categorization for DRPs was published by Strand et al. in 1990 in 
order to focus the role of the pharmacist on patient needs and patient outcomes. According 
to their definition, “a DRP is an undesirable patient experience that involves drug therapy 
and that actually or potentially interferes with a desired patient outcome.” In order for a 
DRP to exist, two conditions must be met: 1) a patient experiences or is likely to 
experience a disease or a symptom; and 2) this condition has actual or suspected 
relationship with drug therapy. Based on the above mentioned definitions, Strand and 
colleagues concluded that the number of DRPs is limited. As a result, their original DRP 
classification consisted of 8 DRP categories (Table 6). The authors emphasized that all 
DRPs can be either actual problems experienced by the patient or potential problems that 
may be prevented (Strand et al. 1990). 
The classification was later revised by renaming DRPs as DTPs and by removing 
interactions, because they were considered merely as causes for DRPs. The remaining 7 
DTPs were grouped around 4 drug-related patient needs: 1) indication; 2) effectiveness; 3) 
safety; and 4) compliance (Cipolle et al. 1998, Cipolle et al. 2004; Table 6). A definition 
for each DRP is available (Cipolle et al. 2004; Table 6). In the published versions of the 
“Cipolle-Morley-Strand (CMS) Classification” causes of DTPs are not categorized, but 
they need to be identified in order to solve the problem (Cipolle et al. 2004). However, a 
computer-based documentation system/software (Assurance Pharmaceutical CareTM) to 
support the practice of pharmaceutical care includes both DTPs and several causes for 
each type of DTP (Table 6), as well as an intervention section (Medication Management 
Systems Inc. 2011). In addition, the system allows documentation of clinical patient 
outcomes and estimated cost savings in regard to use of other health care resources.  
The CMS classification has been used in numerous studies to evaluate pharmacists’ 
medication review services, mainly in the US (Isetts et al. 2003, Becker et al. 2004, Rao et 
al. 2007, Isetts at el. 2008, Ramalho de Oliveira et al. 2010, Angley et al. 2011). Various 
modifications of the classification have also been used in published studies (Ellis et al. 








Table 6. DRP/DTP classes and their definitions in the evolution of Cipolle-Morley-Strand classification (Strand et al. 1990, Cipolle et al. 1998, 2004) 
Strand et al. (1990) Cipolle et al. (1998, 2004) 
DRP and definition  Drug-related need DTP and definition Examples of causes for DTPs 
Untreated indications 
The patient has a medical condition that 
requires drug therapy but is not receiving a 
drug for that indication. 
INDICATION 
    
Need for additional drug therapy 
Additional drug therapy is required to treat or 
prevent a medical condition or illness from 
developing 
Untreated condition 
Preventive therapy required 
Additional synergistic therapy 
needed 
Drug use without indication 
The patient has a medical condition that is 
the result of taking a drug for which there is 
no valid medical indication. 
Unnecessary drug therapy 
The drug therapy is unnecessary because the 
patient does not have a medical indication at 
this time. 
No valid medical indication 
Duplicative therapy 
Non-drug therapy more 
appropriate 
Improper drug selection  
The patient has a medical condition for 
which a wrong drug is being taken. 
EFFECTIVENESS Ineffective drug (‘Wrong drug’ in 1998) 
The product is not being effective at 
producing the desired response. 
More effective drug available 
Condition refractory to drug 
Dosage form inappropriate 
Subtherapeutic dosage 
The patient has a medical condition for which 
too little of the correct drug is being taken. 
Dosage too low 
The dosage is too low to produce the desired 
response. 
Dose too low 
Drug interaction 
Duration of therapy too short 
Adverse drug reactions 
The patient has a medical condition 
resulting from an adverse drug reaction. 
SAFETY 
 
Adverse drug reaction 
The drug is causing an adverse reaction. 




The patient has a medical condition for which 
too much of the correct drug is being taken. 
Dosage too high 
The dosage is too high, resulting in 
undesirable effects. 
Dose too high 
Dosing frequency too short 
Dose administered too rapidly 
Failure to receive drugs 
The patient has a medical condition that is 
the result of not receiving the prescribed drug.  
COMPLIANCE 
 
Noncompliance (‘Adherence problem’ in 1998) 
The patient is not able or willing to take the 
drug therapy as intended. 
Instructions not understood 
Patient forgets to take the drug 
Drug product too expensive 
Drug interactions 
The patient has a medical condition resulting 
from a drug-drug/food/laboratory interaction. 
  






3.1.2 Westerlund Classification 
 
The DRP classification by Westerlund was developed in Sweden as a part of his PhD 
dissertation (Westerlund 2002). The aim was to create a system that could be used in 
community pharmacies during patient encounters to document DRPs and pharmacists’ 
interventions. The classification was originally based on a definition in which a DRP is “a 
circumstance of drug therapy that may interfere with a desired therapeutic objective.” 
Compared to the definition by Strand and colleagues (1990), the selected definition places 
less emphasis on actual patient experience, and was selected to reflect the inability of 
patients to always understand the circumstances that may interfere with therapeutic 
outcomes. Currently, the Westerlund classification relies on the DRP definition “A drug-
related problem is a circumstance related to a patient/customer’s use of a drug that actually 
or potentially prevents the patient from gaining the intended benefit of the drug (van Mil 
et al. 2004, Björkman et al. 2008). Definitions for each DRP category are also available 
(Westerlund 2002). 
In the first phase of development Westerlund used his own professional experience to 
list 20 different options for problem types (Westerlund et al. 1999a). Four of these options 
were adopted from the DRP classification by Strand et al. (1990). The list was piloted by 
personnel from 12 pharmacies in Helsingborg, Sweden who were asked to categorize and 
tally the types of problems they identified during one week (Westerlund et al. 1999a). 
After piloting, some problem categories were merged or omitted. In addition, the 
development included discussions with Swedish and US colleagues who had experience 
with DRPs. The pilot phase and these discussions resulted in a 14-point DRP classification 
and an 11-point intervention classification (Westerlund et al. 1999a,b; Tables 7 and 8). 
Because of the used definition for DRPs, the Westerlund classification includes issues like 
DDIs and contraindications, which are considered to be causes of DRPs in many other 
classification systems (Consensus Committee 2002, PCNE 2010). 
Since its development, the Westerlund classification has been updated four times 
(Tables 7 and 8). Version 2 was developed specially for documenting DRPs identified in 
customers purchasing OTC drugs, and related interventions (Westerlund et al. 2001). A 
computerized system for documenting DRPs and pharmacists’ interventions in Swedish 
community pharmacies, SWE-DRP, was introduced in 2004 and is applied both to 
prescription and OTC customers (Westerlund and Björk 2006). Between April 2004 and 
September 2005 as much as 283 826 DRPs were documented in the database (Westerlund 
and Björk 2006). The computerized documentation of DRPs has been well accepted by 
community pharmacists, and so far, more than 1 million DRPs have been documented 
altogether (Westerlund 2009). In addition, the Westerlund system has been used in 
numerous studies in community pharmacy settings both to assess DRPs in prescriptions 







Table 7. Evolution of DRPs in the Westerlund DRP classification system 
Version 1 
(Westerlund et al. 1999a,b) 
Version 2 
(Westerlund et al. 2001) 
Version 3 
(van Mil et al. 2004) 
Version 4 
(Ax et al. 2010) 
Version 5 
(Westerlund 2009) 
Uncertainty/lack of knowledge of 
the aim/function of drug 
Uncertainty about the 
indication for the drug 
Uncertainty about aim of 
the drug 
= = 
Underuse of medication = = = = 
Overuse of medication = = = = 
Other dosage problem = = - - 
Drug duplication - Drug duplication = = 
Drug-drug interaction = = Interaction = 
Therapy failure  = = = = 
Side effect Adverse effect = Adverse reaction = 
Difficulty swallowing 
tablet/capsule 
= = - - 
Difficulty opening container = = = - 
Other practical problem  = Other problem of 
administration/handling 





Language deficiency - - - 
Prescribing error - - - - 
Other DRP = = = = 
 Contraindication = = = 
   Inappropriate storage - 
   Inappropriate time / 
wrong dosing interval 
= 
= the definition remains the same as in the previous version. Note: The order of DRPs can be different from original publications in order to ease comparison of the 








Table 8. Evolution of interventions to solve DRPS in the Westerlund DRP classification system 
Version 1 
(Westerlund et al. 1999b) 
Version 2 
(Westerlund et al. 2001) 
Version 3 
(Montgomery et al. 2008) 
Version 4 
(Westerlund and Björk 2006) 
Version 5 
(Westerlund 2009) 
No intervention = No intervention (explain) = - 
Patient medication counseling Customer drug counseling Patient counseling = = 
Practical instruction to patient = = = = 
Patient referred to prescriber  = Referral to prescriber or 
other health care provider 
= = 
Prescriber informed only -    
Prescriber asked for information 
or intervention 
- Contact with prescriber/ 
other healthcare provider 
= = 
Intervention proposed by 
pharmacy, approved by prescriber 
- - - - 
Intervention proposed by 
pharmacy, disapproved by 
prescriber 
- - - - 
Switch of drug to _______ Switch of drug = = = 
Referral to colleague = - - - 
Other intervention________ = Other intervention (explain) Other intervention  = 
  Printed information = = 
   Information to patient’s 
representative 
= 
= the definition remains the same as in the previous version. Note: The order of the interventions can be different from original publications in order to ease 






3.1.3 Pharmaceutical Care Network Europe Classification 
Pharmaceutical Care Network Europe (PCNE) was established in 1994 by European 
researchers on pharmaceutical care (www.pcne.org). In 2009 an official PCNE working 
group on DRPs was established, although it has worked informally since 2001. The first 
PCNE DRP classification was developed during a PCNE working conference in 1999 (van 
Mil et al. 2004). The aim was to develop a standardized system that could be used in 
international studies and ensure comparable results. Since its development, the 
classification has been updated several times (www.pcne.org). Major changes in the 
PCNE-system were completed in a Working Symposium in 2009 when the version 6.01 
was created (www.pcne.org). Until then, the new versions had been made compatible with 
the previous ones (e.g., Version 5.01 in Table 9) but the version 6.01 was a totally revised 
classification system: most issues previously classified as DRPs were classified as causes 
of DRPs (www.pcne.org; see latest version V6.2 in Appendix 1). In addition, the 
possibility to determine whether the DRP is actual or potential was added. Remarkably, 
version 6 also enables classification of issues related to inappropriate treatment costs 
(Appendix 1).  
The PCNE DRP classification enables categorization of the causes of DRPs, the 
interventions resulting from the recognition of the DRP and the outcomes of interventions 
in addition to the classification of DRPs (Appendix 1). The structure of PCNE 
classification is hierarchical. This means that each DRP category has primary domains and 
more specific subdomains. A definition for each primary domain DRP is clearly stated.  
According to the published studies, the PCNE classification version 5.00 has been used 
in the hospital setting and in nursing homes (Lampert et al. 2008, Brulhart and Wermeille 
2011) and the version 5.01 in community pharmacies during dispensing (Eichenberger et 
al. 2010), in medication review clinics (Chan et al. 2012) and among diabetics (van 
Roozendaal and Krass 2009). In medication review clinics 5% of DRPs could not be 
classified according to the PCNE classification (Chan et al. 2012). Also in the hospital 
setting the classification lacked some DRP categories, e.g., improper time of drug taking 
related to meals and prescribing errors (Lampert et al. 2008). The usability also in the 
community pharmacy setting was not optimal, since the classification does not include 
technical drug-related problems, such as lack of relevant information in the prescription 

















Table 9. PCNE Classification for DRPs version 5.01 (PCNE 2006) 
Primary domain Code Problem 
1. Adverse reactions 
Patient suffers from an 




Side effect suffered (non-allergic) 
Side effect suffered (allergic) 
Toxic effects suffered 
2. Drug choice problem 
Patient gets or is going to get 
a wrong (or no drug) drug 












Inappropriate drug (not most appropriate for 
indication) 
Inappropriate drug form (not most appropriate for 
indication) 
Inappropriate duplication of therapeutic group or 
active ingredient 
Contra-indication for drug (incl. pregnancy/breast 
feeding) 
No clear indication for drug use 
No drug prescribed but clear indication 
3. Dosing problem 
Patient gets more or less 







Drug dose too low or dosage regimen not frequent 
enough 
Drug dose too high or dosage regimen too frequent 
Duration of treatment too short 
Duration of treatment too long 
4. Drug use problem 




Drug not taken/administered at all 
Wrong drug taken/administered 
5. Interactions 
There is a manifest or 












Patient dissatisfied with therapy despite taking 
drug(s) correctly 
Insufficient awareness of health and disease 
(possibly leading to future problems) 
Unclear complaints. Further clarification necessary. 






3.2 Research on DRPs During Medication Review 
Numerous studies have investigated pharmacists’ ability to recognize and resolve 
drug-related problems during medication review. Such studies have been conducted in 
several countries both in the hospital (Cunningham et al. 1997, Blix et al. 2004, Blix 
et al. 2006, Mannheimer et al. 2006, Lampert et al. 2008), aged care home (Finkers et 
al. 2007, Nishtala et al. 2011) and outpatient settings (Kassam et al. 2001, Krska et al. 
2001, Gilbert et al. 2002, Doucette et al. 2005). Medication review models in different 
countries are diverse in nature and many are not comparable to the Finnish CMR in 
their comprehensiveness. Because the MTM model in the US and the HMR in 
Australia were used as examples when the Finnish CMR model was developed, this 
literature review focuses on DRP studies conducted in these two settings. MTM 
studies are included if the intervention includes the 5 core elements of MTM service 
model (APhA and NADCS 2008) or complies with the principles of pharmaceutical 
care (Cipolle et al. 2004; Chapter 2.1.1). According to the focus of this dissertation, 
only studies involving outpatients are included. Disease-specific interventions are 
excluded. 
3.2.1 DRPs in MTM 
A large number of studies have investigated the DRPs pharmacists document and 
report to physicians during MTM (Table 10). Patient inclusion criteria in various 
studies differ, but usually include at risk patients with multiple medications and/or 
conditions or with specific disease states (Table 10). None of the retrieved studies 
included only patients aged ≥65 years. As a result, studies with at least some 
proportion of elderly patients are included. 
The CMS DRP system has been used in almost all included studies to classify 
DRPs (Table 10). This simplifies the comparison of results between studies. On the 
other hand, the number of MTM encounters/patient has varied greatly in different 
studies, being as many as 9 in some studies (McDonough and Doucette 2003). This 
complicates comparison of the results because the reported mean number of DRPs per 
patient may represent pharmacists’ findings after a single visit or over a period of 
time, of up to two years (Table 10). 
In studies where the number of DRPs per encounter has been reported, the mean 
number of DRPs per patient has varied from 1.0 to 3.6 (Table 10). As an exception, 
one study reported an average of 9.9 problems/patient (Lewis et al. 2008). The results 
of this study are not comparable with the others, as common health-related problems, 
such as need for monitoring or lifestyle changes, were included in the analysis. If such 
issues are excluded, the mean number of problems per patient decreases to 5.4. The 
high prevalence of DRPs may result from the high number of drugs used per patient 
(mean 12.6) as the number of DRPs has been found to correlate with the number of 
drugs taken (Krska et al. 2001, Blix et al. 2004, Viktil et al. 2007, Stafford et al. 
2009). The mean duration of MTM visits are rarely reported, but they can last as little 






different mean numbers of DRPs in different studies, as the length of patient visit 
affects the number of problems addressed and resolved (Ellis et al. 2000b).  
In studies where the total number of DRPs during several MTM visits has been 
documented, the total number per patient has varied from 3.3 to 10.4 (Table 10). In 
the study with the highest prevalence of DRPs (Smith et al. 2011), the patients used 
higher mean number of drugs per person (15.7) compared to other studies (4.5–12.4) 
and the pharmacists had full access to patient medical records, which may have 
affected the results. The number of DRPs per single MTM encounter (1.0–3.6) is 
relatively low compared to the total number of DRPs per patient (3.3–10.4). This may 
reflect the continuous nature of the MTM procedure; the pharmacist does not have to 
address or report all issues after the first patient encounter, because several follow-up 
visits can be scheduled. Among patients with a large number of different medications 
(Smith et al. 2011) the pharmacists are likely to find new DRPs to be addressed 
during subsequent MTM encounters. 
Across studies, the most common occurring DRPs during MTM have been similar 
(Table 10). In almost all studies reviewed the need for additional drug therapy is 
among the three most common DRPs (i.e., the patient has diagnosis, but not 
medication for that condition). Also poor adherence and too low drug doses have been 
common in most studies. Against these findings, it is not surprising that MTM has 
resulted in improved therapeutic patient outcomes in several studies (Chapter 2.2.1, 
Table 4). Interestingly, in the three studies where the mean number of DRPs was the 
highest (Ellis et al. 2000b, Doucette et al. 2005, Smith et al. 2011), poor adherence 
and need for education were the most common DRPs. The reason for this is not clear, 
but it is possible that the pharmacists in the other studies have prioritized clinical 
findings and underreported patient-related adherence issues.  
Few MTM studies have indicated what drugs are most commonly involved in 
DRPs reported by pharmacists (Table 10). Asthma medications and cardiovascular 
drugs have been frequently mentioned in such studies (Strand et al. 2004, Doucette et 
al. 2005, Ramalho de Oliveira et al. 2010, Smith et al. 2011). Undertreatment, i.e., 
need for additional therapy and use of too low doses, has involved especially 
salicylates, calcium supplements, antidiabetics, ACE-inhibitors and statins (Strand et 
al. 2004, Rao et al. 2007, Ramalho de Oliveira et al. 2010). Statins and ACE 
inhibitors have also been involved in poor adherence (Strand et al. 2004, Ramalho de 


























Most common DRPs  
(% of DRPs unless otherwise stated) 
Drugs commonly 
involved in DRPs 
(% of drugs) 








54.9 NS CMS 
1998 
NS ADR (20.1% of care plans) 
Need for additional drug therapy (18.9%) 
Lack of adherence (16.3%) 
NS 
Chrischilles et 









7.5 NS 2.6 
(several 
visits) 
Untreated condition (17.6% of 
recommendations) 






















Potential underuse (71.6% of patients) 
More cost-effective drug available 
(64.2%) 
Suboptimal drug (53.7%) 
NS 
 




















Inappropriate adherence (25.9%) 
Need for additional therapy (22.0%) 
Wrong drug (13.2%) 
Respiratory agents 
(17.7% of DRPs) 
Cardiovascular (15.5%) 
Analgesics (14.4%) 
CNS agents (14.3%) 






≥3 of 6 criteria 
e.g., ≥5 drugs, 
≥3 diseases) 









Requires drug therapy education 
(32.7%) 
Needs a drug but is not receiving it 
(16.0%) 



























Most common DRPs  
(% of DRPs unless otherwise stated) 
Drugs commonly 
involved in DRPs 
(% of drugs) 












Indication but no drug (15.7%) 
Vitamins and minerals, 
ACE-inhibitors, 
salicylates (%NS) 





or lung disease 
231 57 9.1  CMS, 
excluding 
adherence 
NS Dose too low (34% of patients) 
ADR (34%) 
Needs additional drug therapy (25%) 
NS 





clinic patients  









Need for additional therapy (29%) 
Dosage too low (22%) 
Adherence (18%) 
 













7.9 CMS 2.2 
(during 
1 year) 
Additional drug therapy needed 
(33.9%) 
Dose too low (19.9%) 
ADR (14.1%) 
NS 















9.9 Need for additional drug therapy 
monitoring (29.2%) 
Need for lifestyle change (15.7%) 
















































Most common DRPs  
(% of DRPs unless otherwise stated) 
Drugs commonly 
involved in DRPs 
(% of drugs) 
Moczygemba 




patients of a 
mental health 


















Mental health clinic: 
Ineffective drug therapy (27.1%) 
Need for education (26.8%) 
Nonadherence (25.9%) 
Medical clinic: 
Need for education (59.5%) 
Nonadherence (19.0%) 
Need additional drug therapy (9.8%) 
NS 

















Needs additional drug therapy (32%) 




























Needs additional drug therapy (28.1%) 
Dose too low (26.1%) 
Nonadherence (16.5%) 
Needs additional: ASA, Ca, 
statins, antidiabetics  
Dose low: Ca, antidiabetics, 






















Needs additional drug (22.7%) 




Analgesics (NSAIDs and 
opioids) 

























Most common DRPs  
(% of DRPs unless otherwise stated) 
Drugs commonly 
involved in DRPs 
(% of drugs) 
Strand et al. 
2004 
Minnesota 













Needs additional drug therapy (30.6%) 
Dosage too low (21.2%) 
Noncompliance (18.4%)  
Low dose: Ca, statins, 
ACE-inhibitors, insulin, 
warfarin, betablockers 
High dose: salicylates, 
warfarin, Ca, insulin, 
thyroid hormones 
ADR: statins, ASA, SSRIs, 
NSAIDs, ACE-inhibitors 
Adherence: statins, 
steroid inhalants, ACE- 
inhibitors, PPIs 









80 NS NS CMS 
1998 
3.4 Need for additional therapy (20%) 
Wrong drug therapy (18%) 
Poor compliance (17%) 
NS 











459 68.8 NS 
(≥5) 
NS NS DDI (52.7% of patients) 
Nonadherence (34.4%) 
Dose adjustment (26.6%) 
NS 
ADR=Adverse drug reaction, Ca=Calcium supplement, CMS=Cipolle-Morley-Strand (Cipolle et al. 2004), DDI=Drug-drug interaction, HMO=Health maintenance 






3.2.2 DRPs in HMR 
Several studies have investigated the DRPs pharmacist report during HMR (Table 
11). Even though all patients in these studies have not been aged, the mean or median 
age has been high; 66–76 years. Thus, all studies found have been included in this 
chapter.  
Interpretation and comparison of DRP studies during HMR should take into 
account that there is variation between the DRP classification systems used and ways 
of reporting the results. For example, at least three published studies have used the 
same 1000 HMR case reports, but have reported inconsistent results (Gilbert et al. 
2002, Roughead et al. 2004, Rao et al. 2007). Gilbert et al. (2002) and Roughead et al. 
(2004) used a modified CMS classification and found the mean number of DRPs per 
person to be 2.8 and 2.2, respectively. Rao et al. (2007) selected 982 patients aged 
≥40 years from the same HMR case reports and reported mean number of 2.1 
DRPs/person by using the original CMS classification. Likewise, the most common 
DRP classes differed between these studies (Table 11). Gilbert et al. (2002) reported 
“Need for additional test” to be the most common DRP (17.5% of DRPs). As lack of 
monitoring is not regarded as a DRP in the original CMS classification used in the 
study by Rao et al. (2007), they stated “non-compliance” to be clearly the most 
common DTP (31.7%). Roughead et al. (2004), on the other hand, used a different 
method of presenting results and reported most common DRPs as percentages of 
patients experiencing them (Table 11).  
Overall, the mean number of DRPs per patient during HMR has varied from 2.1 to 
9.7 (Table 11). In contrast to MTM studies from USA with varying number of 
encounters, in these studies DRPs were reported after a single HMR patient visit. The 
number of DRPs has been found to correlate with the number of medications taken 
(Krska et al. 2001, Blix et al. 2004, Viktil et al. 2007, Stafford et al. 2009). In HMR 
studies the mean number of drugs used has been high (7.4–11.8). Still, the HMR 
studies with highest mean number of drugs do not report the highest mean number of 
DRPs (Table 11). Also, there is no indication that higher age is associated with higher 
number of DRPs (Stafford et al. 2009; Table 11). Instead, number of DRPs seems to 
be affected by the DRP classification system used as the studies with the lowest mean 
number of DRPs have utilized the original or modified CMS DRP-classification 
system for analysis (Table 11). It is also possible that the prevalence of DRPs is 
affected by the patient population’s clinical conditions. There is some evidence, that 
higher number of clinical conditions is associated with higher number of DRPs 
(Stafford et al. 2009). Also, the mean number of DRPs has been high among mental 
health patients (Bell et al. 2006).  
The most frequent DRPs in most HMR studies have been similar, and related to 
patients’ poor adherence or knowledge, ADRs, and need for additional medication 
(Table 11). Also drug interactions and need for additional tests or monitoring have 
been common. However, the DRP classification used affects the results as different 
coding systems have different number and type of DRP classes. Also, the involved 
patient populations may influence the results. ADRs seem to be more common among 






other hand, when HMR has involved cardiovascular patients recently discharged from 
hospital –a situation where drug regimen is likely to change- ‘uncertainty about aim 
of drug’ comprised a third of all DRPs (Ellitt et al. 2010). 
Most common drugs involved in DRPs have been rarely reported in HMR studies 
(Table 11). The results differ, largely because they are presented on different 
Anatomic Therapeutic Chemical classification (ATC) levels. In the study by 
Roughead et al. (2004) most common drugs on ATC level 1 were cardiovascular 
drugs (26.3%), drugs affecting the nervous system (17.9%), and drugs affecting the 
alimentary tract (15.7%). Stafford et al. (2009) reported their complete results on 
ATC level 3. The most common drug groups involved in DRPs were NSAIDs (7.7%) 
and antithrombotic agents (6.9%) (Table 11). However, when counted from the 20 
most common ATC level 3 drug groups presented (63.9% of all drugs), at ATC level 
1 cardiovascular drugs caused at least 19.5% and nervous system drugs 15.5% of 
DRPs, being the most common drug groups like in the study by Roughead et al. 
(2004). Rao et al. (2004) used the same data as Roughead et al. (2004) but reported 
most common drugs involved in DRPs only in the form of five most common DRP-
drug combinations. In contrast with other studies, this different way of reporting 
placed pneumococcal vaccines in combination with DRP ‘need for additional therapy’ 
as the most common. Regardless of the way of presenting the results, analgesic drugs 
are commonly involved in DRPs during HMR (Table 11). They are mentioned among 
the 3 most common drugs in 3 out of 4 studies in which the drugs are reported 






















Most common DRPs  
(% of DRPs unless otherwise stated) 
Drugs commonly involved 
in DRPs 
(% of drugs) 







9.1 Adapted Clinical 
Pharmacy Activity 
Classification 
System (Jones and 
Whitehead 2004) 
8.2 Suspected or potential ADR (25.1%) 
Potential interactions (7.4 %) 
Patient taking additional drug (6.4%) 
NS 







Modified CMS 1998 4.9 Need for additional medicine (16.1%) 
Investigation test requested (14.2%) 
Rationalization of drug therapy (11.1%) 
NS 




10.8  Westerlund version 4 5.2 Uncertainty about drug aim (32.0%) 
Potential interaction (22.4%) 
Adverse reaction (15.1%) 
NS 









9 Modified CMS 1998  2.8 Need for additional test (17.5%) 
Need for additional medicine (11.6%) 
Wrong or inappropriate medicine (11.5%) 
(20% related to patient knowledge and 










NS 7.7 Interactions (12.6%) 
Side effects (11.7%) 
More appropriate therapy available 
(6.4%) 
NS 






NS 9.7 Query compliance (16.4%) 























Most common DRPs  
(% of DRPs unless otherwise stated) 
Drugs commonly involved 
in DRPs 
(% of drugs) 
Rao et al. 2007 
(Data from 







9 CMS 1998 2.1 Non-compliance (31.7%) 
Needs additional therapy (15.9%) 
Ineffective drug (15.7%) 
DRP-drug combinations: 
Pneumococcal vaccines/ 
needs additional therapy 
(3.9% of DRPs) 




al. 2004  
(Data from 







9 Modified CMS 2.2 Need for additional test (33.4% of 
patients) 
Use of wrong or inappropriate medicine 
(26.8%) 
Need for additional medication (24.9) 
Cardiovascular (26.3%) 
Nervous system (17.9%) 
Alimentary tract (15.7%) 





9.1 Adapted Strand et al. 
1990 
5.5 ADR (16.9%) 
Suboptimal monitoring (16.3%) 
Adherence difficulties (12.8%) 
NS 
Stafford et al. 









Drug selection (24.0%) 
Toxity, ADR or side-effect (19.0%) 
Untreated indications (16.6%) 
NSAIDs (7.7%) 
Antithrombotic agents (6.9%) 
Antidepressants (6.7%) 





(Peterson and Tenni 
2004) 
3.5 Untreated indications (27.5%) 
Drug selection (22.0%) 
Compliance and concordance (13.8%) 
DRP-drug combinations: 
Analgesics/condition not 





a Patients with mental illness, b Recently discharged cardiovascular patients  






4 Potentially Inappropriate Prescribing Among the 
Aged 
Aging involves impairment of functional reserve capacity and results in several 
physiologic, pharmacokinetic and pharmacodynamic alterations in the body that may 
increase the sensitivity of elderly people to drug effects and make them more 
vulnerable to adverse drug effects (Mangoni and Jackson 2004, ELDesoky 2007, 
Klotz 2009). Elderly patients also often have several concomitant clinical conditions 
which results in polypharmacy. In addition, the prevalence of polypharmacy increases 
with advancing age even if adjusted for comorbidity (Haider et al. 2009). 
Polypharmacy has several consequences in older people, including increased risk for 
ADRs and potentially serious DDIs but also undertreatment (Hanlon et al. 2006, 
Hilmer and Gnjidic 2009, Johnell et al. 2009). Excessive polypharmacy (i.e., use of 
10 or more concomitant drugs) has been even associated with increased risk of death 
in patients aged over 80 years (Jyrkkä et al. 2009).   
A significant number of ADEs, ADRs and relating hospitalizations among the 
elderly are preventable, i.e., resulting of suboptimal or inappropriate prescribing or 
monitoring (Beijer and de Blaey 2002, Gurwitz et al. 2003, van der Hooft et al. 
2008a). Suboptimal or inappropriate prescribing may include underprescribing 
(failure to prescribe needed medications), overprescribing (prescribing more drugs 
than needed) and misprecribing (prescribing incorrectly a needed medication) 
(Hanlon et al. 2001, Spinewine et al. 2007).  
As pharmacotherapy among the aged is challenging and may involve various 
risks, several criteria to identify inappropriate prescribing and drug use among elderly 
patients have been developed (Dimitrow et al. 2011). Usually, the development of the 
criteria has been based on literature reviews, clinical expertise of the researchers 
and/or on previous criteria (Dimitrow et al. 2011). Most of the criteria have been 
validated by using consensus methods, but some by using patient medical records.  
The criteria to indicate inappropriate prescribing can be explicit which means that 
they are based on pre-determined standards, are usually drug- or disease-oriented, and 
can be easily applied without significant clinical judgment (Spinewine et al. 2007, 
Dimitrow at al. 2011). Because the explicit criteria are usually quite simple drug-to-
avoid lists, they can only detect small fraction of prescribing problems and do not take 
into account the individual properties of patients (Spinewine et al. 2007, Steinman et 
al. 2009). As a result, they cannot be used alone as quality measures of prescribing or 
assessment of the appropriateness of individual patients’ pharmacotherapy (Steinman 
et al. 2009). However, explicit tools are good for screening the appropriateness of 
prescribing from drug charts or large population databases.  
Implicit tools and criteria, on the other hand, focus usually on the individual 
patient and clinical judgment is needed to assess the appropriateness of 
pharmacotherapy (Spinewine et al. 2007). Thus, they are more time-consuming to use 
and the results are easily affected by the clinical knowledge of the person using them 
(Spinewine et al. 2007). On the other hand, implicit criteria are not easily affected by 






et al. 2011). Whether implicit or explicit, good criteria should have an association 
with adverse health outcomes (Gallagher et al. 2007).  
4.1 Explicit Criteria to Indicate Inappropriate Prescribing 
4.1.1 The Beers Criteria and Their Derivatives 
The most used tool to evaluate potentially inappropriate medication (PIM) use among 
older people is the Beers criteria, which were developed in the US by a consensus 
panel of experts in 1991 and updated twice since then (Beers et al. 1991, Beers 1997, 
Fick et al. 2003). In the Beers criteria drugs are judged as inappropriate if evidence of 
their effectiveness is lacking, if their adverse effects outweigh the benefits or if safer 
alternatives exist. In updates of the criteria inappropriate disease-drug combinations 
are also considered (Beers 1997, Fick et al. 2003). The first set of Beers criteria 
included 30 medications or categories of medications to be avoided in frail nursing 
home residents aged ≥65 years; 19 were considered as generally avoidable and 11 
were considered avoidable based on dose, frequency or duration of treatment (Beers 
et al. 1991). In 1997 the criteria were updated to be used on all persons aged 65 and 
older regardless of frailty or place of residence (Beers 1997). The updated list 
included 28 criteria considering medications or medication categories to be avoided 
generally or depending on the daily dose, and 15 criteria on medications or classes of 
medications that should be avoided in 15 common disease states (Beers 1997). In 
2001 Zhan et al. modified the Beers 1997 criteria by including only the drugs that 
were considered inappropriate irrespective of diagnoses or dose. They also used a 
modified Delphi method to categorize the 33 drugs into 3 categories i.e., “should 
always be avoided”, “are rarely appropriate” and “have some indications but are often 
misused” (Zhan et al. 2001). 
The latest update of the Beers criteria was published in 2003 (Fick et al. 2003). 
Several medications were added (n=44) and dropped (n=15), and as a result the final 
criteria consisted of 48 medications or medication classes to be avoided generally or 
based on dose or duration of treatment, and of 20 diseases or conditions and 
medications to be avoided with these conditions (Fick et al. 2003). The latest update 
also rates each criterion as having high or low severity. Of the 78 individual 
medications listed in the Beers 2003 criteria, 37 were marketed as oral preparations in 
Finland in 2007 (Table 12). Since then carisoprodol, dextropropoxyphene, 
disopyramide and oral piroxicam have been removed from the market in Finland.  
Because the original Beers criteria do not take into account underprescribing, a 
refinement to the Beers criteria to state 13 preferred medications for 4 medical 
conditions was published in 2009 (Stefanacci et al. 2009). The preference of 
medications is based on thorough clinical evidence of their effectiveness and smaller 
risk compared to other alternative medications for that condition. The first set of the 






system (dementia, depression, Parkinson’s disease, and psychosis), but there is an 
intention to expand the criteria with other conditions frequently encountered in older 
adults. 
 Because the Beers criteria are based on drug selection in the US, their 
transferability to other countries with different drug formularies is not optimal. As a 
result, several national modifications have been made and new criteria been 
developed. Most of these criteria are based on the Beers criteria (Dimitrow et al. 
2011).  
In Canada McLeod and colleagues used Delphi consensus method to create their 
own set of explicit criteria by using the Beers 1991 criteria as a foundation (McLeod 
et al. 1997). As a result, 38 inappropriate prescribing practices for people aged ≥65 
years were identified. Eighteen drugs were considered as generally contraindicated, 
16 criteria involved a drug-disease interaction, and 4 criteria a DDI. Another 
Canadian set of criteria, the Improved Prescribing in the Elderly Tool (IPET) was 
created by extracting the 14 most prevalent PIMs or drug-disease combinations from 
the McLeod criteria by using 361 inpatient charts in an acute care hospital in Ontario 
(Naugler et al. 2000). Only 2 drug groups: long-half life benzodiazepines and tricyclic 
antidepressants with active metabolites, were considered to be generally avoidable by 
persons aged 70 and older according to IPET (Naugler et al. 2000). The remaining 12 
criteria consider inappropriate drug-disease combinations. The IPET is quite 
exclusive and weighted towards cardiovascular drugs (4 criteria), psychotropics (5) 
and NSAIDs (3). 
In Europe the French used Delphi method to create a modified version of the 1997 
Beers criteria by using also McLeod criteria as a foundation (Laroche et al. 2007a). 
The French criteria are based on national drug selection in France and consider drug 
groups rather than individual drugs when defining PIMs for people aged ≥75 years. 
As a result, the French criteria include several additional cerebral vasodilators and 
long-acting benzodiazepines (n=13) not found in the original Beers criteria. The 
French also added three new criteria: concomitant use of two (or more) NSAIDs, 
concomitant use of two (or more) psychotropic drugs form the same therapeutic class 
and use of any anticholinergic drug in addition to those listed in the Beers criteria 
(Laroche et al. 2006). The final French list consists of 34 criteria: 29 involve drugs or 
drug classes or drug combinations to be avoided generally, and 5 medications to be 
avoided in specific medical conditions.  
An Italian expert panel refined the Beers 2003 criteria by excluding disease-
specific criteria and several drugs from the original Beers 2003 diagnoses-
independent list (Maio et al. 2010). Several drug groups, like long- and short-acting 
benzodiazepines, antihistamines and stimulant laxatives were deemed inappropriate 
by the expert panel but excluded from the PIM list because they were not 
reimbursable by the 2006 Italian National Formulary (Maio et al. 2010). Two 
criterion; atypical antipsychotics and oral NSAIDs for >15 days, were added. As a 
result, the Italian PIM criteria consist of 23 avoidable drugs or drug classes 
categorized similarly to the Zhan criteria (Zhan et al. 2001) as “always avoidable”, 






subject to inappropriate use”. In addition to these explicit criteria, the Italians are 
currently developing CRIteria to assess appropriate Medication use among Elderly 
Complex patients (CRIME) by translating the recommendations of disease-specific 
clinical guidelines to elderly complex patients with limited life expectancy, functional 
and cognitive impairment and geriatric syndromes (Fusco et al. 2009). The criteria 
have not yet been published. 
The Norwegians developed and validated a list of drugs and combinations of 
drugs to be avoided in patients aged ≥70 years in general practice; the Norwegian 
General Practice (NORGEP) criteria (Rognstad et al. 2009). The Beers criteria (Beers 
1991, Beers et al. 1997, Fick et al. 2003), the Swedish quality indicators for elderly 
pharmacotherapy (Socialstyrelsen 2003) and earlier Norwegian studies and literature 
were used when developing the NORGEP criteria. The NORGEP criteria consist of a 
36-item list, of which 21 are avoidable drugs or doses and 15 include avoidable drug 
combinations (Rognstad et al. 2009). Of the avoidable drug combinations 8 involve 
warfarin or NSAIDs. As in other PIM criteria, tricyclic antidepressants, long-acting 
benzodiazepines and first generation antihistamines were included.  
The most recent European PIM list has been developed in Germany (Holt et al. 
2010). The PRISCUS list was developed based on the Beers, McLeod and The French 
criteria and on the Screening Tool of Older Persons’ Prescriptions (STOPP) and the 
Screening Tool to Alert doctors to the Right Treatment (START) -tool (Barry et al. 
2007, Gallagher et al. 2008a), a literature review and an expert panel. The list consists 
of 18 drug classes including 83 drugs. Of these, 63 were also included in one or more 
of the originally used PIM lists. For all PIMs in the PRISCUS list, a possible 
therapeutic alternative is stated. For the cases in which the use of a PIM is considered 
necessary, the list contains precautions to be taken during the use, e.g., 
recommendations on monitoring.  
A Japanese version of the Beers criteria was developed by a consensus method 
and includes 46 drugs/drug classes to generally be avoided in persons aged 65 and 
older (Akazawa et al. 2010). Of these, 15 were not included in the original Beers 2003 
criteria. 25 conditions and drugs to be avoided with these conditions are also listed, 7 


















Table 12. Potentially inappropriate medications (PIMs) independent of diagnoses and 
conditions according to Beers 2003 criteria (modified from Fick et al. 2003) 
available for outpatient care in Finland in 2007. 
Drug Cause for inappropriateness Severity 
(Low or 
high)  
(Dextro)propoxyphene Few analgesic advantages over 
acetaminophen, yet the adverse effects 
of narcotic drugs. 
Low 
Indomethacin Of all NSAIDs the most CNS adverse 
effects. 
High 
Muscle relaxants and 
antispasmodics: carisoprodol, 
short-acting oxybutynin 
Poorly tolerated: cause anticholinergic 
adverse effects, sedation, and weakness. 






Strong anticholinergic and sedative 
properties, rarely the antidepressant of 
choice for elderly patients. 
High 
Doxepin -‘’- High 




doses greater than lorazepam 3 
mg; oxazepam 60 mg; 
alprazolam 2 mg; temazepam 
15 mg; triazolam 0.25 mg 
Because of increased sensitivity to 
benzodiazepines in elderly patients, 
smaller doses may be effective as well 
as safer. Total daily doses should rarely 






Prolonged sedation, increased risk for 
falls and fractures. Short- and 
intermediate-acting benzodiazepines are 
preferred. 
High 
Disopyramide Potent negative inotrope, therefore may 
induce heart failure. Strongly 
anticholinergic. Other antiarrhythmics 
should be used. 
High 
Digoxin >0.125 mg (except for 
atrial arrhythmias) 
Decreased renal clearance may lead to 
increased risk of toxic effects. 
Low 
Short-acting dipyridamole May cause orthostatic hypotension. Low 
Gastrointestinal antispasmodic 
drugs: belladonna alkaloids, 
clidinium-chlordiazepoxide 















Drug Cause for inappropriateness Severity 
(Low or 
high)  
Diphenhydramine May cause confusion and sedation. 
Should not be used as a hypnotic. When 
used to treat emergency allergic 
reactions, should be used in the smallest 
possible dose. 
High 
Ergot mesyloids  Not effective in the doses studied. Low 
Ferrous sulfate >325 mg/d Absorbed amount not increased, but 
increased incidence of constipation. 
Low 
Ketorolacb Immediate and long-term use should be 
avoided, since a significant number 
have asymptomatic GI pathologic 
conditions 
High 
Amphetamines and anorexic 
agents (dexamphetamine, 
modafinil, methylphenidate 
and sibutramine)  
Potential for causing dependence, 
hypertension, angina, and myocardial 
infarction. 
High 
Long-term use of full-dosage, 
longer half-life non-COX-
selective NSAIDs: naproxen,  
piroxicam       
Risk for GI bleeding, renal failure, high 
blood pressure, and heart failure. 
High 
Daily fluoxetine Long half-life, risk for excessive CNS 
stimulation, sleep disturbances, and 
increased agitation. Safer alternatives 
exist. 
High 
Long-term use of stimulant 
laxatives except in the 
presence of opiate analgesic 
use: bisacodyl 
May exacerbate bowel dysfunction. High 
Amiodarone QT interval problems, risk of provoking 
torsades de pointes. Lack of efficacy. 
High 
Orphenadrine More sedative and anticholinergic than 
safer alternatives. 
High 
Nitrofurantoin Potential to renal impairment. Safer 
alternatives available. 
High 
Short acting nifedipine Potential for hypotension and 
constipation. 
High 
Clonidine Potential for orthostatic hypotension 
and CNS adverse effects. 
Low 
Estrogens only (oral) Evidence of the carcinogenic potential, 
lack of cardioprotective effect. 
Low 
a Available only as an ointment for insect bites. Not considered as a PIM. 
b Available only as eye drops and as an injection for hospital use. Not considered as a PIM. 








4.1.2 Criteria Independent of the Beers Criteria 
In addition to not taking into account variations in national drug selections, the Beers 
criteria have been criticized for including several drugs that are nowadays rarely used, 
lack of structure in the presentation of criteria and omission of several important and 
common instances of prescribing, such as inappropriate under-utilization of drugs, 
DDIs and duplicate drug classes (O’Mahony and Gallagher 2008).  
In Ireland evidence-based literature and experience of the researchers were used to 
develop a two-part tool to counter to the criticism of the Beers criteria and to take into 
account both inappropriate prescribing and underprescribing among persons aged 65 
or older (Gallagher et al. 2008a). Screening Tool of Older Persons’ Prescriptions 
(STOPP) has been validated for European setting to indicate 65 potentially 
inappropriate prescribing practices in older people (Gallagher et al. 2008a, Hamilton 
et al. 2009). The STOPP criteria are arranged according to physiological systems but 
also include criteria on analgesic drugs and on drugs that may adversely affect fallers, 
and a general statement to avoid duplicate drug classes. Most of the STOPP criteria 
concern inappropriate drug-disease combinations (n=42) or inappropriate duration of 
treatment (n=12). Of the remaining criteria 4 concern inappropriate drug 
combinations, 2 inappropriate doses, 3 non-indicated treatments and 2 need for 
combination/supplementary/additional therapy (Gallagher et al. 2008a). However, one 
criterion may contain several aspects of inappropriateness, for example inappropriate 
duration of treatment in certain disease states. The STOPP tool is designed to be used 
alongside with the Screening Tool to Alert doctors to the Right Treatment (START) -
tool (Barry et al. 2007, Gallagher et al. 2008a) in order to address underprescribing. 
The START-tool consists of 22 common disease states found in the elderly (e.g., 
cardiovascular diseases and osteoporosis) and appropriate, indicated, evidence-based 
treatments for these conditions (Gallagher et al. 2008a). 
In Ireland the STOPP tool identified significantly higher proportion of patients 
requiring hospitalization as a result of PIM-related adverse events than the Beers 2003 
criteria (11.5% vs. 6%) and was concluded to be more sensitive in identifying patients 
who could be injured by inappropriate prescribing (Gallagher and O’Mahony 2008). 
In Finland a national database on elderly pharmacotherapy by the Finnish 
Medicines Agency has been available since 2010 to support clinical decision making 
regarding pharmacotherapy of persons aged 75 and older, and to improve medication 
safety in primary care (Fimea 2011). The database consists of 350 drugs commonly 
used by elderly patients in Finland. Of these some are included because they are listed 
in the Beers criteria (Fick et al. 2003), the French criteria (Laroche et al. 2007) or in 
the quality indicators for drug use in elderly persons by the Swedish National Board 
of Health and Welfare (Socialstyrelsen 2003, Ahonen 2011, Fimea 2011). The drugs 
are classified in categories A–D based on the research literature and clinical 
knowledge of the experts involved in the development of the database. Class A drugs 
are appropriate for elderly. For class B drugs there is little research evidence, use 
experience or efficacy among persons aged 75 or older. Class C drugs are suitable for 






4.2 Implicit Criteria to Indicate Inappropriate Prescribing 
The Lipton criteria were developed and validated in the US in 1990 by using expert 
panel discussions and patient cases with the aim to implicitly measure appropriateness 
of prescribing (Lipton et al. 1992, Lipton et al. 1993). The tools is used to evaluate the 
appropriateness of each drug in the patient’s regimen according to six categories; drug 
allergy, dosage, schedule, appropriateness of drug therapy choice (i.e., prescribed 
without an established diagnoses or being a less-than-optimal choice given the 
patient’s overall health status), DDIs, and therapeutic duplication. Each category is 
scored by selecting one value (0=no problem, 1=potential problem, 2=definite 
problem, 9=not enough information to make a decision) for each drug, and the scores 
are summed to form a total prescribing score. Because the Lipton criteria were 
developed to measure prevalence of the drug-therapy problems, that had not been 
studied rigorously before, it lacks important dimensions of inappropriateness, like 
insufficient effectiveness and untreated conditions. 
The Medication Appropriateness Index (MAI-index) was developed in the US in 
1992 by using literature review and expert opinions (Hanlon et al. 1992). The MAI 
index measures the inappropriateness of prescribing by evaluating each drug used by 
ten criteria: indication, effectiveness, dosage, correct directions, DDIs, drug-disease 
interactions, practical directions, costs, duplication, and duration. Each medication is 
ranked as “appropriate”, “marginally appropriate” or “inappropriate” according to 
these 10 dimensions (Hanlon et al. 1992). Later, weighted values from 1 to 3 were 
determined for each of the ten criterion (Samsa et al. 1994). By using the weightings, 
a single summated MAI score from 1 to 18 can be created for each medication used 
(Samsa et al. 1994). Three MAI domains related to unnecessary prescribing (lack of 
indication, lack of effectiveness, and therapeutic duplication) have been renamed 
“Unnecessary Drug Use Measure” (Suhrie et al. 2009). 
Even though the MAI is more comprehensive than the Lipton criteria, it does not 
address underprescribing. As a result, an Assessment of Underutilization (AOU) tool 
was developed to supplement it (Jeffery et al. 1999). Using the tool a health care 
professional compares the patient’s list of chronic conditions to the prescribed drugs 
and each condition is rated with “A=no omission”, “B=marginal omission” or 
“C=omission”.  
4.3 Combination of Explicit and Implicit Criteria 
Australian researchers have created their own set of prescribing indicators for elderly 
patients (aged >65 years) unrelated to any earlier prescribing criteria (Basger et al. 
2008). The criteria are based on medications prescribed most frequently to 
Australians in 2006 and on the most frequent medical conditions for which elderly 
Australians consult a medical practitioner (Basger et al. 2008). The tool consists of 48 
prescribing indicators, of which 45 are explicit and 3 implicit. Of the indicators 18 






certain diseases or conditions, 4 disease monitoring, 3 specific DDIs, 1 presence of 
any DDI, 1 vaccination status, 1 smoking and 1 addresses changes in medications in 
last 90 days. The tool is envisaged to form an important part of medication review 
process.  
The quality indicators for drug use in elderly persons developed by the Swedish 
National Board of Health and Welfare (Socialstyrelsen 2003, 2010) can also be 
considered as a combination of explicit and implicit criteria. The Swedish indicators 
are based on international literature and currently include 9 drug-specific and 11 
disease-specific indicators. The drug-specific criteria relate to: 1) Drugs that should 
be avoided e.g., long-acting benzodiazepines, drugs with a significant anticholinergic 
effect; 2) Drugs that necessitate a correct and timely indication, e.g., opioids, 
neuroleptics; 3) Inappropriate drug regimen: e.g., sedatives every night for more than 
a month, bowel-stimulating laxatives daily for more than a week; 4) Inappropriate 
dosing e.g., for some neuroleptics; 5) Inappropriate polypharmacy; e.g., use of two or 
more drugs from the same therapeutic group regularly, use of three or more 
psychotropic drugs; 6) Drug combinations that can lead to clinically significant 
interactions (i.e., class D according to FASS); 7) Drugs for which the use or dosing 
need to be adjusted according to kidney function, 8) Drugs that may cause or impair 
orthostatism, increase the risk for falls or impair cognition; and 9) Preferred and 
avoidable hypnotics and sedatives (Socialstyrelsen 2003, 2010). Disease specific 
indicators describe inappropriate and appropriate drug use in eleven common diseases 
in elderly persons, e.g., hypertonia, heart failure, pain and depression (Socialstyrelsen 
2003, 2010).  
4.4 Tools to Assess the Appropriateness of Elderly Patients’ 
Pharmacotherapy in Finland 
In Finland the first effort to guide appropriate prescribing and monitoring among the 
aged was developed by the National Institute of Medicines and Social Insurance 
Institution in 2007 when they published a booklet “Geriatric Pharmacotherapy” 
(Kivelä ja Räihä 2007). General section of the booklet describes specific features of 
geriatric pharmacotherapy, including ADRs and DDIs. Diagnoses-specific chapters 
focus on recommended treatments, including preferable and risky drug choices 
(Kivelä and Räihä 2007).  
Of computerized programs to assess DDIs the one with the widest access in 
Finland by all healthcare professionals, including community pharmacists is the 
Swedish, Finnish, Interaction X-referencing database (SFINX) which in 2011 
includes more than 12 000 DDIs (Böttinger et al. 2009, Lääkeinteraktiot SFINX). The 
SFINX is maintained by Finnish Medbase Oy, Swedish Karolinska Institutet and 
Stockholm county council, and updated four times a year by specialists of clinical 
pharmacology and pharmacotherapy. In SFINX interactions are classified according 
to their clinical significance from A to D, and according to the level of documentation 






should be avoided. Another readily available drug-interaction database is Drug-
Reax® by Thomson Reuters (www.micromedex.com). In Drug-Reax® interactions 
are listed according to their severity (unknown, minor, moderate, major, 
contraindicated) and level of documentation (unknown, fair, good, excellent). 
In order to assess the need to change the drug or alter drug doses due to impaired 
kidney function, the Renbase database can be used (Renbase 2011). The database is 
maintained by Medbase Oy and continuously updated by specialists in 
pharmacotherapy. The database covers all drug products licensed in Finland and 
includes information on more than 1000 instances of dosing and safety of drugs in 
different levels of kidney failure by taking into account different drug formulations. In 
the Renbase drugs are classified from A to D according to the need to avoid the drug 
or alter the drug dose. In class A no alterations are needed, in class B information is 
missing or is based on pharmacokinetic properties, in C there is need to alter drug 
dosage or dosing interval, and in D use of drug should be avoided. 
4.5 Prevalence of Use of Potentially Inappropriate Medications 
(PIMs) 
The prevalence of PIM use in different populations and settings has been widely 
studied (Aparasu and Mort 2000, Liu and Christensen 2002, Gallagher et al. 2007). 
The results are highly affected by the criteria that have been used (Fialova et al. 2005, 
van der Hooft et al. 2005, Barry et al. 2006, Bongue et al. 2009, Buck et al. 2009, 
Ryan et al. 2009a, Akazawa et al. 2010). The literature review for this thesis will 
solely focus on studies utilizing the Beers 2003 criteria (Fick et al. 2003). 
4.5.1 PIM Use in the United States 
 
In the US most PIM studies have been conducted by using the Beers 2003 criteria 
independent of diagnoses and conditions (Table 13). The corresponding prevalence of 
PIM use has in most studies been near 25%, but varied substantially from 15% to 
53.5% (Table 13). The lowest prevalence was observed in demented patients of a 
National Alzheimer’s Coordination Centre (Lau et al. 2010). The study with the 
highest prevalence described PIM use over a 3-year-period and is thus not comparable 
with other studies (Albert et al. 2010). The studies that have used the complete Beers 
2003 criteria have involved small study populations and described prevalences 
ranging from 34% to 48.7% (Table 13). Overall, the studies with highest prevalences 
seem to be the ones that have used data from the first years of the 21st century 
(Zuckerman et al. 2006, Fick et al. 2008; Table 13). Because the populations and 
methods of data collection have differed, no conclusions of reduced PIM prescribing 
can be drawn from this finding. However, studies that have utilized Medical 






dwelling people aged ≥65 years, indicate reduction of PIM use between years 2001 
(27.8%), 2005 (20.0%) and 2006 (16.0%) (Fu et al. 2007, Fu et al. 2010). 
The most commonly used PIMs in the US studies have been largely the same 
(Table 13). Propoxyphene has been among the most prevalent PIMs in majority of 
studies. Also amitriptyline, anticholinergics and antihistamines, benzodiazepines, oral 
estrogens, fluoxetine, doxazosin and digoxin are mentioned frequently (Table 13).  
4.5.2 PIM Use in Europe 
The Beers 2003 criteria have been used in numerous European studies (Table 14). 
Fialova et al. (2005) studied the prevalence of PIM use among home care patients in 8 
European countries: Denmark, the Netherlands, UK, Iceland, Norway, Finland, Italy, 
and Czech Republic. The prevalences according to the Beers 2003 independent of 
diagnoses varied from 5.8% in Denmark to 25.2% in Czech Republic and 25.7% in 
Italy (Fialova et al. 2005). In Finland, the prevalence of PM prescribing was 20.3%. 
The differences can be partly explained by different availability of Beers drugs in the 
studied countries, being highest in Italy. In other studies from individual European 
countries the prevalence of diagnoses-independent Beers 2003 PIM use has ranged 
from 11.6% in Ireland to 38.5% in Portugal (Table 14).  
When diagnoses-dependent criteria are included, the prevalence of PIM use has 
varied between 13.0% in Ireland (Ryan et al. 2009a) and 33.6% in the UK (Table 14). 
Changes in PIM prescribing over the years have not been extensively studied in 
Europe. In the Netherlands van der Hooft et al. (2005) found no difference in PIM 
prescribing between 1997–2001. In the UK PIM use remained stable between 1994–
2003 (De Wilde et al. 2007), but decreased between 1996–2005 after commonly used 
propoxyphene was removed from the market (Carey et al. 2008). 
More consistently than in the US studies, benzodiazepines have been involved as 
one of the most prevalent PIMs in all European studies (Table 14). The exceptions to 
this are two Italian studies, in which benzodiazepines were excluded from the analysis 
(Maio et al. 2006b, Maio et al. 2010). Other common PIMs in European studies have 
been, e.g., amitriptyline, ticlodipine and amiodarone (Table 14).  
4.5.3 PIM Use Outside the United States and Europe 
In countries outside the US and Europe, the prevalence of PIM prescribing in 
Australia resembles the situation in Europe both regarding the prevalence and 
commonly used PIMs (Table 15). Also in other countries the prevalences resemble 
European results, but involved small patient populations (Saab et al. 2006, Zaveri et 
al. 2010, Lin et al. 2011) which may impair the reliability of the results. For example, 
in a large Taiwanese study with more than 176 million outpatient visits the annual 
prevalence of PIM use, independent of diagnoses, was over 60% while in smaller 






4.5.4 Factors Associated with PIM Use 
Use of PIMs has been consistently associated with female gender and higher number 
of medications used (Tables 13–15). In addition, higher number of chronic diseases 
has predicted PIM use in several studies (Tables 13–15). Other factors associated with 
PIM use are, for example, history of depression (Blalock et al. 2005, Akazawa et al. 
2010, Weston et al. 2010) and poor economic situation (Fialova et al. 2005, Maio et 
al. 2006b). In some studies older age has been a protective factor (Fialova et al. 2005, 
Barnett et al. 2011), in others a risk for PIM use (Maio et al. 2006b, Landi et al. 






Table 13. Potentially inappropriate medication (PIM) use according to the Beers 2003 criteria (Fick et al. 2003) in the community setting in the United 
States. Presented in alphabetical order. 
Article 
 




Most common PIMs PIM use associated with 






Retirees from a single 
large corporation aged 
≥65 years (n=7 459) 
Employer 
prescription 
claims, 2003–2005  






















26.6 % Propoxyphene, clonidine, 
naproxen, amiodarone 
Lower social support, poorer 
health status, higher disability, 
higher number of medications, 
history of major depression 







Patients with at least 2 
primary care visits in 
the previous 2 years,  









Female sex, polypharmacy (≥6 
medications), number of 
primary care visits  






care patients aged ≥65 





40.7% Estrogens only, 
propoxyphene, short-acting 
benzodiazepines, digoxin, 
longer half-life NSAIDs 
 






representative sample of 
non-institutionalized 




data from 2001 
27.8% in 
2001 
Propoxyphene, digoxin > 
0.125 mg, amitriptyline 
Higher mean number of 
prescriptions 







sample, aged ≥65 






















Article Criteria Population (n), age Data source Prevalence Most common PIMs PIM use associated with 







eligible for Medicare 
and Medicaid, aged 














patients with (n=1 
853) and without 
dementia (n=2 665) 





Data Set from 












Higher number of medications, 
female gender 




Veterans aged ≥65 
visiting primary care 
clinics (n=236)  
Interview and 
medical record 





NS   




Patients of 2 outpatient 




24% Fluoxetine, oral estrogens, 
diazepam, indomethacin, 
naproxen, dicyclomine 
Female gender, not being a high 
school graduate, higher number 






aged ≥60 (n=100) 
Home-visit 
May–July 2002 







using 5 or more 




chart review at 
veterans clinic 
2001–2003 
37% Digoxin, amitriptyline, 
oxybutynin 
Increasing number of drugs 
Zuckerman 






of privately insured 
patients aged ≥65 















Table 14. Potentially inappropriate medication (PIM) use according to the Beers 2003 criteria (Fick et al. 2003) in the community setting in Europe. 
Presented in alphabetical order. 
Article, 
country 




Most common PIMs PIM use associated with 






residents aged 66–99 
years (n=65 742) 
Health care data 
in 2005–2006 (2 
years) 
30.9% Amitriptyline, ferrous 
sulphate, long-acting 
benzodiazepines 
Female gender, younger age, 
higher polypharmacy, living in 
nursing or residential home 







patients from 3 cities, 




31.6% Cerebral vasodilators, long-
acting benzodiazepines,  
short-acting benzodiazepines 
 







Primary care patients 









NS Number of drugs (strong 
association), female gender, 
older age, living in a care home 






Home care patients 
aged ≥65 years from 















In Finland: diazepam, 
amitriptyline, short-acting 
nifedipine  
Poor economic situation, users 
of anxiolytic drugs, use of >6 
medications. 
Less likely: aged ≥85 years, 
living alone  





HMR patients aged 







van der Hooft 






people aged ≥65 years 
(n=18 030–26 378/ 
study year)  
Computer-based 
patient records 














patients aged ≥80 from 




26.0% Long-acting and short-acting 
benzodiazepines, short-acting 
nifedipine, ticlopidine 
Older age, cognitive 













Most common PIMs PIM use associated with 




Beers 2003c  
(iDg, iDo, 
iDu) 
Outpatients aged ≥65 
with ≥1 prescription in 
2001 living in one 











Older age, number of chronic 
disease and medications, male 
sex, low income 




et al. 2006b 
Outpatients aged ≥65 
with ≥1 prescription in 
2006 (n=91 741) 
Local outpatient 
prescription data-
base, year 2006 
25.8% NSAIDs, ticlodipine, 
doxazosin, amiodarone 
Older age, higher number of 
chronic diseases and 
medications, female gender 
De Oliveira 






a prescription in of 12 
community pharmacies, 




38.5% Diazepam, ticlopidine, 
amiodarone 
 








Primary care patients 
alphabetically selected 
from surgery’s 











ferrous sulphate >325 mg 
cDg: depression and long-
term benzodiazepine 
 






Primary care patients 



















Primary care patients 
(includes nursing 
home patients) aged 
≥65 years (annual 
n=130 262–177 123)  
Primary care 










ferrous sulphate >325 
mg/day 
 
cGg=cum diagnoses, iDg=independent of diagnoses, iDo=independent of dosage, iDu=independent of duration of treatment 






Table 15. Potentially inappropriate medication (PIM) use according to the Beers 2003 criteria (Fick et al. 2003) in the community setting in countries 
outside the US and Europe. Presented in alphabetical order. 
Article, 
country 










Patients with at least 2 
pharmacy claims over 
1-year period, aged 












Polypharmacy, inpatient service 
use, comorbidities of peptic 


























Ambulatory care visits 
(n=176 661 994) 
involving a 
prescription by 
















Female gender, number of drugs 
prescribed during a visit 






aged ≥65 years 
prescribed long-term 
medications from a 
tertiary medical centre 
(n=5 741) 






23.7% Dipyridamole, doxazosin, 
amiodarone, chlorzoxazone 
 
Female sex, older age, higher 
number of chronic diseases and 
medications 






patients visiting an 
outpatient clinic, aged 









Older age, higher number of 
























Veterans with eligible 





















Patients of 10 
community 








22.4% Propoxyphene, dipyridamole, 
doxepin, meprobamate 
(Data stated only for wider 
range of inappropriate 
prescribing i.e., combination of 
PIMs, missing doses, DDI, 
duplication etc.) 





Patients presented to 
outpatient department 
of tertiary hospital, 
















4.6 Negative Outcomes and Risks Associated with the Use of 
Potentially Inappropriate Medications 
Evidence on the risks of PIM use is controversial and inconclusive (Jano and Aparasu 
2007; Table 16). Jano and Aparasu (2007) reviewed the literature from October 1991 
to October 2006 to examine health outcomes associated with PIM use according to 
the Beers criteria (Beers et al. 1991, Beers 1997, Fick et al. 2003) among elderly 
patients in different health care settings. This literature review will complement the 
Jano and Aparasu (2007) review with more recent studies (Table 16) but in line with 
other parts of this thesis will focus only on studies on community-dwelling people and 
applying the Beers 2003 criteria (Fick et al. 2003). 
Based on the review by Jano and Aparasu (2007), the use of PIMs was associated 
with hospitalization among community-dwelling elderly. Since the review was 
published several new articles have appeared (Table 16) and have confirmed the 
association (Fick et al. 2008, Lin et al. 2008, Lai et al. 2009, Akazawa et al. 2010, 
Albert et al. 2010). In Ireland a prospective observational study indicated that 16% of 
597 consecutive acute hospital admissions could be linked to adverse effects of Beers 
2003 PIMs (Gallagher et al. 2008b). Of the patients receiving PIMs (n=191), 49% had 
conditions that were likely to be adverse effects of PIMs, for example falls, 
gastrointestinal bleed or cognitive deterioration. However, in another Irish study 
(Gallagher and O’Mahony 2008) Beers criteria PIMs were contributory or causal only 
in 6% of acute admissions to hospital by elderly patients. In the same study, STOPP-
criteria identified a significantly higher proportion of patients requiring 
hospitalization as a result of PIM-related ADE than the Beers criteria (11.5% vs. 6%). 
No association between PIM use and health care use other than hospitalizations or 
mortality was found among community-dwelling people in the review by Jano and 
Aparasu (2007). With regard to mortality, more recent studies have provided similar 
results (Table 16; Lin et al. 2008, Barnett et al. 2011). However, several recent studies 
have found an association between PIM use and higher health care utilization, for 
example higher number of outpatient or ambulatory care visits (Fick et al. 2008, Lai 
et al. 2009, Akazawa et al. 2010) and emergency department (ED) visits (Fick et al. 
2008, Lai et al. 2009). For ED visits the association is not indisputable and other 
drugs than PIMs may play a greater role (Budnitz et al. 2007, Lin et al. 2008). At least 
in an US survey only 3.6% of outpatient ED visits due to an ADE among patients 
aged ≥65 years were caused by diagnoses-independent PIMs and additional 5.2% by 
diagnoses-dependent PIMs (Budnitz et al. 2007). In comparison, the percentage was 
17.3% for warfarin, 13.0% for insulin and 3.2% for digoxin. Accounting for 
outpatient prescription frequency, the risk for ED visits for these 3 medications was 
35 times greater than for diagnoses-independent PIMs.  
Interestingly, in a large US cohort study (n=487 383) the use of PIMs increased 
the risk of nursing home admission by 31% but PIM hormones were found to have a 
protective effect (Zuckerman et al. 2006). On the other hand, antipsychotics, 
antiemetics and analgesics had higher relative risks ranging from 1.97 to 2.03. The 






explained by the underlying conditions rather than the PIM use. Also, it can be 
possible that some PIMs pose more risks than the others. 
There are some studies that indicate PIMs to be associated with ADEs and ADRs 
(Jano and Aparasu 2007, Table 16). However, in several recent studies in the 
community setting no association between PIM use and self-reported ADEs has been 
found (Table 16; Lund et al. 2010, Shiyanbola and Harris 2010, Fiss et al. 2011). 
Similar to ED visits, it is possible that PIMs are not the most significant drug group 
causing ADRs (Laroche et al. 2007b). In a French study among outpatients aged ≥70 
years admitted to hospital the ADR prevalence was higher among PIM users 
according to the French modification of Beers criteria than among non-users (20.4% 
vs. 16.4%) but after adjustment for confounding factors the difference was not 
statistically significant (Laroche et al. 2007b). In addition, among PIM users only 
5.9% of ADRs were directly related to PIMs. Instead, majority of drugs involved in 
ADRs (47.5%) were diuretics and other cardiovascular drugs. 
Falls, a common ADR in elderly patients, may be more common among PIM 
users (Agashivala and Wu 2009, Berdot et al. 2009, Fiss et al. 2011). In a French 
study, the association was mainly due to long-acting benzodiazepines and other 
psychotropics and anticholinergic medications (Berdot et al. 2009). No association 
was found for short- or intermediate-acting benzodiazepines either in occasional or 
regular use. When risk for fractures is considered, there has been no difference 
between users of Beers-criteria benzodiazepines or users of other benzodiazepines 
(van der Hooft et al. 2008b). Instead, the risk for fractures was greater for high doses 
(>10 mg diazepam dose equivalents) or longer-duration treatments (14–90 days), 
irrespective of the half-life of the benzodiazepine (van der Hooft et al. 2008b). On the 
other hand, in nursing home setting the risk for falls for non-Beers 2003 psychoactive 
drugs was smaller (OR 0.83, p=0.028) than for those psychoactive drugs listed in the 
Beers 2003 criteria (Agashivala and Wu 2009). 
Some studies have been published with regard to the effects of PIM use on 
HRQoL (Jano and Aparasu 2007, Landi et al. 2007a). Again, the results are highly 
inconsistent. Still, poorer HRQoL, worse self-perceived health status and impairment 
of physical performance have been reported (Chin et al. 1999, Fu et al. 2004, Landi et 
al. 2007a). 
According to the review by Jano and Aparasu (2007), the use of PIMs was 
associated with increased costs in all health care settings. Later Fu et al. (2007) 
estimated the incremental health care expenditures (related to both drug costs and 
health care visits and stays) due to Beers 2003 PIM use in the community-dwelling 
elderly in the US to be USD 7.2 billion in 2001. In Japan, the use of PIMs was 
associated with 33% higher total medical cost after adjusting for confounding factors 
(Akazawa et al. 2010). 
In conclusion, the results on the adverse outcomes associated with PIM use among 
community-dwelling elderly remain controversial and inconclusive, but suggest that 






Table 16.  Adverse health outcomes associated with potentially inappropriate medication (PIM) use according to the Beers 2003 criteria (Fick et al. 
2003) in the community setting, excluding studies reviewer earlier (Jano and Aparasu 2007). Presented in alphabetical order. 






cohort (1 year) 
Outpatients with at least 2 
pharmacy claims, aged 
≥65 years (n=6 628) 
Outpatient days (Incidence rate ratio1.18), 
hospitalization (OR 1.68), health expenses 
(33% increased, including medical and 
pharmacy services), each p<0.001 
 
Albert et al. 
2010 
Beers 2003  Retrospective 
cohort (3 years) 
Retirees (n=7 459), 96% 
aged ≥65 years  









(n=65 742) and in care 
patients (n=4 557), aged 
≥65 years 













aged ≥65 years (n=6 343) 
 
Falls (if cerebral vasodilators excluded, 
both occasional (OR 1.22, p=0.03) and 
regular (OR 1.19, p=0.049) PIM use, if 
cerebral vasodilators included, only 
occasional use (OR 1.23, p=0.016)) 
 








aged ≥65 years 
(n=16 877) 
Higher prevalence of DRPs i.e., ADEs 
(14.5% vs. 4.7%; p<0.01), inpatient visits 
(OR 1.99), outpatient visits (OR 1.53), 
office visits (OR 1.89), ED visits (OR 1.98) 
and higher healthcare costs (p<0.01) 
 






HMR patients aged ≥65 
years (n=744) 
Slight association with self-reported falls (φ 
coefficient 0.1074, p=0.024)  
Self-reported ADR (φ 
coefficient 0.0185, p=0.619) 





cohort (1 year) 
Community-dwelling, 
aged ≥65 years (n=720) 
Higher health care expenditures compared 
to nonusers (p<0.05) 
 








Patients with ambulatory 
care visits, aged ≥65 years    
(n=2 133 864 in 2004) 
Higher mean number of ambulatory care 
visits (30.78 vs. 16.57; p<0.001), ED visits 
(0.27 vs. 0.15, p<0.001) and hospital 








Study Criteria Study design Population (n) Effect on outcome No effect on outcome 







aged ≥80 years (n=364) 
Impaired physical performance compared 
to non-users (Short Physical Performance 
Battery Score 7.04 vs. 6.16; p=0.01).  
If ≥ 2 PIMs: poorer functional status (ADL 
scale score) compared to nonusers (p=0.01) 
and users of 1 PIM (p=0.03) 
Muscle strength 
 







Ambulatory, aged  
≥65 years (n=5 741) 
Hospitalization (OR 1.62; p=0.03) Death (OR 1.71, p=0.567), ED 
visits (OR 1.13, p=0.481) 








veterans aged ≥65 years 
(n=236) 















≥65 years (n=874) 
 Self-reported ADE 
ADE=Adverse drug effect, ADL=Activities in daily living, ADR=Adverse drug reaction, iDg= independent of diagnoses, iDo=independent of dose, iDu=independent of 






5 Aims of the Study 
This study consists of 4 substudies (Table 17) which examine the Finnish Comprehensive 
Medication Review (CMR) model as a means to improve the appropriateness and safety of 
pharmacotherapy among community-dwelling patients aged ≥65 years. The specific aims 
of the study were: 
 
1) To determine the prevalence of potentially inappropriate medication use according 
to the Beers 2003 criteria among Finnish non-institutionalized population aged ≥65 
years, and the reimbursement costs for these medications (I) 
2) To describe the development of the CMR accreditation training and the curriculum 
used in it. To assess the participants’ perceptions about the training (II) 
3) To describe the development and contents of the CMR model. To develop 
documentation forms for CMR and assess CMR training participants’ satisfaction 
on the documentation (III) 
4) To evaluate the DRPs detected and reported to physicians during CMR. To identify 
drugs most commonly involved in the DRPs and the interventions resulting from 
the CMRs among outpatients aged ≥65 years (IV) 










I Analysis of PIM use 
and costs obtained 




population aged ≥65 years 




II Description of the 
development of 
CMR training,  




attending courses in 
Helsinki and Oulu (n=38), 






content analysis of open-
ended questions 





survey in 2008 
CMR accreditation training 
participants attending 
courses in Helsinki and 
Oulu, responses of 
community pharmacists 




qualitative content analysis 
of open-ended questions 
IV Analysis of CMR 
case reports to 
evaluate drug-related 
problems identified 




and assisted-living (n=51) 





statistical analyzes; t-test, 
Mann-Whitney U-test, 






6 Materials and Methods 
6.1 Study Populations 
6.1.1 National Outpatient Population Aged 65 and Older (I) 
The cross-sectional register-based study involved the entire non-institutionalized 
population of Finland aged 65 or older in 2007. Since the analyzed Social Insurance 
Institution (SII) data included persons deceased during 2007, the number of total elderly 
population was retrieved from the national population statistics of December 31, 2006 
(Statistics Finland 2010). Institutionalized care in Finland is the responsibility of 
municipalities, and the number of inpatients is based on municipal statistics as of 
December 31, 2006 (Sjöholm 2008). In 2007 there were in total 868 717 inhabitants aged 
≥65 in Finland (Statistics Finland 2010). Of these 27 208 (3.1%) were living in 
institutionalized setting (Sjöholm 2008). Thus, the population in the substudy IV consisted 
of 841 509 non-institutionalized persons aged ≥65 years. 
6.1.2 CMR Accreditation Training Participants (II, III, IV) 
The three substudies related to the development of CMR procedure (II, III, IV) involved 
CMR accreditation training participants in 2005–2007 (Table 18). The pilot training 
participants (n=26) were involved in the development of the CMR accreditation training 
curriculum, the CMR procedure and the CMR documentation. The training participants 
were practicing community and hospital pharmacists from different parts of Finland. They 
were selected according to predetermined criteria, which required e.g., that the applicants 
had ongoing cooperation with local health care providers, particularly with physicians. 
Of the 42 accreditation training participants in 2006–2007 in Helsinki and Oulu 38 
responded to an internet-based survey regarding their perceptions of the CMR training 
(response rate 90.5%). The same training participants were also consulted using another 
survey to assess their satisfaction and ideas on improving the CMR documentation. This 
second survey was targeted only to community pharmacists (n=32), because the hospital 
pharmacists indicated that they rarely had the opportunity to use the entire CMR 
documentation in busy hospital settings. Responses were received from 27 community 
pharmacists (response rate 84.4%). However, of the 32 community pharmacists two did 
not use the documentation because they did not have any patients for CMR during the 
accreditation training period. Thus, the response rate among those having actually applied 









Table 18. CMR accreditation training course participants involved in the substudies II-IV 
Course, 
year 








Kuopioa 21 5 Development of the CMR 
accreditation training curriculum (II) 
Development of the CMR procedure 
(III) 








17 5 Testing of the CMR accreditation 
training curriculum (II) and providing 
their perceptions on the training (II) 
Testing of the CMR procedure and 
documentation (III) 
Providing development needs of the 
CMR documentation (III) 
Providing conducted CMR cases for 
the DRP analysis (IV) 
Oulua 15 5b 
a All the training courses included practicing pharmacists from different parts of Finland 
b One hospital pharmacist discontinued the accreditation training 
6.1.3 Patients Receiving CMR (IV) 
The 32 community pharmacist participating in the CMR accreditation training in Helsinki 
and Oulu in 2006–2007 were asked to submit anonymous case reports of the CMRs they 
conducted during the training for use in this study. The patients for CMR were selected by 
the collaborating physicians based on potential problems in their pharmacotherapy, e.g., 
suspected ADRs, poor adherence or excessive polypharmacy. An informed consent was 
requested from the patients or their authorized representatives both to participate in the 
CMR and to use the anonymous case reports in this study. The cases were included if 
written consent was received, if they were a primary care patient aged ≥65 years and if the 
documentation of the case conference was available. Of the total 166 CMRs conducted, 
121 were included and 45 excluded (Figure 8). The 121 included case reports were 













32 community pharmacists 
attending CMR accreditation 
training, 
166 CMRs 
 -5  
(-14 cases) 
 No case conferences during the 
training (3 pharmacists, 4 cases)  
No written case reports (1 pharmacist, 
5 cases) 
Did not return case reports because of 
poor collaboration with the physician 
(1 pharmacist, 5 cases) 
 
 
     
27 community pharmacists, 
152 CMR case reports 
 -26 cases  No consent from the patient (n=17) 
No case conference (n=5) 
Cases concerned inpatients (n=4) 
 
     
126 case reports of primary 
care patients  
 -5 cases  Patient's age <65 years (n=5) 
 
     
121 CMR case reports by 26 
community pharmacists 
    
Figure 8 Inclusion of CMRs by community pharmacists under accreditation training for the 
substudy IV  
Of the 121 CMR patients, 57.9% (n=70) were living in their own homes and 42.1% 
(n=51) in assisted living settings (Table 19). Mean age of the patients was 80.0 years, and 
mean number of regular prescription drugs 12.3. There was no difference in the age and 
mean number of used prescription drugs between home-dwelling and assisted-living 
patients (Table 19). However, the home-dwelling patients were using more ‘as needed’ 
prescription drugs and OTC drugs than the assisted-living patients (Table 19). Seventy-
nine percent of the patients used regularly ≥10 prescription drugs.  









  Women, n (%) 87 (71.9) 53 (75.7) 34 (66.7)  
Age, mean (range) 80.0 (65–95) 79.6 (65–91) 80.5 (66–95) NSa 
Drugs, n mean (range) 
  Regular prescription drugs 12.3 (4–23) 12.5 (4–22) 12.0 (6–23) NSb 
As needed prescription 
drugs 
2.8 (0–9) 3.2 (0–9) 2.1 (0–9) 0.002a 
  Over-the-counter drugs 2.2 (0–11) 2.7 (0–10) 1.5 (0–11) 0.001a 








6.2.1 Use of Potentially Inappropriate Medications (PIMs) Among Non-
Institutionalized Population Aged 65 and Older (I) 
The Social Insurance Institution (SII) maintains a national prescription register of all 
reimbursed drug purchases by outpatients in Finland. Drugs are approved for the 
reimbursement scheme by the Pharmaceutical Pricing Board under the Ministry of Social 
Affairs and Health, based on both clinical significance and the price of the product 
(Wahlbeck et al. 2008). As the scheme is planned to support mainly long-term therapies 
for chronic diseases, small package sizes of 10–30 tablets are usually not reimbursed, 
other than medicines such as antimicrobials used to treat some short-term conditions.  
The data for this study consisted of extraction from the SII prescription register of all 
reimbursed drugs for outpatients aged ≥65 years in 2007. The drugs were classified on the 
fifth level of the Anatomical Therapeutic Chemical (ATC) classification system (WHO 
2011). For each drug, the data includes the total number of individuals aged ≥65 years 
who had received reimbursements of that drug. The following data were derived from the 
obtained SII data: 1) PIMs, independent of diagnoses (Fick et al. 2003), including drug 
formulations that could only be administered orally; 2) the number of elderly outpatients 
who had received reimbursements for each PIM during 2007; and 3) the total 
reimbursements (€) paid for each PIM. For PIMs that were not identifiable based on the 
fifth level of ATC classification, additional data was acquired from the SII using Nordic 
article codes available for identifying each marketed drug product (Pharmaceutical 
Information Centre 2007). These product codes were used to separate long- and short-
acting forms of oxybutynin, dipyridamole and nifedipine preparations. The same method 
was used to separate oral versus local estrogens; temazepam 10 mg and 20 mg tablets; and 
digoxin 0.0625 mg, 0.125 mg and 0.25 mg tablets. To determine the total number of PIM 
users in 2007, relevant ATC codes or Nordic article codes were linked to personal identity 
numbers in the SII. 
The 2003 version of the Beers criteria (Fick et al. 2003), independent of diagnoses or 
conditions, was used to evaluate PIM use. These criteria were selected because they are a 
commonly used tool to address PIM use in international studies (Tables 13–15) and thus, 
allow the best comparison of results. Secondly, the criteria are suitable to be used in large 
population databases.  
The Beers criteria were adopted by excluding the drugs not licensed in Finland in 
2007. Of the 78 drugs listed in the original Beers 2003 criteria, 37 (47.4%) were marketed 
as oral preparations in Finland during the study period (Table 12). Drugs considered 
potentially inappropriate because of dosage or duration of treatment (lorazepam, 
oxazepam, alprazolam, naproxen and piroxicam) were excluded because the SII data do 
not contain this information. The only exceptions to this exclusion were digoxin and 






6.2.2 Development of the CMR Accreditation Training and Procedure (II, III) 
The development of the CMR accreditation training and the CMR procedure started as a 
part of the TIPPA follow-up program in 2004 (TIPPA Project 2004, Figure 9). The TIPPA 
Coordination Group which included representatives from the key pharmacy stakeholders, 
i.e., universities, continuing education centers and professional organizations planned and 
coordinated this work. Aducate, Center for Training and Development, University of 
Eastern Finland, was responsible for organizing the CMR training.  
Before starting the actual development of the CMR training and procedure, suitable 
models for them were sought from abroad (Hakkarainen 2008). No long-term trainings for 
CMR were found, and thus the curriculum was developed by the TIPPA Coordination 
Group. Australian Home Medicines Review (HMR; Sorensen et al. 2004) and US 
Medication Therapy Management (MTM; JAPhA and NACDS 2005) service models were 
found to be suitable as examples for the CMR procedure development. To develop and 
test the CMR curriculum and various CMR models a CMR pilot training was started in 
2005. During the training, the participants were introduced to the principles of clinical 
medication reviews and procedures used in Australia and USA. Then they were asked to 
develop a CMR procedure/model in collaboration with physicians and other health care 
professionals to fit their local health care environment. These potential procedures were 
combined to form a national standard CMR procedure by the TIPPA Coordination Group. 
The Group also accepted the final CMR accreditation training model. Both the CMR 
accreditation training and the uniform CMR model were tested in practice by participants 
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6.2.3 Participant Receptiveness to the CMR Accreditation Training (II) 
The CMR training participants in Helsinki and Oulu in 2006–2007 were asked to evaluate 
the CMR training curriculum and their learning outcomes within a month after they 
completed the training. An Internet-based survey routinely used by the Centre for Training 
and Development, University of Eastern Finland (University of Kuopio at the time of this 
study) was used for this purpose. The survey instrument consisted of 3 sections with three 
types of questions (Table 20).  
In addition, the participants were asked to estimate whether they were going to conduct 
CMRs in the future. The alternatives given for responses were: I will (the plans for the 
future already exist); I intend to continue the practice (the continuation will probably 
succeed); I’m still uncertain; and I will not conduct CMRs in my practice in the future.  
Table 20. Structure of the survey instrument to evaluate the CMR training curriculum (II)  
Section Question type Questions / issues addressed 






2) Curriculum design 
3) Teaching methods 
4) Learning materials 
5) Content validity of the assignments/group 
projects/examinations  
II Alternatives ”yes”, 
”possibly”, ”no” 
1) Did the training meet your educational 
expectations and needs?  
2) Would you recommend this training for your peers? 
III Open-ended questions 1) What factors facilitated your learning during this 
training? 
2) What factors prevented or hampered your learning 
during this training? 
3) What did you learn and how can you apply it to 
practice? 
4) What ideas, comments and suggestions do you 
have for the improvement of the training? 
6.2.4 Development of the CMR Documentation Forms (III) 
The development of the CMR documentation forms involved four, partly overlapping, 
phases (Figure 10). The developed documents included: 1) A Referral and Patient Data 
Collection Form; 2) A Patient Interview Form; 3) A CMR Review Chart; 4) A CMR Case 
Report. In addition, a suitable Health-related Quality of Life (HRQoL) measure for the 
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Figure 10 Development of the CMR documentation 
In the first phase of the development of the CMR documentation the Australian HMR 
documentation (Australian Government 2011c) was familiarized with (Figure 10). In 
addition, a literature review was conducted to find information about issues that should be 
embedded in the CMR documentation forms. Based on this information a pilot CMR 
Interview Form was developed and tested among a pilot group of 9 home-health care 
patients aged >65 years in Lohja. The patients were asked to self-administer the form. A 
week later a face-to-face interview was conducted to compare the answers for accuracy 
and to test the usability of the form. 
At the same time, the CMR pilot training participants developed for themselves the 
documentation they needed during CMR (Figure 10). The preliminary documents were 
collected after the training. They included a CMR Case Report and a CMR Review Chart. 
Various CMR charts were used to form a standard review chart. The standard CMR Case 
Report was developed by combining the various CMR case reports developed by the CMR 
pilot training participants, by using the HMR documentation for ideas and by utilizing the 
results of the abovementioned literature review. 
The developed documentation forms were tested among CMR accreditation training 
participants in 2006–2007. When needed, the forms were modified based on their 
suggestions. 
In addition to other documents, a literature search was conducted to find a suitable 
HRQoL measure to be used during CMR. HRQoL instruments can be either disease 
specific or generic (Kheir et al. 2004). For the purposes of CMR, which involves 
heterogeneous patient populations, a generic instrument is needed. Most CMR patients are 
elderly and the CMR interview may be of a long duration. Thus, the following were 
considered as necessary features for a suitable measure: 1) available in Finnish and in 







6.2.5 Survey on the Need to Modify the CMR Documentation (III) 
The uniform CMR documentation format was tested by the CMR accreditation training 
participants in Helsinki and Oulu (Figure 10). At the end of the training the community 
pharmacist participants were asked to administer a survey to assess their opinions on the 
CMR documentation formats. The participants could send their responses as paper prints 
or via e-mail. 
The survey instrument consisted of two parts. The first part had open-ended questions 
regarding the need to improve the CMR documentation (Table 21). The second part 
included a table with questions with three alternatives (yes, no, on some occasions) 
regarding the participant’s opinion on the need: 1) to include each CMR documentation 
sheet in the CMR procedure in the future, and 2) to include suggested specific questions in 
the interview form (Table 22). In addition, there was space for free commenting at the end 
of the survey. 
 
Table 21. Open-ended questions of the survey instrument to address CMR accreditation 
training participants’ opinions on the CMR documentation forms 
A. CMR referral and data collection form 
1. Is this form necessary/needed or could you get the information regarding patient’s 
medications and diagnoses easier some other way? Does completion of this form 
cause too much work for the physician? Is it enough just to tell the physician what 
patient data is needed for the review? 
B. Patient interview form 
1. Do you think that patient interview is useful/needed during CMR? Please, justify 
your opinion. 
2. In your opinion, what issues are missing from the interview form? What information 
should be added? 
3. Are there unnecessary questions in the interview form? Should certain questions be 
removed? 
4. Questions regarding to anticholinergic adverse effects are included in the interview 
form. Is there a need to add questions regarding other adverse effects or symptoms, 
e.g., sedation, dizziness/vertigo, pain? What other symptoms do you consider 
necessary to ask about? 
C. CMR case report 
1. What issues are missing? What issues should be added?  
2. Are there unnecessary sections (parts) in the report form? What and why? 
D. CMR review chart 









Table 22. Questions in the survey instrument addressing CMR accreditation training 
participants’ opinions on the CMR documentation forms 
Are the following documentation forms needed in the CMR procedure in the future 
(tick)  Yes No On some 
occasions 
A. Referral form with patient clinical data    
B. Patient interview form    
Questions with potential for being added to the patient interview form 
Patient’s weight and height    
Patient’s health behaviors in general    
The following specific health behaviors:    
  - smoking    
  - alcohol consumption    
  - diet    
  - outdoor activities and exercise    
  - sleeping/awake schedule and quality of sleep    
Existing questions: 
Questions regarding DRPs (#9.)a    
Questions regarding adherence (#10. and #11.)a    
Questions regarding stopping a drug (#12. and #13.)a    
Questions regarding wishes for changes in drug 
regimen (#14. and #15.)a 
   
Questions regarding anticholinergic adverse effectsa    
3. A case report form    
4. CMR review chart    
a See Appendix 2 
6.2.6 Analysis of Drug-Related Problems (DRPs) Reported During CMR (IV)  
DRPs were analyzed independently by two researchers from 121 CMR case reports. The 
CMR case report is long and may include documentation of non-significant findings to 
indicate that certain issues, e.g., drug-drug interactions (DDIs) have been checked during 
the CMR. In order to avoid overestimations, only the high-priority issues documented in 
the case report’s separate section entitled “Most important findings and recommendations” 
were classified as DRPs. Drug-cost-related issues were commonly reported, but were not 
coded because the PCNE classification lacks such a DRP category. 
The PCNE Classification for DRPs version 5.01 (Pharmaceutical Care Network 
Europe 2006) was used to code the DRPs, their causes and interventions resulting from 
the recognition of the DRP. Disagreements in classifications were resolved by discussion. 







A few modifications were made to the original PCNE classification. A problem code 
“P3.5. Inappropriate dosing time or interval” was added to cover situations where daily 
drug dose was correct but the administration time was inappropriate (e.g., statins should 
be taken in the evening) or when the dosing intervals were wrong (e.g., nitrates taken 
without an appropriate washout period). Also two new cause codes were added: “C1.9. 
Treatment not discontinued/intervalled appropriately” was added, because in several cases 
drugs were used daily against recommendations for a long period of time (e.g., hypnotics), 
and none of the existing cause codes were suitable. Code “C4.11. Other patient-related 
cause” covered situations where the DRP was caused by some other action of the patient 
than that described in the alternatives of the PCNE classification. To specify the 
physicians' responses to the pharmacists' recommendations, two intervention classes “I1.6. 
Intervention proposed, carried out before case conference”, and “I1.7. Intervention 
proposed, prescriber carried out other intervention”, were added.  
The medications related to the DRPs were classified using the Anatomical Therapeutic 
Chemical (ATC) classification system (WHO 2011). The results are presented on ATC 
level 3, unless only a single active ingredient is responsible for all DRPs in the drug class. 
If multible DRPs were reported for a single drug in a case report, only the DRP perceived 
to be clinically the most relevant was coded, unless (as in rare occasions) different 
recommendations for action were stated for each DRP. For example; the prescribed dose 
of an inhaled corticosteroid is too small, and in addition the patient cannot use the inhaler 
properly. The pharmacist recommends to increase the dose and to use a spacer devise. In 
this case, because there were two different recommendations, two DRPs were coded. In 
the case of some DRPs (drug-drug interactions, therapeutic duplication) two medications 
can be involved in one DRP.  
6.3 Statistical Analyses 
Frequencies of PIM users and percentage of the total outpatient population aged ≥65 years 
were counted from the SII data. The total reimbursement costs (€) for each PIM were 
summed and compared with the total reimbursement costs (direct drug costs) for all drugs 
reimbursed for persons aged ≥65 years. 
The results of surveys were entered to Microsoft Excel. Descriptive statistics, i.e., 
frequencies, means and standard deviations were calculated, when appropriate. For some 
questions, also percentages of all respondents were calculated.  
The DRP data were analyzed using SPSS version 16. Descriptive statistics, i.e., 
frequencies, percentages and means were counted. Comparisons between home-dwelling 
and assisted-living patient groups were made by independent sample t-test or Mann-
Whitney U test, when appropriate. Pearson Chi-Square test was used to compare the 








7 Results  
7.1 Use of Potentially Inappropriate Medications (PIMs) (I) 
Of the non-institutionalized population aged ≥65 years in Finland (n=841 509), 91.8% 
(n=772 700) were dispensed reimbursable drugs in 2007. In total 123#545 individuals 
received reimbursements for PIMs according to the Beers criteria (Table 23). This 
corresponds to 14.7% of the non-institutionalized population aged ≥65 years in 2007. 
Temazepam at doses >15 mg/day was clearly the most commonly reimbursed PIM 
with a prevalence of 4.4% (n=36 923) of the non-institutionalized population aged ≥65 
years (Table 23). The next most common PIMs were products containing amitriptyline 
(2.0%; n=16#752), diazepam and combination products (1.8%; n=15#348), oral estrogens 
(1.8%; n=14#805) and short-acting dipyridamole (1.7%; n=14#280). More than one-third 
(36.9%; n=53#690) of the total PIM use (n=145#309) was associated with benzodiazepines, 
i.e., temazepam, diazepam and chlordiazepoxide (Table 23). 
In 2007, the SII paid a total of 421 million euros for direct drug reimbursements for 
persons aged ≥65 years. The reimbursements for PIMs were 2.9 million euros, 
corresponding 0.7% of the total direct drug reimbursement costs for persons aged ≥65 




























Table 23. Potentially inappropriate medication (PIM) use and drug reimbursements among 
non-institutionalized Finns aged ≥65 years (n = 841 509) in 2007a,b,c  
Potentially inappropriate drug %  n Reimbursement (€) 
Temazepam, doses >15 mg/dd 4.4  36 923 574 872 
Amitriptyline and combinationsd 2.0 16 752 299 877 
Diazepam and combinationsd 1.8  15 348 155 850 
Oral estrogensd,e 1.8  14 805 251 683 
Dipyridamole, short actingd 1.7  14 280 491 489 
Orphenadrine and combinations 1.5  12 533   65 659 
Digoxin >0.125 mg/d (0.25 mg) 1.1  9 323   68 423 
Doxepind 0.5  4 249 114 491 
Indomethacind 0.5  4 050   45 949 
Daily fluoxetined 0.5  3 825   72 496 
Oxybutynin, short actingd 0.4 3 479 132 500 
Amiodarone 0.2  1 885 209 083 
Carisoprodol (combination product)d 0.2  1 630   43 797 
Ergot mesyloids 0.2  1 463 121 771 
Chlordiazepoxide and combinationsd 0.2  1 419   18 188 
Nifedipine, short acting 0.1  1 120   58 767 
Meprobamate (combination products)d  0.1 805  16 235 
(Dextro)propoxyphened 0.1 684   24 929 
Disopyramide 0.1 663  77 870 
Amphetamines and anorexic agents: 
sibutramine, dexamphetamine, 
methylphenidate, modafinil 
0 73  23 321 
Any of the above 14.7  123#545f  
Total  145"309 2  "867"250 
a Table excludes PIMs that were not reimbursable in Finland in 2007: triazolam, belladonna alkaloids, 
diphenhydramine, hydroxyzine, ferrous sulfate, bisacodyl, nitrofurantoin and clonidine. 
b Table excludes lorazepam, oxazepam, alprazolam, naproxen and piroxicam because the dose used or 
duration of treatment could not be defined.  
c Table excludes PIMs that were not available in outpatient care in Finland in 2007  
d Some small packages or product brands were not reimbursable. 
e No information on concomitant progesterone therapy. 
f One individual may have used several PIMs.  
 
Reproduced from [Leikola S, Dimitrow M, Lyles A, et al. Potentially inappropriate medication use among 
Finnish non-institutionalized people aged ≥65 years. A register-based, cross-sectional, national study. Drugs 
Aging 2011;28(3):227-236] with permission from Adis, a Wolters Kluwer business (© Adis Data 






7.2 CMR Accreditation Training and Participant Satisfaction (II) 
7.2.1 CMR Accreditation Training  
The TIPPA Coordination Group defined the aims of the CMR accreditation training as 
follows: 1) to support participant’s professional development to acquire sufficient clinical 
skills and knowledge to conduct CMRs; 2) to establish collaboration needed for CMR 
with other health care professionals, particularly with local GPs; and 3) to create the CMR 
procedure applicable to local circumstances.  
The CMR curriculum is designed to last for three semesters, 1.5 years, and 
corresponds to 35 European Credit Transfer System (ECTS) credits (1 credit corresponds 
to 26.7 hours of student work). The training is intended to be completed while working. 
20–25 pharmacists are accepted to participate in one training course. Both hospital and 
community pharmacists attend the same training in order to facilitate learning from each 
others’ skills and experience. Accreditation from the professional organizations (Association 
of Finnish Pharmacies and The Finnish Pharmacists’ Association) is gained by completing 
the training course and preparing a portfolio for the TIPPA Coordination Group. The 
portfolio needs to reflect the students’ professional and personal growth from the start of 
the training to its completion and to address the participants’ plans for the future.  
Structure of the Curriculum 
The curriculum includes both face-to-face learning and distance learning and it utilizes 
various teaching methods. These methods include written assignments, e.g., essays and 
learning diaries, expert lectures, working in small groups, and most importantly, 
collaboratively conducting actual CMRs.  
Structurally, the curriculum consists of ten two-day seminars and independent distance 
learning in-between, some of which take place in an e-learning environment (Table 24). 
Before each seminar session participants need to complete assignments, including review 
of specific reading materials. Because reflection and self-assessment are strongly involved 
throughout the training, educational needs and goals are described in an essay prior to the 
first seminar and progress is evaluated by written learning diaries completed after each 
seminar session (Table 24). The seminar days include lectures by leading national experts 
on different appropriate fields, as well as small group sessions. Small groups of 4–6 
people are formed at the beginning of the training in order to facilitate interaction between 
students. Hospital pharmacists and community pharmacists are in separate groups in order 
to achieve optimal peer support. Each small group is guided by a tutor who is accredited to 
conduct CMRs. The small groups have their own discussion forums in the e-learning 
environment and they meet during each seminar day to follow everyone’s progress in 
implementing the CMR procedure in their local health care environment, to discuss CMR 






Distance learning consists of the following elements: 1) multidisciplinary networking 
and developing of a local CMR procedure that aim to permanent collaboration; 2) learning 
by reviewing actual patient cases selected from the pharmacist’s own practice; 3) 
theoretical studies and literature; 4) working in an e-learning environment (Moodle). 
Moodle is an interactive discussion forum where participants can discuss their patient cases, 
solve problems and share ideas and knowledge. Secondly, Moodle is a template for almost 
all course-related materials including timetables, assignments, CMR forms and tools, reading 
assignments and instructors’ PowerPoint presentations. A majority of the completed 
assignments are submitted to the discussion areas so that all participants can learn from them.  
Core Contents of the Curriculum 
The CMR curriculum consists of five modules continuing throughout the entire training 
(Figure 11). The case studies integrate the modules by combining different kind of 
knowledge needed in CMR.  
The Multidisciplinary Collaboration module is the most time intensive, with assignments 
intended to guide the participants in creating a permanent CMR collaboration within their 
local health care environment. Conducting actual CMRs is a crucial part of this module. 
Each participant needs to complete 5–10 reviews during the training. In addition, the cases 
are presented and discussed in small groups at every seminar session and brought to the e-
learning environment to support the learning of others. While conducting and discussing the 
CMRs, the participants utilize in practice the theoretical knowledge obtained from other 
modules.  
The Clinical Pharmacy and Pharmacotherapy module includes elements of 
pharmacotherapy, pharmacokinetics, geriatrics, etiology and pathology, psychology, 
nursing science, and ethics. Clinical chemistry, i.e., the interpretation of laboratory results, 
is also included. All topics are approached from the medication review perspective. Thus, 
evidence-based treatment of common diseases and the effects that, for example, aging, renal 
failure, and polypharmacy have on pharmacotherapy are essential topics in this module.  
The Rational Pharmacotherapy module covers the concepts of rational use of medicines 
and patient safety, drug-related problems, adherence, factors influencing medication use 
and selection, and trends in pharmacotherapy and ethics. Evidence-based Finnish Current 
Care Guidelines are studied and the knowledge gained is used in conducting CMRs.  
The CMR Tools module is intended to acquaint participants with the CMR 
documentation forms and their theoretical background, different databases and reliable 
information sources that can be used when conducting CMRs. Development, marketing, 
and pricing of CMR services are crucial assignments in the Tools module. The participants 
study written materials on communication skills and interview techniques and then work 
in small groups with a communications professional to practice their skills and techniques. 
Optional studies can be chosen to complete knowledge on relevant topics but need to 
be related to CMR and include a reflective component, e.g., a written report. They can be 
performed as literature reviews, conventional examinations, short lecture-based courses, or 






Table 24. CMR Curriculum Design 
SEMINARS 
(2 days each) 
LECTURE TOPICS 
(The whole training group, n=20–25) 
SMALL GROUP WORKING 
SESSIONS (n=4–6) 
FIRST SEMESTER (6 months) 
































Case studies  
(actual cases) 
SECOND SEMESTER (6 months) 
  Learning diary of the first semester 
IV Communication and interview skills Current Care 
Guidelines 
Home interview 
rehearsal (role play) 
Case studies 
(actual cases) 




VI Epidemiology Information sources Case studies (actual cases) 
THIRD SEMESTER (6 months) 
  Learning diary of the second semester 
VII Alzheimer’s 








Health policy issues in CMR 
Foreign CMR practices 




Local CMR procedure; pricing; 
marketing 









Case studies  
(actual cases) 
Peer evaluation 
END OF TRAINING: 
  Learning diary of the third semester, final essay 
                                                                 ▼                                                                        
PORTFOLIO SUBMISSION (2 months) 
                                                                 ▼                                                                        
ACCREDITATION 
                                                                 ▼                                      
Multiprofessional collaboration, conducting CMRs, continuing learning, portfolio updating 
(5 years) 










35 ECTS credits 
1.5 years 
 
Rational pharmacotherapy and 
use of medicines (5 cp) 
- Therapeutic guidelines 
- Epidemiology 
- Ethics 
-  Patient counselling 
-  Patient safety!
Multidisciplinary collaboration  (12 cp) 
- Local process plan 
- Medication reviews 
- Reporting 
- Case conferences 
- Evaluation!
Optional studies (3 cp) 
- Literature reviews  
- Short courses 
- Examinations 
 
Clinical pharmacy and 
pharmacotherapy (11 cp) 
- Clinical chemistry 
- Pharmacokinetics 
- Gerontology and geriatrics 
- Special topics: heart diseases, 
  Alzheimer’s disease, diabetes 
Tools (4 cp) 
- Electronic databases 
- Literature 
- CMR process and forms 
- Negotiation and dialogue 
  skills 
- Productization and pricing 
 
Figure 11 Core contents of the CMR accreditation training (35 ECTS credits (cp), 1.5 years). 
7.2.2 Participant Satisfaction on CMR Accreditation Training  
A majority (92.1%, n=35) of the pharmacists who completed the CMR accreditation 
training in 2006–2007 perceived that the course met their educational needs. Even more 
(94.7%; n=36) would recommend the training to their peers. The mean score for different 
survey statements assessing satisfaction on training was 4.5 ± 0.7 (Table 25). The highest 
ratings were given to learning (4.6 ± 0.7) and curriculum design (4.6 ± 0.5).  
 
Table 25. Pharmacists’ (n=38) perceptions of the CMR accreditation training right after 
completing it (1 = poor to 5 = outstanding) 
Variable evaluated Mean score ± SD (range) 
Learning 4.6 ± 0.7 (2–5) 
Curriculum design 4.6 ± 0.5 (4–5) 
Teaching methods 4.4 ± 0.7 (3–5) 
Learning materials 4.4 ± 0.6 (3–5) 
Content validity of assignments/group 
works/examinations 
4.3 ± 0.7 (3–5) 







A majority (83.3%, n=35) of the training participants responded to the open-ended 
questions concerning factors which facilitated, prevented or hampered their learning 
(Figure 12). The most commonly mentioned facilitating factors could be grouped under 
nine main themes (Figure 12). Almost all of the respondents (91.4%, n=32) mentioned 
that the small group format (42.9%, n=15), working in groups (28.6%, n=10), or other 
participants (20.0%, n=7) had improved their learning. The hampering factors were 
grouped under six main themes (Figure 12). The most commonly mentioned preventive or 
hampering factors were “lack of time” and ”busyness” (40.0%, n=14) and job constraints 




Figure 12 CMR training participants’ opinions on factors facilitating and hampering learning 
during the CMR accreditation training (content analysis of open-ended questions) 
The most common response (response rate 85.7%, n=36) to the question “What did 
you learn and how can you apply it to practice?” was simply “I learned a lot” (36.1%, 
n=13). Ten respondents (27.8%) mentioned issues related to pharmacology or 
pharmacotherapy. Both multidisciplinary collaboration and development of CMR 
procedure were mentioned by 8 participants (22.2%), geriatric pharmacotherapy by 6 
(16.7%), and interpretation of laboratory test values by 5 (13.9%). Several participants 
mentioned “broader perspective” or “seeing things as a whole” (16.7%, n=6) or 
application of existing knowledge (11.1%, n=4). Half of the respondents (n=18) 
mentioned the learning was useful in everyday work regardless of whether it involved 
conducting CMRs. 
Twenty-nine participants (69.0%) suggested ideas to improve the training. Even 
though working in small groups was seen as a useful way of learning, some of the 
respondents wished for more communication between all participants (13.8%, n=4) or 
occasional mixing of tutor groups for a broader perspective (10.3%, n=3). Six respondents 






was seen as difficult and time consuming, so a few students (10.3%, n=3) wanted that to 
be started at an earlier phase of the training and an additional 3 (10.3%) wanted a lecture 
on an operational local CMR practice. 
Most of the respondents (68.4%, n=26) planned to conduct CMRs in the future. Five 
(13.2%) answered “I will (the plans for the future already exist)” and 21 (55.3%)  “I intend 
to continue the practice”. Eleven respondents (28.9%) were still uncertain. Only 1 
respondent who had discontinued her studies indicated that she will not conduct CMRs in 
the future. The respondents mentioned the following barriers to conducting CMRs in the 
future: financing (13.2%, n=5); still unclear, whether the employer wants to provide CMR 
services (8.0%, n=3); and development of the local CMR procedure is still under way 
(5.3%, n=2).  
7.3 CMR Procedure and Documentation (III) 
7.3.1 CMR Procedure  
The intensive development phase resulted in a comprehensive medication review 
procedure which requires access to clinical patient information, a home visit with a patient 
interview, and a case conference with the collaborative physician. The procedure covers 
four main dimensions critical for safe and appropriate pharmacotherapy for the elderly: 
Aging and Safety; Co-Morbidities; Polypharmacy; and Adherence (Figure 13). The 
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Figure 13 Four dimensions covered by the CMR procedure to ascertain safe and appropriate 






The phases of the CMR procedure follow the structure of the HMR in Australia 
(Sorensen et al. 2004) and MTM in the US (APhA and NACDS 2008) (Figure 14). The 
CMR is usually initiated by the physician on the basis of potential problems in the 
patient’s drug treatment (Figure 14: Phase 1). Other caregivers can actively suggest CMR 
for a particular patient. The criteria for conducting CMRs are currently set locally in 
Finland. After receiving a written consent from the patient, the collaborative physician 
provides the pharmacist with sufficient patient information, including medication lists, 
diagnoses, laboratory test results and other relevant data needed in conducting CMR 
(Appendix 3).  
After becoming acquainted with the clinical patient information the pharmacist visits 
the patient at home and conducts a face-to-face interview (Figure 14: Phase 2) by using 
the Interview Form (Appendix 2). The aims of the interview are 1) to complete and update 
medication lists to reflect the patient’s actual drug use, including OTC drugs, herbal 
products and complementary medicines; 2) to recognize various clinical and practical 
DRPs, including underreported adverse drug effects (Lampela et al. 2007); 3) to gather 
monitoring data; 4) to assess behaviors and living conditions that may influence medicine 
use and adherence; 5) to measure HRQoL. In addition, the patient is advised on his/her 
medication use throughout the interview. If an interview with the patient is not possible, or 
if additional discussions are considered useful, the pharmacist may consult nurses or other 
caretakers. 
Like the patient interview, the actual review of medications (Figure 14: Phase 3) also 
follows a literature-based, structured case report format (Appendix 4). The format is 
designed to cover the previously mentioned four dimensions that are crucial in assuring 
rational pharmacotherapy among the elderly patients (Figure 13). In addition to having 
good basic knowledge on pharmacology based on their degree and additional knowledge 
on elderly pharmacotherapy gained through the CMR accreditation training, the 
pharmacists use several resources and tools while conducting the review. These include 
the national current care and geriatric pharmacotherapy guidelines (Kivelä and Räihä 
2007, www.kaypahoito.fi), criteria for potentially inappropriate medications for the aged 
(Fick et al. 2003, Socialstyrelsen 2010, Fimea 2011), an electronic drug-drug interaction 
screening database (e.g., Lääkeinteraktiot SFINX), and a database to select appropriate 
drugs and doses for patients with kidney failure (Renbase 2011). Special attention is paid 
to potentially harmful sedative load (Linjakumpu et al. 2003), and to excessive use of 
serotonergic and anticholinergic drugs (Hilmer et al. 2007, Looper 2007).  
The CMR case report with findings and recommendations is discussed with the 
physician in a face-to-face case conference (Figure 14: Phase 4). It is desirable that other 
caregivers, e.g., a nurse or a family member, possibly also the patient, also participate in 
the conversation to ensure the proper implementation of changes in practice. The 
physician is in charge of all medical decisions. After there is an agreement on the actions 
and follow-up, the pharmacist documents all decisions on the CMR case report. The 
patient and caretakers can be provided with a shortened version of the report.  
A follow-up home visit focuses on identification of current medications, ascertaining 
that the agreed changes have been implemented and DRPs resolved, as well as re-






a follow-up are found more likely to improve adherence (George et al. 2008). Usually the 
follow-up occurs three months after the case conference but different intervals may be 
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Figure 14 Phases of the CMR procedure and related documentation forms 
7.3.2 CMR Documentation 
CMR Referral Form 
The Australian HMR documentation that was used included a referral form for physicians 
to refer patients to HMR and to provide relevant patient information to pharmacists, and a 
Medication Management Plan (Australian Government 2011c, Commonwealth 
Department of Health and Aged Care 2011). The developed CMR Referral and Patient 
Data Collection Form (Appendix 3) resembles the corresponding Australian form. 
A majority (70.4%, n=19) of the accreditation training participants in 2006–2007 who 
responded to the survey on the development needs of the CMR documentation forms 
indicated that the CMR Referral Form is needed in the CMR procedure in the future at 






(63.3%) stated, that prints of medical records were a more efficient, easy and/or reliable 
way to acquire patient data. However, some indicated that the Referral Form may be 
useful if completed by the pharmacist to gather relevant information from patient records 
(n=3) or to be used as a checklist that all relevant data has been gathered (n=2). As a 
result, the CMR Referral Form is an optional document that can be used during the 
procedure if considered to be useful. 
 
Table 26. CMR training participants’ opinions on the need to include CMR documents and 
specific interview question in the CMR procedure (n=27; response rate 84.4%)  








A. Referral form with patient clinical data 29.6 (8) 29.6 (8) 40.7 (11) 
B. Patient interview form 92.6 (25) 0 7.4 (2) 
Questions with potential for being added to the patient interview form 
Patient’s weight and height 88.9 (24) 3.7 (1) 7.4 (2) 
Patient’s health behaviors in general 92.6 (25) 0 7.4 (2) 
The following specific health behaviors: 
  - smoking 88.9 (24) 0 7.4 (2) 
  - alcohol consumption 92.6 (25) 0 7.4 (2) 
  - diet 96.3 (26) 0 3.7 (1) 
  - outdoor activities and exercise 85.2 (23) 0 14.8 (4) 
  - sleeping/awake schedule and quality of sleep 88.9 (24) 0 11.1 (3) 
Existing questions: 
Questions regarding DRPs (#9.)a 88.9 (24) 3.7 (1) 7.4 (2) 
Questions regarding adherence (#10. and #11.)a 81.5 (22) 7.4 (2) 11.1 (3) 
Questions regarding stopping a drug (#12. and 
#13.)a 
88.9 (24) 3.7 (1) 7.4 (2) 
Questions regarding wishes for changes in drug 
regimen (#14. and #15.)a 
88.9 (24) 3.7 (1) 7.4 (2) 
Questions regarding anticholinergic adverse 
effectsa 
92.6 (25) 0 7.4 (2) 
C. A case report form 100 (27) 0 0 
D. CMR review chart 85.2 (23) 7.4 (2) 7.4 (2) 






CMR Interview Form  
The literature review for this thesis provided the theoretical basis of the CMR Interview 
Form (Table 27). Because pharmaceutical care and medication review models aim to 
recognize, prevent and resolve DRPs, it was concluded that the CMR documentation 
should ascertain that all relevant DRPs are addressed during CMR. A literature review on 
DRP classification systems by van Mil et al. (2004) was used to identify potential DRPs to 
be included in the CMR documentation. Based on an examination of the various DRP 
classifications (van Mil et al. 2004), it was concluded that classification by Cipolle et al. 
(2004) has several advantages for the purposes of CMR. It addresses comprehensively 
clinical DRPs, such as untreated conditions, drug use without valid indication and 
inappropriate doses (Table 6). Such issues can be addressed during CMR because the 
pharmacist has access to diagnostic data and laboratory test results. As a disadvantage, the 
DRP classes of the CMS system are sparse and many issues that need to be checked 
during CMR to ascertain appropriateness of pharmacotherapy, e.g., drug-drug interactions, 
duration of therapy, practical difficulties, and drug expenses are causes of DRPs in the 
CMS system. Lack of classification system for these causes impaired the usability of the 
CMS system when specific questions for CMR patient interview were developed. 
The DRP classification by Westerlund et al. (1999a,b, 2002), on the other hand, 
considers several practical problems related to drug administration, such as difficulties in 
swallowing tablets/capsules and opening containers (Table 7). It also pays attention to the 
patients’ knowledge of their medications. Such DRPs may unnecessarily complicate 
taking drugs appropriately but are usually easily resolved by CMRs, e.g., by patient 
counseling or changing the drug formulation. On the other hand, the Westerlund 
classification has disadvantages that impair its usability during CMR. It lacks several 
clinical DRPs that are important during CMR, e.g., untreated indications and unnecessary 
drug therapy. However, if combined, these two DRP classification systems address most 
domains of inappropriateness of pharmacotherapy and thus, all DRPs from both were 
embedded in the CMR Interview Form (Table 27).  
The PCNE Classification for DRPs (Pharmaceutical Care Network Europe Foundation 
2010, Appendix 1) allows classification of causes for DRPs, interventions and even 
outcomes of the intervention. The subdomains of the DRPs and causes are detailed, so 
classification of various upcoming issues are likely to succeed. On the other hand, due too 
the great number of subgroups interrater variability may be poor. A positive feature in the 
PCNE classification in CMR is the possibility to also classify potential DRPs, i.e., the 
risks of pharmacotherapy that the pharmacist may recognize and aim to prevent. 
Currently, the PCNE DRP classification version 6.2 (PCNE 2010, Appendix 1) is used by 
accredited pharmacists when the findings and outcomes of CMRs are documented for 
research purposes and it can be used as an evidence of the effects of CMR by individual 
CMR pharmacists.  
In addition to DRPs, some more specific issues were included in the CMR Interview 
Form. Based on published studies elderly patients commonly use OTC drugs, natural 
products and complementary medicines and physicians may be unaware of this and lack a 






Pharand et al. 2003, Kaunisvesi 2005). This is important because OTC medications, 
dietary supplements and natural products may interact with pharmacotherapy (Hoblyn and 
Brooks 2005, Qato et al. 2008). For these reasons, the first part of the Interview Form was 
developed to focus on revealing patient’s actual drug use (Table 27).  
Anticholinergic adverse effects are known to be harmful for elderly patients, because 
they may lead to impaired cognitive and physical function (Hilmer et al. 2007, Landi et al. 
2007b, Cao et al. 2008). The Udvalg for Kliniske Undersøgelser (UKU) Side-effect Rating 
Scale was developed for physicians to assess unwanted effects of psychotropic drugs, 
including anticholinergic effects (Lingjaerde et al. 1987). The scale has in total 7 questions 
relating to anticholinergic adverse effects. Of these, three i.e., constipation, dryness of 
mouth and urinary disturbances are easy for the patient to self-report and simple for the 
pharmacist to interpret. Thus, these 3 questions were included in the CMR Interview 
Form.  
The pilot testing of the literature-based preliminary interview form (Questions marked 
with * in Appendix 2) among home health care patients (n=9) revealed no need to change 
the form. However, it became evident that the form was not suitable for self-

































Table 27. Literature-based evidence for the developed CMR Interview Form  
DISCUSSED ISSUE  THEORETICAL BASIS 
Medication management   
Number of physicians involved in 
patient’s care 
Number of prescribing physicians is an independent 
risk factor for adverse drug events among elderly 
outpatients (Green et al. 2007). 
Way of taking medicines (self from 
original containers, dose dispensing 
device, automated dose dispensing, 
help from relatives or caregivers) 
DRP/ Non-compliancea                                       
DRP/ Difficulty opening drug containerb, other 
practical problemb 
Medication use  
Prescription and OTC medications, 
natural products, dietary supplements 




Discrepancies between the medication lists of 
physicians and actual drug use are common, and may 
result in drug interactions and adverse events (Barat 
et al. 2000, Frank et al. 2001, Pharand et al. 2003). 
OTC medications, dietary supplements and natural 
products may interact with pharmacotherapy (Hoblyn 
and Brooks 2005, Hu et al. 2005). 
DRP/Unnecessary drug therapya 
DRP/Too low dosagea, too high dosagea 
DRP/Overuseb, underuseb 
DRP/ Non-compliancea 
Medication-related knowledge DRP/Uncertainty about the indication for the drugb 
Drug-related problems  
Practical difficulties (ability to use as 
instructed) 
DRP/Difficulty swallowing tablet/capsuleb, difficulty 
opening drug containerb, other practical problemb 
Concerns related to drug costs DRP/Non-compliancea 
Adherence (use against instructions, 
discontinuation of treatment, 
forgetfulness)c 
DRP/Non-compliancea 
Adverse drug reactions (including 
questions concerning dizziness, falls 
and anticholinergic side-effects 
constipationd, dryness of mouthd, and 
urinary disturbancesd) 
DRP/Adverse drug reactiona,b 
Elderly people underreport adverse effects to their 
physicians (Lampela et al. 2007). 
Anticholinergic adverse effects can be very harmful 
to the elderly, because they may lead to impaired 
cognitive and physical function (Hilmer et al. 2007, 
Landi et al. 2007b, Cao et al. 2008). 
Undertreatment or suboptimal 
treatment results (as defined by the 
patient), including pain, mood, 
sleeping disorder 
DRP/Need for additional therapya, ineffective druga 
Undertreatment of pain in community-dwelling older 
people is common (Pitkälä et al. 2002a).  
Monitoring  
Laboratory test results and other 
measurements available at home (e.g., 
blood glucose, blood pressure) 
DRP/ Ineffective druga, therapy failureb 
DRP/Need for additional therapya 
Many adverse drug events that result in 
hospitalization could be prevented by better 
monitoring (Thomsen et al. 2007). 
More recent measurements by e.g., visiting nurses 







DISCUSSED ISSUE  THEORETICAL BASIS 
Health habits and related issues  
Weight, height 
 





Outdoor activity, exercise 
Weight is needed to count the Body Mass Index (BMI) 
and glomerular filtration rate to define kidney function. 
Smoking and alcohol consumption may have 
clinically significant interactions with drugs 
(Weathermon and Crabb 1999, Kroon 2007).  
Quality of nutrition affects e.g., need for calcium, 
iron and vitamin supplements. 
Exposure to sunlight affects the need for 
supplementary vitamin D (Holick and Chen 2008). 
DRP=Drug-related problem, OTC=over-the-counter 
a Based on DRP Classification System by Cipolle et al. (2004) 
b Based on the DRP Classification System by Westerlund et al. (1999 a,b, 2001) 
c Morisky adherence scale as an attachment (Morisky et al. 1986) 
d Adopted from Udvalg for Kliniske Undersøgelser (UKU) side-effect rating scale (Lingjaerde et al. 1987) 
 
Almost all (96.3%, n=26) of the accreditation training participants in 2006–2007 who 
responded to the survey indicated that the patient interview is an important part of the 
CMR procedure. Only one pharmacist who conducted CMRs in an assisted living setting 
answered that the patient interview was not useful, as the collaborating nurses provided 
more reliable information. However, she indicted that the interview might be useful 
among home-dwelling patients. Several pharmacists mentioned that the interview revealed 
important issues that were not evident in the patient records or known by the physician 
(55.6%; n=15). One respondent even mentioned that the interview would be useful among 
demented patients, because potentially dangerous or outdated medications can be removed 
from closets. Several respondents (n=6) mentioned that it is crucial to understand the 
patient’s opinions regarding their pharmacotherapy and taking of medicines. A few (n=5) 
pointed out the importance of giving advice and improving adherence.  
All respondents indicated that the Interview Form is needed in the CMR procedure 
(Table 26). In the open-ended question regarding need to add new questions to the 
Interview Form, several suggestions (n=18) arose, but only health habits, such as smoking 
and diet (n=10), weight (n=7), pain (n=3), laboratory test results (n=2), sleep (n=2), 
dizziness (n=2), fatigue (n=2) and itching (n=2) were mentioned by more than one 
participant. The first 6 of these were added to the Interview Form (Appendix 2).  
When specifically asked if questions regarding some other symptoms needed to be 
added to the Interview Form, the examples presented in the survey (Table 21), i.e., pain 
(n=22), dizziness (n=25) and issues relating to quality of sleep, like insomnia, fatigue and 
other sleeping disorders (n=16) were mentioned by several respondents. These were added 
to the Interview Form by formulating the questions similarly to the ones in the UKU Side-
effect Rating Scale or the version of it used for patient self-administration (Lingjaerde et 
al. 1987, Lindström et al. 2001; Appendix 2). Falls, nausea and stomach ache were 
suggested to be added to the Interview Form by two participants, and palpitations, 
pruritus, headache, arrhythmias and memory disturbances by one each. Of these, only falls 
were added, because they are considered to be a severe and common adverse effect among 







Almost all of the respondents considered useful to include questions about weight, 
height and health habits in the Interview Form (Table 26). Thus, questions on these topics 
were added to the Interview Form (Appendix 2).  
With regard to need to remove existing questions from the Interview Form, 48.1% 
(n=13) stated “No”. No individual question to be removed was mentioned by more than 
one respondent, but 5 participants expressed the need to condense the text or to develop a 
simpler version to be used after the CMR training. Also in alternative questions the 
majority of the CMR training participants responded, that the existing questions of the 
CMR Interview Form are needed also in the future (Table 26). As a result, no questions 
from the preliminary form were removed, but the form was simplified (Appendix 2). 
CMR Case Report Form 
The developed standard CMR Case Report Form (Appendix 4) follows the structure of the 
CMR patient interview and the same DRPs (Westerlund et al. 1999a,b, Cipolle et al. 2004) 
are also included in the Report.  
All survey respondents indicated that the CMR Case Report is needed in the CMR 
procedure (Table 26). In open-ended questions the pharmacists suggested several issues 
that should be added to the report. These included e.g., a section documenting follow-up 
findings (n=7), Body Mass Index (n=2), Glomerular Filtration Rate (GFR) formula (n=2), and 
space for physician’s comments (n=2) and laboratory test results (n=1). All of these were 
added (Appendix 4). A few respondents wanted to remove the list of used drugs (n=6) and 
the table to indicate the drug costs before and after CMR (n=4). During CMR, pharmacists 
can remove these sections from the report if they consider them unnecessary. 
CMR Review Chart 
Integration of various preliminary CMR Review Charts developed by pilot CMR 
accreditation training participants resulted in a standard Review Chart Form (Appendix 5). 
All used medications and their effects on e.g., CYP-enzymes, blood pressure and serum 
electrolytes can be collected on the form. The aim of the Chart is to facilitate review of 
medications with regard to their effects during concomitant use, for example 
pharmacokinetic and pharmacodynamic interactions as well as sedative, anticholinergic 
and serotonergic drug load.  
Of the CMR training participants in 2006–2007 who responded to the survey, 92.6% 
(n=25) indicated that the CMR Review Chart is needed in the CMR procedure at least 
occasionally (Table 26). In the open-ended questions more than half (59.3%, n=16) of the 
pharmacists stated the CMR Review Chart to be “OK” or “fine”. Some (n=7) answered it 
to be otherwise fine, but too laborious to fill in, or it was regarded to be useful in the 
beginning when the pharmacist learns to conduct CMRs. Thus, the review chart remains in 






Health-Related Quality of Life Measure for CMR 
Based on the literature search to find a suitable HRQoL measure to be used during CMR, 
six generic HRQoL measures with a Finnish and Swedish translation were found (Figure  
15). For SF-12 (Ware et al. 1996) no published studies regarding validation of the Finnish 
translation could not be found, and thus it was excluded. Of the remaining measures, the 
EuroQol (EQ-5D; Brooks 1996, Appendix 6) was considered to be the most suitable for 
CMR, because of its superior simplicity and quick administration time. Also, its suitability 
for elderly patients is well documented (Tidermark et al. 2003, Holland et al. 2004). 
 
 
6 generic HRQoL measures 
found in Finnish and 
Swedish: 
SF-12, SF-20, SF-36/RAND-
36, 15-D, NHP, EQ-5D 
 -1  SF-12 (Ware et al. 1996) 
- No documented validation of Finnish translation 
was found  
 
     
SF-20, SF-36/RAND-36,   
15-D, NHP, EQ-5D 
 -1  15-D (Sintonen 2001) 
- Complicated, long sentences  
- Usability among older patients not documented  
     
SF-20, SF-36/RAND-36, 
NHP, EQ-5D 
 -1  SF-36 (Ware and Sherbourne 1992, Hagman 1996) 
RAND-36 (Hays et al. 1993, Aalto et al. 1995) 
- Too long, too time-consuming  
     
SF-20, NHP, EQ-5D  -1  SF-20 (Stewart et al. 1988, Aalto et al. 1997) 
- Slightly complicated, administration time longer  
among elderly patients (Carver et al. 1999)  
     
NHP, EQ-5D  -1  Nottingham Health Profile (NHP) 
(Hunt et al. 1981, Koivukangas et al. 1995) 
- Very simple, but more questions and thus slower 
to administer than EQ-5D 
 
     
EQ-5D (Brooks 1996) 
- Very simple and quick to administer 
- Suitability for elderly patients well documented (Tidermark et al. 2003, Holland et al. 
2004). 






7.4 Drug-Related Problems Reported During CMR (IV) 
The community pharmacists taking accreditation training in 2006–2007 reported 
altogether 785 DRPs, an average of 6.5 per patient. Mean number of DRPs was higher 
among home-dwelling patients (7.2), than among those in the assisted-living setting (5.5) 
(p=0.014) but the DRPs were similar in nature. Inappropriate drug choices were the most 
common DRPs (n=136; 17.3% of DRPs), they most often involved hypnotics and 
sedatives (Table 28). Indications with no prescribed drugs were the second most common 
DRPs (n=125; 15.9%) and involved most often calcium supplements, lipid-lowering drugs 
and ACE-inhibitors. 
Causes of DRPs were most often related to selection of drug or dose (n=623; 79.4% of 
DRPs) (Table 29). Of these, the most common was inappropriate drug selection (n=179; 
22.8%). Causes related to lack of information (n=16; 2.0%) or other patient-related causes 
(n=21, 2.7%) were rare (Table 29). 
The most common drug classes involved in DRPs were drugs affecting the nervous 
system (ATC class N, 28% of drugs, n=236) and cardiovascular drugs (ATC class C, 21%, 
n=178). The most frequently reported drug groups were antidepressants, and hypnotics 
and sedatives (Table 30). Three individual drugs: calcium supplement (n=39), furosemide 
(n=32) and paracetamol (n=27), each caused DRPs in more than 20% of the patients 
(Table 30), as did opioid analgesics (n=37). 
Of the 785 DRPs, 83% (n=649) resulted in intervention recommendation to the 
physician from the pharmacist (Table 31). Physicians accepted 55% (n=360) of the 
recommendations as made. As a result of the case conference, interventions at the drug-
level were agreed to in 51% (n=403) of DRPs (Table 31). Of these interventions, most 
common was to stop the drug (32% of the drug-level interventions, n=128) or to change 
drug dose (23%, n=93). Drug-level interventions related to analgesics were agreed to often 
and included e.g., discontinuation of non-steroidal anti-inflammatory drugs (NSAIDs), 















pa Three drug groups most commonly involved in the DRPs listed 
(n) 
 % n % n   
P2.1. Inappropriate drug 16.2 82 19.3 54 NS Hypnotics and sedatives (16), anxiolytics (14), meprobamate (9) 
P2.6. No drug prescribed but clear indication 15.4 78 16.8 47 NS Calciumb (14), statins (12), ACE inhibitors (9) 
P3.2. Drug dose too high or dosage regimen 
too frequent  
11.9 60 12.5 35 NS Drugs for ulcer (16), furosemide (13), hypnotics and sedatives (10) 
P1.1. Side-effect suffered (non-allergic) 10.1 51 11.8 33 NS Opioid analgesics (9), ACE inhibitors (8), furosemide (7) 
P3.1. Drug dose too low or dosage regimen 
not frequent enough  
10.1 51 6.8 19 NS Paracetamol (12), calciumb (9), adrenergic inhalantsc (6) 
P5.1. Potential interaction 6.5 33 6.1 17 NS Antidepressants (11), warfarin (10), iron (8) 
P2.5. No clear indication for drug use 5.7 29 6.4 18 NS Antidepressants (6), drugs for ulcer (3), antipsychotics (3) 
Other DRPs 24.0 121 20.4 57   
Total 100.0 505 100.0 280  Antidepressants (52), hypnotics and sedatives (47), calciumb (39) 
a Pearson Chi-Square test 
b Includes calcium supplements with vitamin D 












Table 29. Causes for DRPs (n=785) in CMR patients aged 65 and older (n=121) 
Cause  % n 
C1. Drug/Dose selection 79.4 623 
C1.1. Inappropriate drug selection 
C1.2. Inappropriate dosage selection 
C1.3. More cost-effective drug available 
C1.4. Pharmacokinetic problems, incl. ageing, interactions 
C1.5. Synergistic/preventive drug needed and not given 
C1.6. Deterioration/improvement of disease state 
C1.7. New symptom or indication revealed/presented 
C1.8. Manifest side effect, no other cause 



















C2. Drug use process 11.3 89 
C2.1. Inappropriate timing of administration and/or dosing intervals 
C2.2. Drug underused/under-administered 
C2.3. Drug overused/over-administered 
C2.4. Therapeutic drug level not monitored 
C2.5. Drug abused (unregulated overuse) 













C3. Information 2.0 16 
C3.1. Instructions for use/taking not known 
C3.2. Patient unaware of reason for drug treatment   
C3.3. Patient has difficulties reading /understanding patient information form 
C3.4. Patient unable to understand local language 











C4. Patient/Psychological 2.7 21 
  C4.1. Patient forgets to use/take drug 
  C4.2. Patient has concerns with drugs 
  C4.3. Patient suspects side-effect 
  C4.4. Patient unwilling to carry financial costs 
  C4.5. Patient unwilling to bother physician  
  C4.6. Patient unwilling to change drugs 
  C4.7. Patient unwilling to adapt lifestyle 
  C4.8. Burden of therapy 
  C4.9. Treatment not in line with health beliefs 
  C4.10. Patient takes food that interacts with drugs  























C5. Logistics 0.3 2 
C5.1. Prescribed drug not available (anymore) 
C5.2. Prescribing error (only in case of slip of the pen) 







C6. Other 4.3 34 
C6.1. Other cause; specify 











Table 30. Ten therapeutic drug groups most commonly involved in DRPs (n=785) in CMR 
patients aged 65 and older (n=121) 







Potential interaction (11), drug dose too high (6), no 
clear indication (6)  






Inappropriate drug (16), duration of treatment too long  







No drug but clear indication (14), drug dose too low (9), 
potential interaction (4) 




Potential interaction (14), inappropriate drug (4), 
inappropriate duplication (4), drug dose too high (4) 






Side-effect suffered (9), inappropriate drug (8), 
potential interaction (5), inappropriate drug form (5) 
Proton pump inhibitors 4.1 
 
34 Drug dose too high (16), no drug but clear indication 





Drug dose too high (13), side-effect suffered (7), 







Inappropriate drug (14), duration of treatment too long 
(5), side-effect suffered (3) 






Drug dose too low (12), drug dose too high (4), patient 
dissatisfied with therapy (4) 
Beta blocking agents 3.2 27 Side-effect suffered (5), inappropriate drug (5), no drug 
but clear indication (4), drug dose too low (4) 
Sum 44.0 366  
Others 56.0 465 
Total 100 831 
a Includes combination products with vitamin D       
b Includes paracetamol n=27 
















Table 31. Interventions for DRPs (n=785) in CMR patients aged 65 and older (n=121) 
Intervention % of DRPs n 
I1. At prescriber level 100 785 
I1.1. Prescriber informed only 
I1.2. Prescriber asked for information 
I1.3. Intervention proposed, approved by prescriber 
I1.4. Intervention proposed, not approved by prescriber 
I1.5. Intervention proposed, outcome unknown 
I1.6. Intervention proposed, carried out before case conferencea 















I2. At patient/carer level 23.2 182 
I2.1. Patient (medication) counseling 
I2.2. Written information provided only 
I2.3. Patient referred to prescriber 









I3. At drug level 51.3 403 
I3.1. Drug changed 
I3.2. Dosage changed 
I3.3. Formulation changed 
I3.4. Instructions for use changed 
I3.5. Drug stopped 













I4. Other intervention or activity 9.4 74 
I4.1. Other intervention (specify)b  





a Intervention classes added to the PCNE Classification for DRPs version V5.01. 
b Other interventions included for example laboratory tests or dosing aids 



















Table 32. Drugs most commonly involved in drug-level interventions (n=403) in CMR 
patients aged 65 and older (n=121) 
Drug-level intervention  % n Three drug groups most commonly 
involved in the interventions listed (n) 




Opioid analgesics (6), antidepressants (5), 
hypnotics and sedatives (5) 
I3.2. Dosage changed 23.1 93 Paracetamol (11), drugs for peptic ulcer (11), 
furosemide (8) 




Calcium supplementa (2), antidepressants (2), 
several single drugs (1) 




Organic nitrates (7), hypnotics and sedatives 
(4), calciuma (4), iron (4), anxiolytics (4) 




Hypnotics and sedatives (14), NSAIDs (9), 
antidepressants (8) 




61 Calcium supplementa (9), lubricant eye drops 
(6), ACE inhibitors (5) 
Total 100 403  
NSAIDs=non-steroidal anti-inflammatory drugs 







8.1 Appropriateness of Pharmacotherapy Among Home-Dwelling 
Aged (I, IV) 
 
Based on this study approximately 15% of the entire Finnish outpatient population aged 
65 or older used potentially inappropriate drugs according to the Beers criteria (Fick et al. 
2003) in 2007 (I). Compared to most international studies (Tables 13–15) the percentage 
is low. The main cause for the fairly low prevalence, especially compared to studies from 
the USA (Table 13), is probably the limited number of PIMs available in Finland, as is the 
case in most other European countries (Fialova et al. 2005). At the time of this study only 
37 of the 78 individual drugs listed in the Beers 2003 criteria (Fick et al. 2003) were 
available as oral medications in Finland. Since then 4 additional PIMs have been removed 
from the market in Finland. Thus, the authorities responsible for licensing drugs may have 
great influence on PIM prescribing. Also, there is a need for both national modifications 
and regular updating of PIM criteria to take into account changes and national differences 
in drug compendia (Dimitrow et al. 2011). 
During CMR among outpatients aged ≥65 years, a choice of inappropriate drug (i.e., 
not most appropriate for indication) was the most commonly reported DRP (IV). Of the 
drugs involved in this DRP the most common were hypnotics, sedatives, anxiolytics and 
meprobamate (Table 28), i.e., similar drugs that are listed in the Beers criteria (Fick et al. 
2003). Still it must be acknowledged that the Beers criteria is just one tool that the 
pharmacists use during the CMR to evaluate the appropriateness of pharmacotherapy (III). 
In CMR inappropriateness has a broader meaning and may be related to e.g., choice of 
ineffective drug, inappropriate drug-drug or drug-disease combinations, or unsuitability 
due to impaired kidney function or according to care guidelines (Figure 13). Thus, several 
sources of information should be utilized to address inappropriate use in addition to the 
Beers criteria (www.kaypahoito.fi, Socialstyrelsen 2003, 2010, Kivelä and Räihä 2007, 
Lääkeinteraktiot SFINX 2011, Renbase 2011). Furthermore, individual clinical evaluation 
should be the basis for all recommendations during CMR.  
8.1.1 Benzodiazepines (I, IV) 
The common use of benzodiazepines and especially the prominent high-dose temazepam 
prescribing in Finland (I) is a worrying and a more distinctive finding compared to most 
studies that have assessed PIM use in other countries (Tables 13–15). In Finland, the high 
use of benzodiazepines and other psychotropic drugs among the aged has been evident in 
numerous earlier studies (Linjakumpu et al. 2002b, Pitkälä et al. 2002b, Hartikainen et al. 
2003a,b, Hartikainen and Klaukka 2004, Hosia-Randell et al. 2008) and recognized as a 
significant concern by the Ministry of Social Affairs and Health (2006). Compared to the 






that the results underestimate the use of benzodiazepines by excluding the 
benzodiazepines that are not included in the Beers criteria (Fick et al. 2003) or could not 
be analysed by using the SII data, i.e., non-reimbursable products or packages and certain 
dose- and duration dependent PIMs. 
The negative outcomes associated with benzodiazepine use among older people are 
well documented. These include e.g., increased risk for falls and fractures (Ensrud et al. 
2002, Wagner et al. 2004, Landi et al. 2005), impaired cognitive function (Barker et al. 
2004), decline in physical performance and increased risk for urinary incontinence – a 
common cause for institutionalization (Landi et al. 2002, Gray et al. 2003). In addition to 
the harm to individual patients, the benzodiazepine-related ADEs may result in a 
significant economical burden for the health care system. In the European Union the 
estimated total hospital costs of benzodiazepine-related fall injuries alone were 1.5–2.2 
billion euros in 2000, of which 90% occurred among elderly patients (Panneman et al. 
2003). Regarding costs associated with all PIMs, in the USA their use was estimated to 
cause incremental healthcare costs of USD 7.2 billion in 2001 (Fu et al. 2007). Thus, 
actions targeted in reduction of benzodiazepine and other PIM prescribing for elderly 
patients seem reasonable. 
A large part of the prescribing of benzodiazepines for elderly outpatients is likely to be 
for insomnia and other sleep disorders (Ohayon et al. 1998). A meta-analysis on the risks 
and benefits of sedative hypnotics in older people with insomnia indicated that the benefits 
are marginal and outweighed by the risks (Glass et al. 2005). Behavioral treatment 
methods of insomnia are effective and should be given preference among the aged because 
of the various potential adverse effects of benzodiazepines and benzodiazepine receptor 
agonists (Bloom et al. 2009).  
If prescribing a benzodiazepine is still considered necessary, the national 
recommendations in Finland indicate temazepam as the preferred treatment among the 
aged (Kivelä and Räihä 2007). This is the probable explanation for its high prevalence of 
use in the current (I) and earlier Finnish studies (Raivio et al. 2006, Hosia-Randell et al. 
2008). For temazepam the maximum recommended dose for elderly patients is only 10 mg 
(Kivelä and Räihä 2007). According to the current and previous studies, this dose-
recommendation is not followed well in Finland (Raivio et al. 2006, Hosia-Randell et al. 
2008). In addition to the recommendation of small doses, benzodiazepine treatment for 
insomnia should be short term and intermittent (Kivelä and Räihä 2007). In this study 
small package sizes, potentially prescribed for occasional or short-term use, were excluded 
from the analysis, because they are not reimbursed by the SII. Thus, the results of this 
study are likely to reflect regular or long-term use of benzodiazepines, and indicate that 
the recommendation of short-term treatment is not followed well either. The results of the 
study among CMR patients (IV) are consistent with the above mentioned conclusions. 
Hypnotics, sedatives and anxiolytics, i.e., ATC classes including mostly benzodiazepines, 
caused nearly 10% of all DRPs (Table 30). The most common DRPs with these drugs 
were, in addition to inappropriate drug choice, too high dose and too long duration of 
treatment. 
Withdrawal of long-term benzodiazepine treatment should be accomplished by 






individual schedule from 4 weeks to several years (Lader et al. 2009). For a primary care 
physician discontinuation of an elderly patient’s benzodiazepine treatment may be 
challenging even if the potentially harmful long-term use of it is recognized. This is 
especially true if the physician sees the patient rarely and the prescriptions are repeated 
without a face-to-face contact with the prescriber, which is not exceptional in Finland 
(Saastamoinen et al. 2008). In international studies medication reviews involving 
pharmacists have been found to reduce suboptimal prescribing and to reduce psychotropic 
drug prescribing (Chrischilles et al. 2004, Nishtala et al. 2008, Castelino et al. 2009). In 
this study (IV) stopping of hypnotics and sedatives was the most commonly agreed drug-
level intervention resulting from CMR. Because pharmacists visited patients at home, it is 
possible that they informed the collaborating physicians about psychotropic drug use that 
the physicians were not previously aware of. On the other hand, when physicians referred 
patients to the CMR, they may already have recognized the potentially harmful 
psychotropic drug use. As a result of the collaborative CMR procedure where the 
physician has the support of nursing staff and the pharmacist in the realization of long-
term drug changes and follow-up, intervening with the problem may be easier. For this 
reason it is critical, that e.g., the home health care nursing personnel participate in the 
CMR case conference or are otherwise effectively informed about the decisions because 
they are in a key position to implement the drug changes. 
The results of this study do not reveal whether the actions agreed during CMR case 
conferences were actually implemented or if the changes in drug regimen were sustained 
over time. Further studies are needed to identify effective and practical ways to implement 
medication changes during CMR. Particularly, it is important to ascertain that the patients 
are properly informed about the changes and their reasons in order to engage them in 
following the new drug regimen. Otherwise it is possible that the changes will not be 
sustained or discontinued drugs may be substituted by others (Pitkälä et al. 2001).  
8.1.2 Anticholinergic Drugs (I, III, IV) 
Anticholinergic drugs may cause several ADEs that are more frequent among the aged, 
e.g., falls, dry mouth, dry eyes, constipation, dizziness, confusion, delirium and impaired 
cognitive function (Rudolph et al. 2008, Campbell et al. 2009). Of the anticholinergic 
drugs listed in the Beers criteria (Fick et al. 2003), the tricyclic antidepressant 
amitriptyline was used by 2% of the elderly outpatient population in this study (I). The 
common use of amitriptyline is consistent with numerous international studies (Tables 13–
15). There are some indications where amitriptyline may be useful in elderly care (Zhan et 
al. 2001). In Finland, it is commonly used to treat neuropathic pain, for which purpose it 
has the best evidence and is available at an affordable price (Attal et al. 2010). Among 
elderly patients amitriptyline could be replaced with desipramine, nortriptyline, 
venlafaxine, duloxetine or pregabalin, all of which have more favourable adverse effect 
profiles (Davis and Srivastava 2003, Barber and Gibson 2009, Attal et al. 2010). However, 
desipramine is not on the market in Finland and nortriptyline is not officially indicated for 






recommendations in relation to use of these agents for this purpose (Davis and Srivastava 
2003, Barber and Gibson 2009). 
During the CMR accreditation training, pharmacists learn about the potential adverse 
effects of anticholinergic drugs among elderly patients. In addition, questions regarding 
anticholinergic ADRs are included in the CMR interview to highlight their importance 
(III; Appendix 2). Never the less tricyclic antidepressants (TCAs) or other anticholinergic 
drugs were not prominently evident in DRPs during CMRs in this study (IV). This may 
partly be due to the study method, which grouped TCAs under the same ATC group with 
other antidepressants. However, in a more detailed analysis of the same CMR data, 13 
persons were using amitriptyline or doxepine, but after CMR these medicines were 
stopped only for three patients (Dimitrow 2009). Instead, need for regular use of these 
agents was emphasized for four patients and added as a new treatment for two more in 
order to improve management of chronic pain. This indicates that the individual properties 
and needs of the patients are more important in CMR than general recommendations with 
regard to avoidable drugs. As a consequence, each patient’s medications need to be 
reviewed against their personal clinical data during CMR before any recommendations 
can be made for changing their treatment.  
8.1.3 Undertreatment (III, IV) 
Simple application of PIM criteria to a patient population addresses a narrow part of the 
appropriateness of pharmacotherapy and does not consider individual patient 
characteristics. CMR is designed especially to take into account the individual needs of the 
patient with regard to all important dimensions of appropriate pharmacotherapy, including 
undertreatment, treatment outcomes and factors that may influence adherence (III). In this 
study (IV) the patients used a very high mean number of drugs (12.3 regular prescription 
drugs/person). Still, the second most common DRP reported by pharmacists was, 
somewhat surprisingly, an indication with no treatment (IV). Undertreatment was related 
most often to prevention or treatment of cardiovascular diseases and osteoporosis. This 
finding is consistent with several earlier studies (Strandberg et al. 2003, Gaw 2004, 
Higashi et al. 2004, Sloane et al. 2004, Barry et al. 2007, Rao et al. 2007, Ramalho de 
Oliveira et al. 2010). As a result of CMR, calcium supplements for prevention or treatment 
of osteoporosis were started often but for example statins for hypercholesterolemia not 
(Table 32). This again points out the importance of individualized decisions during CMR; 
the pharmacist can make recommendations based on patient’s conditions, test results and 
current care guidelines (www.kaypahoito.fi) but the physician must judge whether 
preventive therapies, such as statins, are likely to benefit the individual patient. 
Undertreatment or poor control of pain among Finnish home-dwelling older people has 
been shown in earlier studies (Pitkälä et al. 2002a, Hartikainen et al. 2005). In CMR 
procedure, the patient interview includes questions related to pain and also ADRs that may 
be caused by analgesics, e.g., constipation resulting from opioid use (III; Appendix 2). 
Treatment of pain seemed to have room for improvement among elderly CMR patients, 






(IV; Table 30). Opioids increase the risk for fractures and cognitive impairment and the 
adverse gastrointestinal, cardiovascular and renal effects of non-steroidal anti-
inflammatory drugs (NSAIDs) are well established, so it is particularly important to assure 
their rational use (Griffin et al. 1991, Vestergaard et al. 2006, Wright et al. 2009, 
American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain 
in Older Persons 2009). In this study several changes that comply with care 
recommendations were made on pain medications as a result of CMR, e.g., 
discontinuation of NSAIDs, increasing doses of paracetamol and changing opioids for 
other alternatives (Table 32). In the future, studies to evaluate the impact of CMR on pain 
and health-related quality of life are needed.  
8.2 CMR Accreditation Training (II) 
The new collaborative clinical role of the pharmacists during CMR requires skills and 
knowledge that are currently more or less lacking in their education in Finland. These 
include, e.g., collaboration with other health care professionals, selection of evidence-
based pharmacotherapy, interpretation of laboratory test results, knowledge on special 
features of geriatric pharmacotherapy and developing individualized drug treatment plans. 
The CMR accreditation training was developed to meet these competency needs. 
According to this study the participating pharmacists’ satisfaction with the training was 
high and the training met their educational needs. A majority of the course participants 
believed they would continue to conduct CMRs after the training and none of the 
participants mentioned lack of skills as a barrier for future CMRs. This suggests that the 
goals of the training were achieved.  
This study was performed in the early phase of starting the CMR service 
implementation in Finland. Since then 1–2 CMR accreditation training courses have been 
organized annually with about 40–50 pharmacists from hospital and community 
pharmacies participating. Surveys to measure participant responsiveness to the training 
have been conducted after every course. Participant satisfaction with the training has 
continued to be high. Contents of subsequent courses are always planned based on the 
feedback from the previous ones. So far, there has been no need to make major changes to 
the curriculum. If more clinical pharmacy and collaborative skills are taught in the basic 
training of pharmacists in the future, this may also affect the contents of the CMR 






8.3 CMR Procedure and Outcomes (II, III, IV) 
8.3.1 CMR Procedure (II, III) 
Internationally, there are numerous different medication review procedures which differ in 
their comprehensiveness, pharmacists’ access to patient data and patient involvement 
(Chapter 2.2). Published literature generally lacks information how these procedures have 
been developed, what is the evidence behind their actions, and what measures are used in 
the procedures and why. Also, in published studies the medication review procedures are 
often poorly and inadequately described even if the interventions are likely to affect the 
outcomes of such studies (Holland et al. 2005, Smith et al. 2006). The development 
process of CMR is unique in its extensiveness; it involved a strong component of 
literature-based development to find evidence for the actions and measures of the 
procedure but also remarkable practical development and testing to make the procedure 
applicable to the Finnish health care system.  
A crucial idea in CMR was to develop a service that is carried out in a uniform manner 
by each reviewer, so that the patients and the payers of the service can count on a high 
standard of quality (see Stubbings et al. 2011). This is first accomplished by the CMR 
accreditation training (II) that ascertains that all accredited pharmacists are competent to 
conduct the reviews. A basic requirement to be accepted to the CMR training course; the 
Bachelor’s or Master’s degree in Pharmacy, was to guarantee sufficient skills in 
pharmacology and pharmacotherapy. This allows the training to focus on supplementing 
existing knowledge with more detailed information on geriatric pharmacotherapy. 
Secondly, the CMR procedure follows a standard structure that has undergone extensive 
evidence- and practice-based development and testing to meet the needs of the patients 
and collaborating health care professionals and to be compatible with the Finnish health 
care system (III). Finally, the CMR documentation, if used properly, is a guarantee of 
uniform quality as it systematically guides every step of the CMR procedure. This is 
especially important during the patient interview, so that all necessary information for the 
medication review can be gathered, and at the time of the actual medication review and 
reporting of the findings to the collaborating physician.   
Due to its focus on standard quality goals and comprehensiveness, especially with 
regard to the home-visit, the CMR procedure is laborious and takes at least several hours. 
In spite of the time required to do it, the CMR accreditation training participants in this 
study (III) saw the patient interview as a crucial part of the CMR procedure. The training 
participants saw this as necessary to provide information to promote rational drug use and 
adherence and to attain relevant information that was not available in patient records or 
known by the attending physician. Also, the pharmacists participating in the training did 
not want to remove any questions from the extensive interview form. Instead, new 
questions were added based on their suggestions. Indeed, the added questions, e.g., 
regarding health habits are very important when medications are reviewed. For instance, 
smoking and alcohol may have clinically significant interactions with drugs and such 






1999, Kroon 2007). Delicate issues, such as alcohol consumption, are easier to bring up to 
discussion, if they are part of a standard procedure.  
Internationally the benefits of in-home interviews are well documented, and include 
recognition of problems in drug administration that are otherwise difficult to detect, e.g., 
hoarding, inappropriate storage conditions, expired medications or confusion between 
generic and brand names (Hsia Der et al. 1997, Frank et al. 2001, Sorensen et al. 2006). It 
is also known that discrepancies between the medication lists of physicians and actual 
drug use are common, and may result in drug interactions and ADEs (Frank et al. 2001, 
Tulner et al. 2008). In-home visits have been shown to produce the most reliable 
medication lists (Yang et al. 2001). In the future electronic health records may help to 
attain reliable prescription drug lists (Westerling 2011), but do not provide information on 
OTC drugs, herbal products and actual use of drugs. It could be possible that 
multiprofessional collaboration, e.g., home health care nurses could be utilized more 
efficiently in CMR to acquire the data on actual drug use. On the other hand, they lack the 
skills of pharmacists in providing medication counseling at home, which also is an 
important component of CMR. 
The CMR clearly expands the Finnish community and hospital pharmacists’ role in the 
health care compared to the traditional tasks, which have mainly consisted of preparing 
and dispensing of drugs and patient counseling. Importantly, in CMR the pharmacists 
have access to clinical patient data, including diagnoses and laboratory test results and can 
discuss, e.g., individualized treatment goals with the physician. This is a clear distinction 
from traditional counseling during which the pharmacists base their advice on the often 
insufficient or unreliable information available on the prescription or provided by the 
patient.  
Access to extensive clinical patient data is crucial for the pharmacists to undertake 
reliable analysis of the patient’s pharmacotherapy and make valid recommendations for 
the collaborating physician during CMR. Still, there is currently no efficient way to 
transfer patient data from physician to pharmacist. The CMR Referral and Data Transfer 
Form developed for this purpose in this study was judged by the study pharmacists as 
being too laborious for the collaborating physician (III). This may prevent the physicians 
from making the referrals and also gaining the intended benefit of CMR as a practical, 
time-saving decision-making support tool. Prints of patient medical records, a way 
preferred by several pharmacists in this study, may, on the other hand, be an impractical 
and time-consuming way for the pharmacist to gather relevant data. In the future more 
effective and reliable ways for this data transfer will need to be developed (see also 
Westerling 2011). This also applies to transfer of information after CMR case conference 
to all persons that are involved in patient’s medical care and following-up his/her 
condition at home. Electronic health records and community pharmacists’ access to them 
or other protected electronic data transfer system would make the CMR process more 






8.3.2 Outcomes of CMR Compared to MTM and HMR (IV) 
In this study (IV) the pharmacists were able to recognize a large number of DRPs among 
the elderly outpatients. They reported an average of 6.5 DRPs per person to the 
collaborating physicians. Because the DRPs that were resolved at the patient’s home by 
the pharmacist were probably not reported to physicians, this result is likely to 
underestimate the number of actual DRPs. Still, the number of DRPs was high compared 
to MTM studies from the USA (1–3.6 DRPs/encounter; Table 10). There are several 
potential explanations for this. First, in MTM, patient encounters usually take place at the 
pharmacy or even by phone, and may last for as little as five minutes (Ellis et al. 2000b). 
The more thorough discussions and comprehensiveness of the review in Finland may be 
the cause of significantly higher mean number of DRPs reported by the pharmacists in this 
study. Secondly, in MTM there are usually several follow-up encounters. Thus, the 
pharmacist is not compelled to report all findings at once, which means that the number of 
DRPs per encounter may be smaller. Also in the Australian HMR studies the mean 
number of DRPs/patient (2.1–9.7; Table 11) has been generally lower than in this study, 
even though the procedure involving a home visit seems to be similar to CMR. As HMR 
and MTM are not solely targeted at elderly patients, part of the lower number of DRPs 
may relate to the younger mean age of patients and lower number of used drugs in most 
reviewed studies (Tables 10, 11).  
The older patient population in this study may also explain the difference in the most 
common DRP types found in this study compared to those found in MTM and HMR 
studies (Tables 10, 11). In this study “inappropriate drug choice”, involving especially 
hypnotics and sedatives, was the most commonly reported DRP (IV). This different 
finding compared to MTM and HMR is understandable, because the specific risks of 
psychotropic drugs, e.g., falls and fractures, are pronounced among elderly patients and 
the criteria and recommendations to indicate inappropriate drugs only apply to people 
aged 65 or 75 and older who were not solely represented in most HMR and MTM studies 
(Chapters 3.2.1, 3.2.2). On the other hand, DRPs related to poor adherence and patients’ 
lack of knowledge were common in the majority of MTM and HMR studies. In this study 
such patient-related DRPs or causes of DRPs were rare. This may either indicate that 
CMR focused more on clinical findings or that the study method prevented recognition of 
adherence-related DRPs that were solved by the pharmacist at the patient’s home. 
Even though MTM and HMR were used as models when the CMR procedure was 
developed, the above mentioned differences in the medication review models, pharmacists 
findings and patient populations, make it unreliable to draw any direct comparisons 
between the potential outcomes of CMR and those based on MTM and HMR studies 
(Tables 4, 5).  
8.3.3 CMR in the Finnish Health Care System (II, III, IV) 
After completing the CMR accreditation training, about one third of the accredited 






if they knew that keeping up both practical and theoretical competencies is required for 
reaccreditation. Several mentioned that the development of a local CMR service was 
difficult and time-consuming. Indeed, Finnish hospital and community pharmacists have 
not traditionally been expected to be involved in patient care. In addition, they are not 
used to develop professional services based on their special expertise. Also, they are not 
used to actively promote this kind of expert services and make contracts with public or 
private purchasers (see also Stubbings et al. 2011). As a result, in recent CMR 
accreditation training courses the assignment to establish a CMR service has been 
rescheduled to start in an earlier phase of the training to facilitate development of a 
permanent CMR collaboration. The TIPPA Coordination Group intends to conduct a 
survey among all approximately 150 pharmacists accredited to conduct CMRs to see how 
the CMR practice is evolving in Finland and how many of those accredited stay active in 
conducting CMRs.  
The greatest challenge for CMR in Finland is that there are no national systems in 
place to integrate CMRs in the health care, including lack of specific eligibility criteria 
and guidelines for reimbursement of CMR. During the development phase of CMR the 
pharmacists tested various CMR procedures in collaboration with their health care 
partners in order to develop a model that the partners find useful and that could fit in the 
Finnish health care system (III). Some pharmacies with accredited pharmacists have 
succeeded to make contracts with municipalities and agree on payment and other 
conditions. Such contracts are not common even though already in 2007 the Ministry of 
Social Affairs and Health recommended that the municipalities should assure that the 
medications of the elderly residents are reviewed annually even if no changes were made 
in their regimen. Collaborative medication reviews were recommended as a way of 
conducting the medication reviews and community pharmacists were urged to charge for 
the medication reviews on an hourly basis (Ministry of Social Affairs and Health 2007).   
The current patient selection criteria for CMR is broad and varies locally. There is no 
national, evidence-based standard criteria, but the pharmacists, collaborating physicians 
and nurses agree on applicable patients. In this study a mean of 3 drug changes per patient 
were agreed on during the CMR case conference (IV). The high number of drug changes 
indicates that there is room for improvement in the patients’ pharmacotherapy and that the 
patient selection was successful. However, the intentional selection of elderly, high-risk 
patients with potential problems in their pharmacotherapy for this study makes the results 
non-generalizable to all elderly patients. On the other hand, this kind of time-consuming 
expert service should be targeted to those patients who have some special potential 
problems in their medication use, and thus, can benefit from the service. 
In the future it is important to study which patients are likely to gain the best benefit 
from CMR and to develop more specific guidance regarding suitable eligibility criteria. 
Currently, a risk assessment tool to identify potential risk patients among home health care 
patients is being pilot tested (Salminen 2011). Such tool may be useful in development of 






8.4 Future Studies  
There are several issues that may have influenced the prescribing of PIMs since 2007, 
when this study (I) was conducted. Firstly, the Finnish Medicines Agency published its 
criteria to indicate potentially inappropriate drugs for people aged 75 and older in 2010 
(Fimea 2011). As an open-access database it can be widely used by health care 
professionals and affect prescribing practices. Secondly, there are changes in drug 
compendium that may affect PIM prescribing, e.g., removal of drugs from the market. In 
addition, in 2007 the Ministry of Social Affairs and Health pointed out the potential 
problems in elderly care in Finland and gave national recommendations for actions for 
municipalities responsible for organizing healthcare for their residents. One of the 
recommended actions was annual medication reviews for all aged residents (75 years or 
older). It would be interesting to conduct a national follow-up study to evaluate whether 
these recommended actions have been acted on and have had any impact on medication 
use of elderly. As part of such study, it would be necessary to assess the implementation 
rate of actions and possible regional variation in quality of care. Regarding CMR, sound 
evidence is still missing on its clinical, humanistic and economic outcomes. The same 
applies to other medication reviews procedures applied in other countries (Lipsanen 2009). 
The current study was conducted at the time when CMR procedure was under 
development and the collaboration between pharmacists and physicians was just starting 
to evolve in Finland. Now, there is need for studies that would assess the effects of CMR 
on health outcomes, including clinical outcomes, HRQoL, and health care costs. The 
outcomes of HMR and MTM studies (Tables 4, 5) can provide limited insight with regard 
to the potential benefits, but as most related studies are not targeted to elderly patients, 
their results are not directly applicable to CMR. Also, the differences in the procedures, 
e.g., lack of home visit in MTM, and the specific competences of CMR pharmacists 
gained during the long-term accreditation training may affect the results. The Finnish 
Medicines Agency Fimea has shown interest in CMR and is currently planning a research 
project to evaluate the effects of CMR, possibly compared to some less comprehensive 
medication review model. The results of such studies may greatly affect policymaking and 
demand for CMR services in Finland. It would be useful if such studies could indicate 
which patients are likely to benefit from an in-depth review procedure like CMR and if 
less resource-intensive medication review models are useful, perhaps as a routine practice, 








Approximately 15% of the entire Finnish outpatient population aged 65 and older use 
potentially inappropriate drugs. One third of this drug use involves benzodiazepines, 
particularly high-dose temazepam. Compared to international studies the prevalence of 
PIM use in Finland is low. However, the common use of benzodiazepines is a worrisome 
finding, as they increase the risk for falls and fractures and are associated with impaired 
cognitive function. 
The CMR accreditation training and CMR procedure are developed to increase 
pharmacists’ involvement in assuring rational and safe pharmacotherapy. The CMR 
training provides the hospital and community pharmacists with sufficient knowledge and 
skills to conduct CMR in collaboration with other health care professionals, particularly 
with physicians. The pharmacists’ satisfaction with the training is high, but several factors 
inhibit pharmacist from conducting CMRs after the training. 
The CMR procedure is based on a detailed development process. The development 
involved a literature review, inventory of international medication review procedures, 
development of potential procedures by CMR accreditation training participants, 
integration of potential procedures to a national standard procedure and piloting in practice 
setting. The resulting collaborative CMR procedure includes access to clinical patient 
information, a patient home interview and a case conference with the physician. The CMR 
procedure covers four relevant dimensions of ascertaining rational and safe 
pharmacotherapy among elderly patients: Aging and Safety; Co-Morbidities; 
Polypharmacy; and Adherence. Extensive CMR documentation is developed to support 
the procedure and guarantee uniform quality of CMRs. 
By using the CMR procedure, pharmacists are able to recognize DRPs. Among 
outpatients aged 65 and older, an average of 6.5 DRPs per patient were reported to 
physicians during CMR. Most common DRPs were inappropriate drug selection, 
especially involving psychotropic drugs, and undertreatment of cardiovascular diseases 
and osteoporosis. Also treatment of pain was often found to need improvement. 
Approximately half of the pharmacists’ recommendations led to medication changes and 
an average of 3 changes to drug regimen were made per patient. Positively, most common 
agreed change was to stop hypnotics or sedatives. 
The results of this study confirm many well-known problems in elderly 
pharmacotherapy: prescribing of inappropriate drugs, undertreatment, and issues related to 
inadequate management of pain. The CMR procedure could be beneficial for improving 
pharmacotherapy among older outpatients as a large portion of identified problems lead to 
medication changes. Actions to facilitate implementation of the model to Finnish health 
care system are needed. Also, further studies are needed to evaluate the effects of CMR on 
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Appendix 1. Pharmaceutical Care Network Europe (PCNE) Classification scheme for drug-
related problems V6.2 (www.pcne.org) 
 
  
   The Problems 
 





There is a (potential) 
problem with the (lack of) 






No effect of drug treatment/ therapy failure  
Effect of drug treatment not optimal  
Wrong effect of drug treatment  
Untreated indication  
2. Adverse reactions  
Patient suffers, or will 
possibly suffer, from an 




Adverse drug event (non-allergic)  
Adverse drug event (allergic)  
Toxic adverse drug-event  
3. Treatment costs  
The drug treatment is 




Drug treatment more costly than necessary  
Unnecessary drug-treatment  
4. Others P4.1  
 
P4.2  
Patient dissatisfied with therapy despite optimal clinical 
and economic treatment outcomes  
Unclear problem/complaint. Further clarification 
necessary (please use as escape only)  
 
☐  Potential Problem 













































Appendix 1. Continued. 
The Causes 
 
Primary Domain  Code  
V6.2  
Cause  
1. Drug selection  
The cause of the DRP is 
related to the selection of 











Inappropriate drug (incl. contra-indicated)  
No indication for drug  
Inappropriate combination of drugs, or drugs and food  
Inappropriate duplication of therapeutic group or active 
ingredient  
Indication for drug-treatment not noticed  
Too many drugs prescribed for indication  
More cost-effective drug available  
Synergistic/preventive drug required and not given  
New indication for drug treatment presented  
 2. Drug form  
The cause of the DRP is 
related to the selection of 
the drug form 
C2.1  Inappropriate drug form  
3. Dose selection  
The cause of the DRP is 
related to the selection of 








Drug dose too low  
Drug dose too high  
Dosage regimen not frequent enough  
Dosage regimen too frequent  
No therapeutic drug monitoring  
Pharmacokinetic problem requiring dose adjustment  
Deterioration/improvement of disease state requiring 
dose adjustment  
4. Treatment duration  
The cause of the DRP is 




Duration of treatment too short  
Duration of treatment too long 
5. Drug use process  
The cause of the DRP can 
be related to the way the 
patient uses the drug, in 
spite of proper dosage 









Inappropriate timing of administration and/or dosing 
intervals  
Drug underused/ under-administered (deliberately)  
Drug overused/ over-administered (deliberately)  
Drug not taken/administered at all  
Wrong drug taken/administered  
Drug abused (unregulated overuse)  
Patient unable to use drug/form as directed  
6. Logistics  
The cause of the DRP can 
be related to the logistics 





Prescribed drug not available 
Prescribing error (necessary information missing) 
Dispensing error (wrong drug or dose dispensed) 
7. Patient  
The cause of the DRP can 
be related to the 
personality or behaviour 





Patient forgets to use/take drug 
Patient uses unnecessary drug 
Patient takes food that interacts 
Patient stored drug inappropriately 
8. Other C8.1 
C8.2 
Other cause; specify 






Appendix 1. Continued. 
   The Interventions 
 
Primary Domain  Code 
V6.2  
Intervention  
No intervention  I0.0  No Intervention  





Prescriber informed only 
Prescriber asked for information 
Intervention proposed, approved by Prescriber 
Intervention proposed, not approved by Prescriber 
Intervention proposed, outcome unknown 




Patient (medication) counselling 
Written information provided only 
Patient referred to prescriber 
Spoken to family member/caregiver 






Drug changed to… 
Dosage changed to… 
Formulation changed to… 
Instructions for use changed to ….. 
Drug stopped 
New drug started 




Other intervention (specify) 
Side effect reported to authorities 
 
 
The Outcome of the Interventions 
 
Primary Domain  Code  
V6.2  
Outcome of intervention 
0. Not known  O0.0  Outcome of intervention not known  
1. Solved O1.0  Problem totally solved  
2. Partially solved O2.0  Problem partially solved  




Problem not solved, lack of cooperation of patient  
Problem not solved, lack of cooperation of prescriber 
Problem not solved, intervention not effective 






















Appendix 2. CMR Patient Interview Form. Questions marked with* were present already 
in the preliminary interview form.  
  
 
  COMPREHENSIVE MEDICATION REVIEW INTERVIEW FORM 
 
 
Patient name: _____________________________________________ Date _________ 
□ at home      □ at the pharmacy    □ at ward    □ _______________________ 
 
The reason for this interview is to review the state of your current drug therapy. The answers you 
provide will be used to ascertain that your drug treatment is appropriate. The medication review will be 
discussed with your physician, who may change your drug regimen, if needed.  





*1. Which physicians have you visited during the past year (12 months) 
    □ Primary care physician 
    □ Specialist at hospital (e.g., internist, ophthalmologist) 
    □ Private sector physician (e.g., dermatologist, gynecologist) 
    □ Other, what? _______________________________ 
 
2. Which physician is primarily responsible for your drug treatment?_______________________ 
  
 3. Do you receive any help regarding medication management? Is dose dispensing used? 
□ Managed self     □ Home health care         □ Relative _____________     □ Other_______________ 
   □ Dose-dispensing devise           □ Automated unit dose dispensing 
 
USED PRESCRIPTION AND OTC DRUGS, NATURAL PRODUCTS AND DIETARY SUPPLEMENTS 
 
*4. Please, let me see all prescription drugs you use. (The patient is asked to show all prescription drug 
products in use. The following issues are discussed regarding every product: storage conditions, 
patient’s understanding of the purpose, actually used dose and dosing interval, is use only as needed, 
are there any difficulties regarding the drug. Drugs and doses are documented on a separate table, 
and compared to the medication list received from the collaborating physician.) 
 
Dosing times: morning at ____, day at ____, afternoon at____, evening at ____, night at____ 
 
*5. Do you use any non-prescription drugs? 
    □ Yes                   □ No 
 
*6. Please, let me see all non-prescription drugs you use. (Discussed and documented like prescription 
drugs. Additionally, it is asked who has recommended the use of the product.) As a reminder the 
pharmacist may bring up various drug groups for discussion: 
 
    □ Analgesics______________________________________________________________________ 
    □ Analgesic ointments_______________________________________________________________ 
    □ Other ointments _________________________________________________________________ 
    □ Drugs for allergy _________________________________________________________________ 
    □ Eye drops_______________________________________________________________________ 
    □ Antacids, proton pump inhibitors ____________________________________________________ 
    □ Laxatives_______________________________________________________________________ 
    □ Cough medicines_________________________________________________________________ 
    ☐ Vitamins, minerals________________________________________________________________ 
   
*7. Do you use any natural products, dietary supplements or related products available e.g., in natural 
product shops or grocery shop? 
    □ Yes       □ No 
 
*8. Please, let me see all natural products etc. you use. (Discussed and documented like non-






Appendix 2. Continued. 
  
 
DRUG-RELATED PROBLEMS (DRPs) 
 
*9. Do you have problems or difficulties with some drugs you use? What kind of problems? (The 
interviewer uses the table to describe examples of potential problems) 
 
Problem Related drug/drugs 
The drug is not helping  
The drug seems to cause adverse effects  
Indication for use is not known  
Difficulties with administration: 
- Opening containers 
- Swallowing tablets/capsules 
- Using eye-drops 
- Using asthma inhaler 
- Insulin 
- Using the dose dispensing device 
 
Forgetting to take drugs  
Expensive drug/drugs  




□ Drugs with improper storage conditions found 
 
 
      
 
ADHERENCE 
If nonadherence is the cause for CMR, Morisky adherence scale can be attached here.!!!!
 
*10. Do you currently use any drugs more or less than ordered by the physician? 
      □ Yes, more          □ Yes, less        □ All as instructed                      
 
*11. If you use any drugs more or less than prescribed, tell which drug/drugs and for what reason 
 
Drug Different dose / dosing 
frequency 
Cause for different dosing (e.g., the 
drug does not help on prescribed dose) 
   
   
   
 
*12. Have you discontinued a drug without telling your physician during the past 6 months (e.g., because 
of adverse effects or because the price was too high) 
      □ Yes                     □ No 
 






*14. Would you like to have any changes made in your drug regimen? (The interviewer may describe 
examples, e.g., switch of tablet to liquid during swallowing difficulties.) 
      □ Yes                     □ No 
 

















17. Do you self monitor e.g., blood pressure, blood glucose at home or does a visiting nurse etc. visit 
you to do the measurements? 
      □ No                     □ Yes, ______________________________________ 
 
Laboratory test results not included in preliminary patient data can be documented here: 
  
Test Result Date Goal Note 
Blood 
pressure 
  General goal 
<140/85 
mmHg 





  4-6 
< 8 
 
Hb1Ac   < 6-7 If no hypoglyceamias 













great risk (e.g., diabetes) <4.5 
 




  ♀: 50-90 
♂: 60-100 
> 90  
GRF= 
♀: (140 – age) x weight / 0,95 x P-
krea (µmol/l). 





    
 
 
□ Monitoring needed regarding:_____________________________________________________ 
 
 
ADVERSE EFFECTS, THEIR SEVERITY AND POSSIBLE TREATMENT 
 
The next questions are about symptoms, that are common among elderly patients and may be 
associated with use of certain drugs. We want to know if you have experienced any such symptoms. 
Please, choose the alternative that best describes your situation during the past few days (weeks). 
 
*DRYNESS OF MOUTHa (due to decreased salivation) 
 
Has a dry mouth troubled you? 
□ Not at all 
□ Slight dryness, not disturbing 
□ Moderate and slightly disturbing dryness of mouth  
□ Marked dryness of mouth which clearly disturbs daily life  
 
If dryness of mouth has troubled you, how has it been treated? 












Appendix 2. Continued. 
  
 
*CONSTIPATIONa (reduced frequency of defaecation and/or thicker consistency of faeces) 
 
Have you been troubled by constipation? 
□ Not at all 
□ Slight constipation, but bearable 
□ More marked, hampering constipation  
□ Very pronounced constipation (need to take laxatives) 
 
If you have been troubled by constipation, how has it been treated? 
□ Not treated               □ Diet              □  Product: _________________________ 
 
 
*MICTURITION DISTURBANCESa (feeling of difficulty in starting and of resistance to micturition, 
weaker stream and/or longer time of micturition) 
 
Have you experienced difficulties in passing your urine? 
□ Not at all 
□ Clearly present, but bearable (Difficulty in beginning urination) 
□ Poor stream, takes longer to empty bladder, feeling of incomplete emptying of bladder  
□ Cannot empty bladder, need help (retention of urine) 
 
If you have experienced urinary disturbances, how have they been treated? 
□ Not treated      □ Reduced fluid intake    □  Product: _________________________       
 
 
DIZZINESS/FAINTING (orthostatic dizziness)a 
(Dizziness can manifest as feeling of weakness, everything going black, buzzing in the ears or 
increasing tendency to faint when changing from supine or sitting position to upright position) 
 
Does dizziness or fainting trouble you when getting up from a lying or sitting position? 
□ Not at all 
□ Sometimes, but I can stand up without problems  
□ Must rise slowly from sitting or lying position  
□ Difficulty in standing up due to dizziness of feeling faint 
 
 
OTHER UPCOMING ADVERSE EFFECTS OR SYMPTOMS 
□ Falls 
□ Confusion 
□ Others: __________________________________________________________________________ 
     
!
 
During medication review it is important to get information regarding your current health. The next 




Have you suffered from pain during the last week? 
□ Not at all 
□ Mild or temporary pain 
□ Moderate pain 
□ Severe pain 
 
If you have suffered from pain, how has it been treated? 
□ Not treated    □ OTC: ________________□ Prescription: _______________ □ Other: _____________ 
 







Appendix 2. Continued. 
  
 
INSOMNIA/SLEEPING DISORDERS (e.g., troubles falling asleep, night time awakenings)  
 
Have you been troubled by insomnia or other sleeping disorders? 
□ No at all 
□ Mild or temporary sleeping disorders 
□ Moderate sleeping disorders 
□ Severe sleeping disorders 
 
What kind of sleep-related problems? __________________________________________________ 
 
If you have suffered from insomnia or sleeping disorders, how have they been treated?  





Weight: _________ Height:_____________ 
 
It is important to get enough vitamins and minerals. Is your diet balanced? (Issues relating to diet and 









Alcohol may change the effects of some drugs. Do you use alcohol? 
□ No □ Yes 
 
If yes, how often: 
□ once a month or less       □ 2-4 times a month     □ 2-3 times a week      □ more than 4 times a week 
 
How many doses of alcohol do you use at once (one dose corresponds to one bottle of beer or cider,  
12 cl of wine, 8 cl strong wine, 4 cl of spirits (40%)  
□ 1-2            □ 3-4            □ 5-6            □ 7-9            □ more than 10 doses    
 
Smoking may adversely affect treatment of some conditions or change drug effects. Do you smoke? 
□ No             □ Yes, for  ____ years     □ Quit____ years ago 
 
If yes, how many cigarettes per day?   
□ less than 10      □ 11-20        □ 21-30        □ more than 30 cigarettes 
 
 
*If you have any other concerns or questions regarding your drug treatment, please feel free to ask.  







Reporting: ________________________________________  □ Written report for the patient 
Decision on the timetable of follow-up: ______________________________________________ 
 
a Formulation of questions modified from the UKU side effect rating scale (Lingjaerde et al. 1987) or its 










Appendix 3. CMR Referral and Patient Data Collection Form  
 
 







Date of data collection 




HEALTH STATE AND MEDICATIONS  



















     
     
     
     
     
     
     
     
     
     
 
LABORATORY TEST RESULTS (e.g., blood pressure, serum electrolytes etc., if relevant) 
 
TEST DATE RESULT THERAPEUTIC GOAL 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
















                  COMPREHENSIVE MEDICATION REVIEW 
Name Identity number 
Address Physician 




SHORT SUMMARY OF PATIENT CLINICAL DATA 
Diagnoses: 
Medication list (or drug chart as an attachment) 
- Regular:                                                                                                                    
- As needed:                                                                           
 
Relevant laboratory test results and therapeutic goals 
 
Test Result Goal Note 
Blood pressure  General goal 
<140/85 mmHg 
Diabetics and other high-risk patients 
<130/80 mmHg 
BG (feasting) 




Hb1Ac  < 6-7 If no hypoglyceamias 











great risk (e.g., diabetes) <4.5 




 ♀: 50-90 
♂: 60-100 





♀: (140 – age) x weight / 0,95 x P-krea 
(µmol/l). 




   
 
 
SUMMARY OF NURSE’S / CARETAKER’S COMMENTS 
 
  
SUMMARY OF PATIENT INTERVIEW  ___.___.201__  (Drug use, DRPs, adherence, adverse drug 





□ Date of follow-up:  _______.201_                           □ A written report for the patient 
Symptom Severity Frequency Current treatment 
 mild remarkable severe   
Dryness of mouth      
Constipation      
Urinary disturbances      
Pain      
Insomnia/sleep 
disorders 
     
Dizziness      
Falls      
Confusion      












Reimbursements and economical issues (Special reimbursements, generic substitution...) 
 
 






Sedative drugs:  
 
Inappropriate drugs / doses / treatment duration (= in regard to conditions / age / care guidelines, 
potential adverse effects, as needed drug in regular use, needed drug not in use/prescribed…)  
 
 
Treatment of patient’s most significant conditions (e.g., compliance with care guidelines, meeting of 
therapeutic goals, appropriateness of drug choices and dosage…) 
 
 





_________________________  __ / __ 201_           __________________________ 
reviewer 
 








DURATION OF CMR 
Groundwork ____, interview ____, review ____, case conference  ____ = Total  _____ 
 
 




DRUG COSTS (for 3 months supply) 
 
Before CMR _____, after changes _____, after follow-up ______ 
Product Interaction class 
(A-D, 1-4) 
Clinical significance 
                                   /   
                                   /   
                                   /   

















Appendix 5. CMR Review Chart  
  
 


















 M  D  A  E  N 
 
Purpose of use / 
clinical 
condition 


























































                     
  
 
                     
 
 
                      
 
 
                      
  
 
                     
  
 
                     
 
 
                      
 
 
                      
 
 
                      
 
 
                      
Abbreviations: 
Sed. = sedative properties  HR = effect on heart rate   AC = anticholinergic effect 
BG = effect on blood glucose  SS = serotonergic effects  K+ = effect on serum potassium   









Appendix 6. EQ-5D Finnish version (Descriptive system and the Visual Analoque Scale) 






Auttaaksemme ihmisiä sanomaan, kuinka hyvä tai huono 
jokin terveydentila on, olemme piirtäneet lämpömittaria 
muistuttavan asteikon. Parasta terveydentilaa, jonka voitte 
kuvitella, merkitään siinä 100:lla ja huonointa 0:lla. 
 
Haluaisimme Teidän osoittavan tällä asteikolla, miten hyvä 
tai huono Teidän terveytenne on mielestänne tänään. Olkaa 
hyvä ja tehkää tämä vetämällä alla olevasta laatikosta viiva 
siihen kohtaan asteikolle, joka osoittaa, miten hyvä tai 



























Huonoin          
kuviteltavissa 









Olkaa hyvä ja merkitkää rastilla (x), yksi rasti kunkin alla olevan ryhmän kohdalle, 




Minulla ei ole vaikeuksia kävelemisessä    
Minulla on jonkin verran vaikeuksia kävelemisessä    
Olen vuoteenomana    
 
Itsestään huolehtiminen 
Minulla ei ole vaikeuksia huolehtia itsestäni    
Minulla on jonkin verran vaikeuksia peseytyä tai pukeutua itse     
En kykene peseytymään tai pukeutumaan itse    
 
Tavanomaiset toiminnot (esim. ansiotyö, opiskelu, kotityö, 
vapaa-ajan toiminnot) 
Minulla ei ole vaikeuksia suorittaa tavanomaisia toimintojani     
Minulla on jonkin verran vaikeuksia suorittaa tavanomaisia toimintojani   
En kykene suorittamaan tavanomaisia toimintojani     
 
Kivut/vaivat 
Minulla ei ole kipuja tai vaivoja    
Minulla on kohtalaisia kipuja tai vaivoja    
Minulla on ankaria kipuja tai vaivoja    
 
Ahdistuneisuus/Masennus 
En ole ahdistunut tai masentunut    
Olen melko ahdistunut tai masentunut    
Olen erittäin ahdistunut tai masentunut   
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